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  Abstract 
Background: The mechanisms involved in the development of diabetic 
nephropathy (DN), which affects more than 30% of patients with diabetes 
worldwide, are not fully understood. DN is believed to result from 
hyperglycaemia-induced pathways in the kidney.  
Hypothesis: Hyperglycaemia/high glucose causes early changes in mitochondrial 
DNA (MtDNA), possibly contributing to mitochondrial dysfunction.  
Methods: Human renal immortalised and primary cultured mesangial cells 
(HMCL, HMCs) and transformed tubular epithelial cells (HK-2) were cultured in 
5mM (NG) and 25mM (HG) glucose and in 5mM glucose plus 20mM mannitol. 
Organs and whole blood samples were collected from streptozotocin-induced 
(STZ), prohibitin 2 knockout (β-PhB2-/-) and leptin deficient (Lepob/ob) diabetic 
mice. MtDNA content was measured in cultured renal cells, mouse organs and 
circulating cells using qPCR. The cellular bioenergetics of HMCs and HK-2 cells 
was measured using XFe96 Seahorse analyser. Genes involved in mitochondrial 
life cycle and in the TLR-9 pathway in HMCs were measured using real-time 
qPCR. Reactive oxygen species (ROS) production and cell viability were assessed 
in HMCs using fluorescence and luminescent assays and hyperglycaemia-induced 
MtDNA damage using elongase PCR. Mitochondrial morphology and protein 
content were assessed by MitoTracker staining and Western blot respectively. 
Results: Increased MtDNA levels in circulation in STZ-induced and β-PhB2-/- 
diabetic mice (P<0.05) was observed. In the STZ-induced mouse kidneys, MtDNA 
was reduced after 4 weeks diabetes (P<0.05); a similar trend was observed in the 
kidneys of the ob/ob mice (P=0.08). Growth of HMCs in HG resulted in 3-fold 
higher MtDNA and 2-fold higher TFAM (P<0.05), no significant changes were 
observed in HK-2 cells. The expression of two mitochondrial genome encoded 
mRNAs were reduced (P<0.05) in parallel with increased MtDNA damage, cellular 
ROS and apoptosis (P<0.05) in HMCs exposed to HG. Mitochondrial length and 
degree of branching were reduced in HMCs cultured in HG (P<0.01, P<0.001). NF-
κB and MYD88 expression were up-regulated in HMCs exposed to HG (P<0.05). 
Hyperglycaemia caused a decrease in basal, maximal and ATP-linked respiration 
(P<0.001) in the HMCs. Although no alteration in the MtDNA content was 
observed in HK-2 cells exposed to HG,  bioenergetic profile of HK-2 cells was 
affected by hyperglycaemia  with reduced basal, ATP-linked and maximal 
respiration (P<0.01).  
Conclusion: These data show that hyperglycaemia can directly increase MtDNA 
in cultured renal and circulating cells in mouse models of diabetes. 
Hyperglycaemia-induced damage to MtDNA caused a dysregulation between 
MtDNA levels and mitochondrial transcription, suggesting the increased MtDNA 
may not be functional. Induction of the TLR-9 pathway suggests a potential 
inflammatory role of the damaged MtDNA. 
Therefore, the in-vitro and in-vivo data suggest altered MtDNA content may be a 
biomarker of an adaptive mechanism of failing mitochondrial function under 
stress conditions. Such changes may be the foundation of the damage seen in 
patients with DN and needs further investigation. 
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Chapter 1 
1.1 Diabetes 
Diabetes mellitus belongs to a group of metabolic syndrome diseases and has 
been characterised as persistently occurring high blood glucose 
(hyperglycaemia), caused by insulin deficiency or insulin resistance. Diabetes 
mellitus was first described as a disease linked to the urinary tract and kidney 
dysfunction. In 1674, the English physician, Thomas Willis (1621-1675), was the 
first to distinguish diabetes from other cases of polyuria and described the 
‘sweetness’ of the urine and blood of affected patients.  Matthew Dobson (1735-
1784) reported that diabetic blood and urine contain sugar. A major 
breakthrough came in 1921, when Fredrick Banting (1891-1941) and Charles Best 
(1899-1978) in Toronto discovered insulin in the islets of the pancreas (Williams 
and Pickup, 1988, Eknoyan, 2006). 
To the date more than 382 million people in the world have been diagnosed with 
diabetes and it has been predicted that by the year 2030, it will reach the 
pandemic levels, with 553 million diabetes patients (Wild et al., 2004, Whiting et 
al., 2011, WHO, 2013) (Fig.1.1.). It has also been projected that diabetes will be 
the 5th leading cause of death in 2030 with reduced life expectancy, 
approximately 20 years for T1D and up to 10 years in T2D (WHO, 2013). 
Currently more than 10% of the National Health Service (NHS) budget is spend 
on diabetes, which accounts for £173  million per week (DIABETES UK, 2014).  In 
the United States, there are currently 24 million patients diagnosed with 
diabetes (IDF, 2014) and the predicted number is stated to be 29 million by 2050 
(Boyle et al., 2001, IDF, 2013). In the United Kingdom, there were more than 3 
million adults diagnosed with diabetes in 2013, which was an increase, when 
compared to year 2012 and accounts for more than 6% of population (DIABETES 
UK, 2014). 
There are several pathogenic processes contributing to the onset of diabetes. 
The pancreatic β-cells and secretory insulin are known to be central to the 
pathophysiology of diabetes (Ferrannini, 2010).  
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Two main distinguished types of diabetes are known (Zimmet et al., 2001) : 
Type 1 diabetes (T1D) or insulin dependent diabetes occurs in only 10-15% of 
patients and is characterised by a deficiency in insulin secretion with the 
presence of autoimmune destruction of pancreatic β-cells responsible for 
production of insulin. Although T1D can appear at any age, it is usually diagnosed 
under the age of 40 years and very often during childhood. 
Type 2 diabetes (T2D) or adult - onset diabetes was previously known as non-
insulin dependent diabetes and is observed in 85-90% of diabetic patients. T2D is 
characterised by a resistance to insulin, combined with a failure to produce 
sufficient insulin. 
 
Fig.1.1. Global diabetes epidemic. There are approximately 382 million people with 
diabetes in the world. Taken from IDF diabetes Atlas 6th edition, 2013 (IDF, 2013). 
 
A third main type of diabetes called gestational diabetes mellitus (GDM), 
previously known as a level of glucose intolerance at onset or first recognition in 
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pregnancy (Nolan, 2011). GDM is a common disorder in pregnancy and is 
associated with adverse pregnancy outcomes, including fetal macrosomia, 
stillbirth, neonatal metabolic disturbances and related problems. GDM, defined 
as a deficient insulin supply relative to increased demands that are characteristic 
of pregnancy is an increasing problem with an incidence of 7.6%. The causes are 
not known but are closely related to a constitutional risk of type 2 diabetes in 
later life and strongly associated with obesity (Mistry et al., 2012, Williams and 
Mistry, 2013). 
Some other, less common forms of diabetes are directly inherited by the specific 
genes mutations. Mutation in the A3243G mitochondrial encoded tRNA (Leu, 
UUR) gene leads to mitochondrial diabetes, which is maternally transmitted and 
associated with hearing loss (maternally inherited diabetes and deafness, MIDD). 
The A3243G form of mitochondrial diabetes impairs metabolic pathways in  beta 
cell function (de Andrade et al., 2006). Between 1-2% of all cases of diabetes is 
diagnosed with maturity onset diabetes of the young (MODY),  caused by the 
mutation in the glucokinase or liver transcription genes, which lead to mild beta 
cell dysfunction and insulinopenia (Winter, 2000).   Diabetes is also recognised as 
a first symptom of the autosomal recessive Wolfram syndrome (Zmyslowska et 
al., 2014) also called DIDMOAD syndrome after its four most common features 
(diabetes insipidus, diabetes mellitus, optic atrophy and deafness) and in Alport 
syndrome associated with T2D, kidney failure and obesity (Kruegel et al., 2013).  
1.1.1 Diagnosis and risk factors  
It is currently recognised that T2D and GDM are caused by different aetiological 
factors including: genetic (family history, genetic markers), demographic (sex, 
age and ethnicity), metabolic (impaired glucose tolerance, insulin resistance, 
pregnancy) and life-style dependent. T1D is postulated to be caused by genetic 
and environmental factors; however in some cases, the reasons behind the 
development of this type of diabetes are unknown (Zimmet et al., 2001). T2D has 
the strongest association with obesity as the 20th century’s radical changes in 
lifestyle and food abundance have made a major contribution to the increased 
body mass index (BMI) in population (American Diabetes  Association, 2014). 
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Hypertension, coronary heart disease, obesity and insulin resistance form the 
basis of the metabolic syndrome. The exact mechanism of development of 
metabolic syndrome is not known, but low physical activity, diet (Dunn et al., 
2014) and genetic factors, especially maternal obesity (Armitage et al., 2008) are 
listed as major contributors to obesity and insulin resistance.  
Well established criteria for diabetes recognition are: high levels of impaired 
fasting plasma glucose (IFG) ≥5.6mM, impaired glucose tolerance (IGT) ≥11mM 
and high levels of glycated haemoglobin (HbA1c) ≥6,5% (Perry et al., 2001). 
1.1.2 Diabetic complications 
Sustained exposure to hyperglycaemia is a well-known cause of diabetic 
complications, including cardiovascular, renal and retinal disease (Table 1.1.). 
Patients with diabetes are at risk of stroke, kidney failure, retinopathy, 
myocardial complications and limb amputations (Vlassara and Striker, 2011, 
Brownlee, 2001).  








The pathophysiological effect of high glucose concentration on cells, tissues and 
organs involves induction of many factors, including, but not limited to oxidative 
stress, activation of pro-inflammatory gene expression and hypertension 
(Brownlee, 2005). Based on numerous studies, it is widely accepted that 
hyperglycaemia leads to increased cytosolic glucose concentrations in cells, with 
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consequent biochemical dysfunction, resulting in the activation of various 
signalling pathways (e.g. the polyol pathway, accumulation of advanced glycation 
end products (AGEs), activation of the hexosamine pathway; Fig. 1.2.) [reviewed 
in (Brownlee, 2005, Brownlee, 2001)]. Michael Brownlee suggested a unifying 
hypothesis linking all of hyperglycaemia-activated pathways, raised 










Fig.1.2. Hyperglycaemia induced tissue damage. Potential mechanism by which 
hyperglycaemia-induced mitochondrial superoxide (O2.-) overproduction activates four 
pathways of hyperglycaemic damage. Excess O2.-partially inhibits the glycolytic enzyme 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), thereby diverting upstream 
metabolites from glycolysis into pathways of glucose overutilization. This results in 
increased flux of dihydroxyacetone phosphate (DHAP) to diacyl-glycerol (DAG), an 
activator of proteinase kinase C (PKC), and of triose phosphates to methylglyoxal, the 
main intracellular advanced glycation end products (AGE) precursor. Increased flux of 
fructose-6-phosphate to UDP-N-acetylglucosamine increases modification of proteins by 
O-linked N-acetylglucosamine (GlcNAc) and increased glucose flux through the polyol 
pathway consumes nicotinamide adenine dinucleotide phosphate (NADPH) and depletes 
glutathione (GSH). Adapted from (Brownlee, 2005). ↑increase 
 
 
1.2 Diabetic nephropathy 
Diabetic nephropathy (DN) is one of the microvascular complications associated 
with diabetes and is the main cause of end stage renal disease (ESRD) (Wada and 
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Makino, 2013). Between 30-40% of patients with both types of diabetes will 
develop DN and it has been estimated that ESRD will affect up to 60% of diabetic 
patients with recognised proteinuria (Singh et al., 2008). 
The basic mechanisms behind the pathology of the disease are similar in both 
types of diabetes and the main cause of progressing fibrosis in the kidney, is 
hyperglycaemia. Results from the Diabetes Control and Complications Trial 
(DCCT, 1982-93) and the Epidemiology of Diabetes Interventions and 
Complications (EDIC, 1994-2006) follow-up study reported that insulin therapy 
with effective glycaemic control reduces the development of microalbuminuria 
by 39%, in patient with T1D. The DCCT was a randomized trial comparing 
different treatments used in diabetes while the EDIC examined longer-term 
effects of interventions used in DCCT, particularly focusing on diabetic 
complications. Data from both trials suggested that hyperglycaemia was a major 
mediator for progression of kidney disease (DCCT, 1993, de Boer and Group, 
2014) and results from the DCCT trial indicated that strict glucose control 
reduces complications in patients with T1DM. Another multicentre trial, UK 
Prospective Diabetes Study (UKPDS) demonstrated that the risk of diabetic 
complications can be decreased significantly in patients with T2D under strict 
glycaemic control.  UKPDS trial recruited 5,102 newly diagnosed patients 
monitored for up to 10 years. Results from this study showed, that patients with 
complications such as nephropathy, retinopathy and neuropathy can benefit 
from optimizing blood glucose control combined with pharmacological therapy in 
T2DM and their overall progression rate was decreased by 25%. Results from 
UKPDS also demonstrated that hyperglycaemia is the major contributor to these 
complications, but lowering blood glucose levels had no effect on macrovascular 
complications unlike control of blood pressure in all patients (King et al., 1999).  
Results from DCCT, EDIC and UKPDS suggested that early metabolic control has 
beneficial effect on management of both types of diabetes. Furthermore, in the 
EDIC study, the phenomenon of ‘metabolic memory’ was  proposed, as data 
showed that strict glycaemic control reduces development and progression of 
overall diabetes complication, by as much as 76% and between 60-84% of 
incidents of micro-and macroalbuminuria, respectively (Pop-Busui et al., 2010, de 
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Boer and Group, 2014). The molecular basis of this putative ‘metabolic memory’ 
remains unknown but strict glycaemic control should start as early as possible in 
a course of diabetes (Ceriello, 2009, Ihnat et al., 2007). 
1.2.1 Pathology and development of diabetic nephropathy 
The development of DN is complex and is proposed to involve at least three 
different mechanisms: 
The first mechanism involves haemodynamic and structural abnormalities. 
Hyperfiltration/hypertension has been characterised in DN patients as an 
increased blood pressure in glomeruli which may cause cell damage and 
contribute to the development of glomerulosclerosis. Structural changes in the 
kidney involve thickening of the glomerulal basement membrane and expansion 
of extracellular matrix, with deposition of collagen type IV and VI, fibronectin and 
laminin (Fig.1.3.) (Wolf, 2004). Changes in the kidney glomeruli also correlate 
with reduced glomerular filtration rate (GFR). Tervaert et al., proposed an 
approved classification of structural changes in DN to assess the disease 
development; starting from mild glomerular basement thickening in stage one 
and advanced glomerulosclerosis in the last stage four (Tervaert et al., 2010).  
The second mechanism involves the non-enzymatic reaction of glucose, where 
the carbonyl group reacts with proteins leading to accumulation of advanced 
glycation end products (AGEs) which have a long life time and cause renal tissue 
damage (Brosius et al., 2010). Accumulation of AGEs triggers the activation of 
transcription factors, like nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) involved in the inflammatory response and production of 
cytokines and growth factors (Lehmann and Schleicher, 2000). 
Following the inflammation, fibrosis and lesions in kidney structure lead to 
leakage of proteins into the urine, mostly albumin and this stage is called 
microalbuminuria with urinary albumin secretion from 30-300 mg/24h. Without 
proper glycemic control, microalbuminuria progresses to proteinuria, which 
manifests as a severe leakage of protein (>300mg/24h) and low GFR (Dabla, 
2010). Patient with ESRD require kidney transplants as they cannot filtrate 
metabolites from their blood effectively. 
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Fig.1.3.Progression of diabetic nephropathy. Renal biopsies (electron microscopy) taken 
from different patients, suffering fromT1D for various periods (3months to 12 years). 
There is a progressive increase in the thickness of the glomerular basement membrane 
from the normal kidney biopsy (left panel) to the narrowing capillary loops and 
expansion of extracellular matrix in nephropathy kidney biopsy (right panel). Adapted 
from (Wolf, 2004). 
 
 
A third proposed mechanism involved in the development of DN and other 
diabetic complications involves enzymatic reactions of glucose, which leads to 
increased oxidative stress. It is now well established, through animal models and 
human studies, that imbalanced free radical production and failed antioxidant 
defence are major contributors in the development of diabetic complications, 
including DN (Jennings et al., 1987, Zhai et al., 2011, Asaba et al., 2005, Lee et al., 
2003). 
1.2.2 Definition of diabetic nephropathy 
There are various tests used for detection of the renal disease, however the most 
commonly used are measurements of urine albumin and serum creatinine, as 
microalbuminuria and proteinuria are the major indications of occurrence of DN. 
To date DN is detected by monitoring kidney function through measuring urine 
albumin to creatinine ratio (ACR) and estimated GFR (eGFR; Table 1.2) 
(Mogensen, 2003, Mogensen et al., 1995). Most of the patients are diagnosed 
when the albuminuria is present and filtration rate affected (Fassett et al., 2011), 
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therefore there is a need for the discovery of new precursors of kidney damage. 
Current methods for detection of the DN are limited to the recognition of the 
albumin protein in diabetic patients’ urine samples, combined with glomerular 
filtration rate (GFR) and  albumin/creatinine ratio (ACR) (Tonelli et al., 2011). 
Albuminuria is a sign of the kidney damage; kidneys cannot properly filtrate 
substrates of metabolism and become ‘leaky’. 
 
Table 1.2. Definition of diabetic nephropathy. Adapted from (Mogensen, 2003, 
Mogensen et al., 1995) 




2.5-25mg/mmol Europe (men) 


























Currently, that there are no markers available, which either predict the 
development of the disease, or indicate early stages of kidney failure before the 
occurrence of the structural changes that are irreversible. 
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 Over the last decades a definition of five different stages of the development of 
DN have been characterised (Ritz, 2013, Pugliese, 2014): 
a) Stage 1 is defined as an early kidney hypertrophy and early hyperfiltration rate 
(increased GFR) and can be partly reversible by glycaemic control.  
b) Stage 2 is a clinically silent phase, which takes years to develop and it is 
characterised by morphologic lesion of the kidneys with increased GFR but 
without any clinical symptoms. Increased albumin excretion can be present 
during exercise (microalbuminuria with albumin loss >30mg/day). In parallel to 
albuminuria there is an increase in blood pressure 
c) Stage 3, called microalbuminuria or incipient DN is defined by the presence of 
the albumin in the urine (albuminuria with albumin loss 30-300mg/day) and 
increased GFR, some of the patients at this stage will receive hypertensive 
treatment. At this stage kidneys are not able to filtrate blood properly and 
therefore urea and creatinine levels are raised in the blood. 
d) Stage 4 is identified by the persistent proteinuria and by this stage GFR 
declines (<60ml/min). This stage is also known as advanced clinical nephropathy 
or chronic kidney failure (CKF). 
e) Stage 5 is end-stage renal failure with extensive proteinuria and very low GFR 
(less than 15ml/min). At this stage patients require dialysis or transplantation to 
survive. 
The average time for the progression from first stages of kidney dysfunction to 
stage 4 is 17 years per person and to stage 5, ESRD is 23 years. Therefore, there 
is a need for identification of new markers of kidney dysfunction in patients with 
DN in the clinically silent stage, which would help early detection of the disease 
and prevention of the organ damage.  
1.3 Oxidative stress  
Brownlee at al., (2001) suggested that one of the causes of the 
pathophysiological pathways activated in diabetes and its complications is 
hyperglycaemia-induced oxidative stress, produced by dysfunctional 
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mitochondria (Brownlee, 2001). Oxidative stress occurs when the balance 
between endogenous antioxidants and intracellular reactive oxygen species 
(ROS) is disturbed; with the body’s natural antioxidant defence capacity 
becoming defective, thus creating an pro-oxidative environment (Halliwell, 
2007). Postulated to play an important role in many mammalian diseases, 
oxidative stress contributes to cell damage and cell death through pathological 
reactions of free radicals (Coughlan et al., 2009, Halliwell and Gutteridge, 2007). 
1.3.1 Free radicals 
Free radicals are the molecules with an extra electron and are called either ROS 
or reactive nitrogen species (RNS) (Posada et al.) due to their spontaneous ability 
to bind to other molecules and compounds (Halliwell, 2011). Most of ROS are 
oxygen derivates (e.g. superoxide ion (O2•-), peroxyl radical (HO•), hydrogen 
peroxide (H2O2). Oxygen derivates contribute to oxidative stress, while  RNS, 
such as nitric oxide (NO) and peroxynitrate (HNOO-) cause nitrative stress 
(Bashan et al., 2009). Proteins, lipids and nucleic acids serve as targets for 
oxidative reactions, which lead to creation of reactive intermediates (Hensley et 
al., 2000).   
The main source of ROS/RNS in the cell are (a) the mitochondrial respiratory 
complexes, where accidental leakage of the electrons can occur (Halliwell and 
Gutteridge, 2007) and (b) the nicotinamide adenine dinucleotide phosphate-
oxidase (NADPH oxidase) located in the cellular membrane and nitric oxide 
synthase (NOS) (Halliwell, 2011). The production of free radicals is also triggered 
by hormones and growth factors, endoplasmic reticulum (ER) stress, 
inflammation and nutrients (Bashan et al., 2009). Under normal conditions, 
oxidants are scavenged by endogenous antioxidant enzymes such as manganese 
superoxide dismutase (MnSOD, SOD2), catalase (Catherwood et al.), and 
glutathione peroxidase (GSH), which are abundantly present in cells. However, in 
the case of chronic over production of free radicals, antioxidant defences 
become overwhelmed and there is a resultant imbalance in the redox state of 
cells. Interestingly, free radical production is not always a bad thing and it is 
important to mention there is always a certain level of ROS molecules within the 
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cell, required for cell signalling. It has been shown that ROS molecules are very 
important in the immune and cardiovascular system, gene stimulation and 
protein production (Halliwell, 2011, Stanton, 2011). 
1.4 The Mitochondrion 
A commonly accepted ’endosymbiotic theory’ proposes that mitochondria 
developed from a symbiosis between eukaryotic cell and α-proteobacterium 
more than 1.45 billion year ago (Gray et al., 1999). Mitochondrial ribosomes and 
transfer RNA molecules are similar to those of bacteria, as are components of 
their membrane. Mitochondria are key cellular organelles involved in energy 
metabolism and are often called the ‘powerhouses’ of the cells. The main role of 
mitochondria is production of adenosine triphosphate (ATP), an energy molecule 
required for cell biological processes. ATP is synthesised in the mitochondrial 
matrix through the Krebs cycle (also known as a tricarboxylic acid cycle, TCA), 
during oxidative phosphorylation (OXPHOS). Mitochondria also play a part in 
cellular division and sustaining the redox state of cells (Shadel, 2005) as well as 
many other important processes like apoptosis, calcium homeostatis, cellular 
differentiation and growth (Green and Reed, 1998, Chan, 2006). The main 
compartments of mitochondrial structure are the: outer membrane, 
intermembrane span, inner membrane, matrix and cristae (membrane 
compartments) (Fig.1.4).  
Electron transport chain (ETC) proteins are located in the inner mitochondrial 
membrane. There are five main complexes distinguished (Gray et al., 1999, Sivitz 
and Yorek, 2010) (Fig.1.5.): 
* complex I (NADH- ubiquinone oxidoreductase ) 
* complex II (sdh -succinate dehydrogenase) 
*complex III (bc1, ubiquinol-cytochrome c oxidoreductase) 
*complex IV (cytochrome c oxidase, COX) 
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Fig.1.4. Structure of the mitochondria. Mitochondria are built from outer and inner 
membrane and mitochondrial matrix and cristae. The outer membrane is permeable for 
molecules such as ATP/ADP, the inner membrane is more complex in structure and 
folded into cristae. The inner membrane is permeable only to oxygen, ATP and it also 
helps in regulating transfer of metabolites across the membrane. Matrix contains 
proteins, mitochondrial ribosomes, tRNAs and circular mitochondrial DNA. Taken from 
(Tutorvista, 2014).  
 
90% of the oxygen is channelled into mitochondria and energy derived from 
OXPHOS accounts for approximately 88% of total cellular energy produced 
(about 28/32 total ATP molecules). The rest of cellular energy is produced about 
equally from substrate level phosphorylation through glycolysis in the cytoplasm 
and through the TCA cycle in the mitochondrial matrix (2 ATP molecules each) 
(Seyfried and Shelton, 2010). 
The ATP is synthesised through the redox potential created by nicotinamide 
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), reduced 
coenzymes, generated by the acceptance of electrons derived from the 
breakdown of organic substances in the TCA cycle. Four protein complexes in the 
inner membrane make up the ETC, which converts the redox energy, stored as 
NADH and FADH2 into chemical energy in the form of ATP. Complexes I and II 
receive electrons, donated from NADH and FADH2, respectively, followed by 
their shuttling to complexes III and IV and their final donation onto an oxygen 
molecule, creates H2O. 
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Fig.1.5. Mitochondrial electron transport chain and oxygen radical production by 
respiratory chain complex, located in the inner mitochondrial membrane. Electrons 
donated by NADH enter mitochondria at complex I. Electrons generation in complex II 
have many ways: through conversion of succinate to fumarate, electron transfer 
flavoprotein and mitochondrial type of GAPDH. Reduction of ubiquinone (coenzyme Q10) 
in complex III produces protons and electrons which are transferred to cytochrome C 
and cytochrome c oxidase in complex IV. Complex IV reduces oxygen to water and this is 
the end stage of respiration. Generation of protons by complexes I, II and III contributes 
to the synthesis of ATP by the ATP synthase. Mitochondrial DNA (MtDNA) codes for 13 
OXPHOS polypeptides while nuclear DNA (nDNA) codes for 74 OXPHOS proteins. 
Adapted from (Blake and Trounce, 2014). 
 
 
1.4.1 Mitochondrial biogenesis  
Mitochondria are present in the cytoplasm in hundreds to thousands per cell and 
each mitochondrion can contain 2-10 copies of 5-μm circular MtDNA (Fig.1.6.). 
The number of mitochondria in cells is dependent on energy requirements and 
can vary from more than hundred thousands of mitochondria in oocytes (Piko 
and Matsumoto, 1976), to thousands in the brain (Uranova et al., 2001) and less 
than a hundred in the white blood cells (Selak et al., 2011). 
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Fig.1.6. Mitochondria contain their own circular genome. Each mitochondrion contains 
between 2-10 copies of circular, double-stranded MtDNA. Adapted from National 
Human Genome Research Institute (NIH, accessed on 1st Sep, 2014). 
 
The organisation of MtDNA is strongly conserved between organisms, in humans, 
MtDNA is present as a 16,569 bp double-stranded, circular structure, which 
encodes 37 genes; 13 mRNAs, 2 rRNAs and 22 tRNAs (Falkenberg et al., 2007). 
MtDNA is present in cells as a super coiled structure and unlike nDNA, is not 
protected by proteins, MtDNA is doubled stranded and built form heavy (H, on 
the outside) and light (L, on the inside) strands (Fig.1.7). Large number of MtDNA 
molecules in the cells are present as triple stranded structures, which contain D-










Fig.1.7. Human mitochondrial DNA. MtDNA encodes 22 tRNA, the 12 S and the 16 S 
rRNA and 13 genes of OXPHOS system subunits. Taken from (Bellance et al., 2009). 
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Most of the genes from the symbiont were transferred to the nuclear 
chromosomes, therefore despite essential mitochondrial coding, mitochondrial 
transcription and replication involves nuclear engagement as the majority of 
1,500 mitochondrial proteins are encoded in nuclei, then synthesised as 
precursors in the cytosol and transported to mitochondria for further processing. 
Mitochondrial DNA (MtDNA) codes for 13 OXPHOS polypeptides while nuclear 
DNA (nDNA) codes for 74 OXPHOS proteins (Blake and Trounce, 2014). Genes 
coding for all 13 proteins that are subunits for OXPHOS complexes are 
asymmetrically distributed in MtDNA and localised on both strands, the H-strand 
contains coding information for 12 OXPHOS polypeptides, while L-strand has only 
coding information for one of the complex I subunit, ND6 (Fernandez-Silva et al., 
2003). 
MtDNA is transcribed and translated within mitochondrion, however cells can 
control its transcriptional activity and MtDNA do not replicate like phase-
restricted nDNA and can be continuously multiplied (Maechler and Wollheim, 
2001, Falkenberg et al., 2007). Unlike nDNA, which is biparental, MtDNA is of 
uniparental inheritance and also have a higher mutation rate (Fernandez-Silva et 
al., 2003). MtDNA do not contain introns and only have two non-coding regions, 
a 1000 bp long D-loop region (which contains the origin of replication for H-
strand) and the origin of replication for L-strand, which is approximately 30 bp 
long (Fernandez-Silva et al., 2003). 
MtDNA replication is regulated by heterotrimeric MtDNA polymerase (POLG), 
the hexameric DNA helicase TWINKLE and the tetrameric single-stranded DNA-
binding protein (mtSSB)(Milenkovic et al., 2013). MtDNA transcription requires 
mitochondrial RNA polymerase (POLRMT) and also transcription factors, which 
help POLRMT recognise MtDNA promoters. These three transcription factors 
include, mitochondrial transcription factor A (TFAM); mitochondrial transcription 
factor B 1 and 2 (TFB1M, TFB2M); nuclear respiratory factor 1 and 2 (NRF1 and 
NRF2) and Peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α) (Leigh-Brown et al., 2010, Fernandez-Silva et al., 2003). 
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MtDNA is organised in cells in the form of nucleoids, which contain molecules of 
MtDNA and several proteins involved in mitochondrial replication e.g. TFAM, 
which seem to be a major regulatory element of MtDNA copy number and also 
play a protective role against oxidative stress (Falkenberg et al., 2007). However, 
it has been shown using a transient over-expression of TFAM in cultured human 
embryonic kidney (HEK) cells, that only small increase of TFAM protein can have 
stimulatory effects on mitochondrial transcription, and high levels of TFAM have 
an inhibitory effect on the transcription rate (Maniura-Weber et al., 2004). Choi 
at al., (2001) have suggested a link between increased TFAM levels and MtDNA 
damage, caused by oxidative stress (Choi et al., 2001). 
Although several proteins can bind to MtDNA, it is not protected against 
oxidative damage or repaired like nDNA. One has to remember that MtDNA are 
exclusively responsible for coding only 13 subunits of OXPHOS proteins, which 
are detrimental to the ‘well-being’ and proper function of the cells. Accidental 
leakage of electrons in the electron chain stimulates ROS production and 
oxidative damage to MtDNA, which causes accumulation of mutations. Increased 
numbers of mutations in MtDNA are the main cause of mitochondrial 
dysfunction and also results in increased free radical production by the 
overworked mitochondria, damaging MtDNA even more through a vicious cycle. 
Moreover, mitochondrial lipids are very sensitive to ROS-induced lipid 
peroxidation as they contain great amounts of unsaturated fatty acids, when 
oxidised, their derivates can further damage mitochondrial proteins and DNA 
(Ma et al., 2009). It has been shown in isolated rat cardiomyocytes exposed to 
H2O2, that the amount of intact MtDNA decreased by half as quickly as within 15 
minutes after treatment (Suematsu et al., 2003). 
Therefore, any mutation in the MtDNA sequence may have a detrimental effect 
on mitochondrial function and contribution to the increase of the ROS though 
the vicious cycle caused by malfunctioning mitochondria. When the number of 
mutated mitochondria is greater than the wild type, there are disturbances in 
energy production and this may contribute to the development of several 
diseases such as cancer, diabetes, HIV as detailed in section 1.4.3 (Wallace and 
Fan, 2010). 
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1.4.2 Mitochondrial dynamics 
Mitochondria are not static organelle and they are constantly undergoing a 
process of fusion and fission. Fusion is maintained by mitofusin1, 2 (MFN1 and 
MFN2) and optic atrophy gene 1 (OPA1) (Fig.1.8). The way mitochondria select 
their ‘partners’ to fuse is not known. One possibility is a membrane potential, as 
by the fusion process some mitochondria can rescue their falling membrane 
potential (Twig and Shirihai, 2011). Fission which leads to mitochondrial 
fragmentation ismediated by three proteins, mitochondrial fission protein 1 
(FIS1), mitochondrial fission factor (MFF) and dynamin-related protein 1 (DRP1). 
Fission can precede mitochondrial removal, process called mitophagy which is 








Fig.1.8. A schematic illustration of mitochondrion’s life cycle. Mitochondria cyclically 
shifts between a post fusion state (networked) that lasts tens of seconds and a post 
fission state (solitary) that can last tens of minutes. Following a fission event, the 
mitochondrion can depolarize and restore an intact potential (thick arrow) or remain in 
a depolarized level. Removal of dysfunctional mitochondria by autophagy is based on 
drop in mitochondrial membrane potential which triggers cleavage of OPA1, 
accumulation of PINK1/PARK2, and reduction in mitofusin capacity. The mitochondrion 
may spend several hours in this pre-autophagic state before targeted by the autophagy 
machinery. Adapted from (Twig and Shirihai, 2011). 
 
 
39 | P a g e  
 
Chapter 1: Introduction 
All of the listed proteins are located in the mitochondrial outer and inner 
membranes, but DRP1 is restricted cytosolic protein and has to translocate to the 
mitochondria during the fission process. OPA1 has also been shown to take part 
in the apoptosis process, when it is released from the mitochondria into cytosol. 
Both fission and fusion take place due to the hydrolytic activities of the 
mediating proteins (Ashrafi and Schwarz, 2013). It has been reported that by the 
addition of mitochondrial membrane potential couplers and uncouplers, the 
process of fusion and fission can be modulated, another important factor is 
nutrient availability or excess, which can affect mitochondrial network structure 
(Liesa and Shirihai, 2013). 
1.4.3 Diseases linked to mitochondrial dysfunction and altered levels of 
mitochondrial DNA 
In healthy conditions, the amount of MtDNA is proportionally correlated with 
mitochondrial function, as well as the number of mitochondria. They are flexibly 
regulated, due to the energy metabolism demand and redox state of the tissues 
(Hock and Kralli, 2009, Williams, 1986) . However, this does not seem to be the 
case in disease states. To date there have been many diseases attributed to 
mitochondrial dysfunction [reviewed in (Malik and Czajka, 2013)]. Altered 
mitochondrial genome, impairment of respiratory chain function and changes in 
mitochondrial copy number have an impact on development of variety of 
diseases such as Alzheimer’s (Coskun et al., 2010), several types of cancers 
(Harbottle and Birch-Machin, 2006, Hosgood et al., 2010, Radpour et al., 2009, 
Lee et al., 2005, Shen et al., 2010), cardiovascular complications (Makazan et al., 
2007, Tsutsui, 2006), myopathy (Durham et al., 2005) and maternally inherited 
mitochondrial diabetes (Alcolado et al., 2002). As shown in the tables 1.3 and 
1.4, MtDNA content has been assessed in different tissues and body fluids in 
various diseases. The onset of clinical symptoms, caused by mitochondrial 
dysfunction/MtDNA mutations are caused by a number of factors, including the 
threshold effect, mitotic segregation, and a genetic bottleneck (Tuppen et al., 
2010). 
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Table.1.3. Mitochondrial DNA content in human tissues and cells. Taken from (Malik 
and Czajka, 2013). 









Tissue Ovarian tumour ↑ (Wang et al., 2006) 
Breast cancer ↓ (Yu et al., 2007) 
↓ (Fan et al., 2009) 
↓ (Bai et al., 2011) 
↑ (Hsu et al., 2010) 
Hepatocellular  carcinoma ↓ (Yamada et al., 2006) 
Biliary artresia and non-
alcoholic fatty liver disease 
↓ (Tiao et al., 2007) 
 
Pancreatic islets-aging ↓ (Cree et al., 2008) 
Adipose tissue in metabolic 
syndrome 
↑ (Lindinger et al., 
2010) 
↑ (Kaaman et al., 2007) 
↓ (Bogacka et al., 
2005) 
Renal carcinoma ↓ (Meierhofer et al., 
2004)  
Brain- aging ↑ (Barrientos et al., 
1997)  
Multiple sclerosis ↑ (Blokhin et al., 2008)  
Nasal polyps ↑ (Park et al., 2009)  
Cells/ Cell 
lines 
Prostate cancer cells ↑ (Mizumachi et al., 
2008) 
Adipocytes in HIV therapy ↓ (Hammond et al., 
2004)  
Nerve cells in HIV ↓ (Dalakas et al., 2001)  
Lymphoblast cells In HIV 
therapy 
↑ (Bjerke et al., 2008)  
Oocytes –fertilisation  and its 
complications 
↓ (Zeng et al., 2009) 
↓ (May-Panloup et al., 
2005) 
↓ (Santos et al., 2006)  
Pimary culture neurons after 
radio frequencies exposure 
↓ (Xu et al., 2010)  
 
Endometrial adenocarcinoma ↑ (Wang et al., 2005)  
41 | P a g e  
 
Chapter 1: Introduction 
 Table.1.4. MtDNA content in body fluids. Taken from (Malik and Czajka, 2013). 
↑, increased; ↓, decreased 





Breast cancer ↑ (Shen et al., 2010) 
Breast cancer ↓ (Xia et al., 2009) 
Lymphoblastic lymphoma ↑ (Kwok et al., 2011)  
Type 2 diabetes ↓ (Lee et al., 1998) 
Type 2 diabetes ↑ (Wong et al., 2009) 
Type 2 diabetes ↓ (Xu et al., 2011) 
Type 2 diabetes ↓ (Song et al., 2001) 
Type 2 diabetes ↑ (Weng et al., 2009a) 
Type 2 diabetes ↑ (Cormio et al., 2009) 
Diabetic nephropathy ↑ Malik et al., 2009  
Intrauterine  growth 
restriction 
↑ (Colleoni et al., 
2010) 
Benzene exposure ↑ (Carugno et al., 
2012) 
PBMCs Sepis ↑ (Pyle et al., 2010) 
HIV -treatment ↓ (Chene et al., 2007) 
PBMCs  
Leukocytes 
Non-Hodgkin lymphoma ↑ (Lan et al., 2008) 
Hepatitis B virus related 
carcinoma 
↓ (Zhao et al., 2011) 
Colorectal cancer ↑ (Qu et al., 2010) 
Type 2 diabetes ↓ (Gianotti et al., 
2008a) 
Renal failure ↑ (Chen et al., 2008) 
Autosomal dominant optic 
atrophy 




HIV complications ↑ (Cossarizza et al., 
2003) 
HIV- treatment interruption ↑ (Mussini et al., 2005) 
 Type 2 diabetes ↓ (Khan et al., 2011) 
Lymphoblasts HIV ↑ (Bjerke et al., 2008) 
Blood Serum Testicular cancer ↑ (Ellinger et al., 2009) 
Blood plasma Hemodialysis ↑ (Wang et al., 2011) 
Sepsis ↑ (Garrabou et al., 
2012) 
Urine pellets Urothelial cell carcinoma ↑ (Dasgupta et al., 
2012) 
Saliva Head and neck cancer ↑ (Jiang et al., 2005) 
Smoking ↑ (Masayesva et al., 
2006) 
Sperm Infertility ↓ (Kao et al., 2004) 
Fertility ↑ (Amaral et al., 2007) 
Cerebrospinal 
fluid 
Lymphoblastic  leukemia ↑ (Egan et al., 2010) 
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1.4.4 Mitochondrial dysfunction in diabetes 
It has been proposed that ROS/RNS play an important role in insulin action and 
resistance, as they are produced in response to insulin and they are also 
necessary for its action (Bashan et al., 2009).  Insulin  secretion in response to 
glucose can be divided into two phases, the first involves activation of ATP – 
sensitive K+ channels (KATP ) and the second phase is KATP channel independent, 
with calcium signalling and ROS formation (from both mitochondria and cellular 
NADPH) as the main factors (Szabadkai and Duchen, 2009).  Goldstein at al., 
(2005) discussed in great detail the involvement of insulin in ROS production. 
They reported stimulation of ROS production, mostly H2O2 in adipocytes treated 
with insulin. When cells were then treated with NADPH oxidase blocker, reduced 
insulin-stimulated H2O2 production was observed, followed by reduction in IRS-
1/2 tyrosine phosphorylation, through inhibition of protein-tyrosine 
phosphatases (PTPases). PTPases are key negative regulatory enzymes in insulin 
action, therefore when ROS blocks their enzymatic activity, an increase in 
activation of phosphorylation of insulin receptor substrates is observed. The 
generation of ROS by insulin may be enhanced by high glucose conditions, which 
increases mitochondrial superoxide production (Figure 1.9.)(Mahadev et al., 
2001, Goldstein et al., 2005).  
Mitochondrial ROS production may also be important in development of T2D 
through mediating tumor necrosis factor-alpha (TNF-α) signalling pathway. TNF-
α inhibits insulin action by regulating apoptosis signal-regulating kinase 1 (ASK1), 
followed by the activation of proteins involved in serine phosphorylation of 
insulin receptor substrates (IRS-1 and IRS-2) and decrease in insulin-stimulated 
tyrosine phosphorylation of IRS-1 (Nishikawa et al., 2007).  
Imoto at al., (2006) conducted experiments on hepatocarcinoma cells and 
reported stimulatory effect of TNF-α on mitochondrial ROS production and ASK1 
activation. All of the stimulatory actions of TNF-α were reverted by over 
expressing the mitochondrial antioxidant defence enzyme MnSOD and 
uncoupling protein 1 (UCP1), which take part in reducing the proton gradient in 
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oxidative phosphorylation. These data suggest a key involvement of 








Fig.1.9. Insulin stimulated mitochondrial free radicals production. The generation of 
cellular reactive oxygen species (ROS) to insulin is coupled to the plasma membrane 
NADPH oxidase mechanism. Superoxide generated by the NADPH system is converted to 
H2O2 by superoxide dismutase. Both of these ROS can play a role in regulation of the 
catalytic activity of thiol dependent regulatory enzymes in the cells. The generation of 
ROS by insulin may be enhanced by high glucose conditions, which increase 
mitochondrial superoxide production and may also activate NADPH oxidase system. 
Taken from (Goldstein et al., 2005). 
 
Another pathway of glucose action has also been observed; generation of 
glucose derived metabolites such as pyruvate (created in the process of 
glycolysis) also contributes to ROS production. Pyruvate is transported into 
mitochondria and after being metabolised, it increases the ATP/ADP ratio, 
consequently enhancing ROS/RNS formation (Szabadkai and Duchen, 2009). Free 
radicals serve as intracellular messengers and can also stimulate the same 
pathway as glucose (e.g. activation of the PKC). Excessive activation of PKC leads 
to tissue injury, through activation of transforming growth factors and NF-κB, 
causing an inflammatory response within the cells (Pugliese et al., 1994). Lee et 
al.,(2003) demonstrated that culturing renal cells under high glucose conditions 
augments the production of ROS and that this stimulation of free radical 
generation can be effectively blocked by PKC inhibitors (Lee et al., 2003). 
Catherwood et al., (2002) used in vitro cultured mesangial cells and observed 
unpaired antioxidant activity, including MnSOD under high glucose conditions 
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(Catherwood et al., 2002). These studies show an increased formation of free 
radicals and defective antioxidants systems in cells exposed to hyperglycaemia. 
The key evidence of mitochondrial contribution and importance in 
hyperglycaemic damage was demonstrated previously by Nishikawa et al., 
(2000), who by using pharmacological inhibitors and over-expressed proteins, 
showed three different pathways potentially involved in mitochondrial 
superoxide ion production in bovine aortic epithelial cells cultured in high 
glucose. Normalising high glucose-induced ROS levels prevented increased 
activation of protein kinase C and NF-κB, aldose reductase pathway and 
formation of AGE (Nishikawa et al., 2000). Oxidative stress markers have been 
reported previously in the urine and serum of the diabetes patients with DN and 
microalbuminuria (Cvetkovic et al., 2009) and in the kidneys of diabetic rats (de 
Haan et al., 2005) 
Altered MtDNA content in circulating cells has been previously reported in 
diabetes, some reports showing an increase (Malik et al., 2009, Weng et al., 
2009b, Khan et al., 2011), whereas others show a decrease (Lee et al., 1998, 
Gianotti et al., 2008b, Chien et al., 2012) or no change (Asmann et al., 2006, 
Garcia-Ramirez et al., 2008). The discrepancies observed in the results from 
different studies are caused by the problems/variations with the methodologies 
used, including different methods of DNA extraction and accurate detection 
MtDNA content, without measurement of the pseudogenes (Malik et al., 2011). 
Also, the direction of changes may vary between different tissues and the way 
they responded to glycaemic stress may be dependent on their energy 
requirements. 
Dysfunction of mitochondria in correlation to MtDNA levels has been shown in 
diabetic mouse muscle tissues (Bonnard et al., 2008), in connection with 
increased ROS. A recent study identified 12 differentially expressed urinary 
metabolites linked to mitochondrial metabolism, lower MtDNA content and 
mitochondrial activity in the DN patients (Sharma et al., 2013). Altered 
mitochondrial structure and lower mitochondrial membrane potential have been 
highlighted in ischemic kidney injury in the rat kidney (Plotnikov et al., 2007), and 
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depleted mitochondrial function, which correlated with increased mitochondrial 
fragmentation in mouse in-vitro model of acute kidney injury (Brooks et al., 
2009). 
1.5 Model systems used in the current study to assess early 
stages of diabetic nephropathy. 
Diabetic nephropathy is a very complex disease and it takes more than 10 years 
to develop in patients with diabetes. Therefore using animal models and in-vitro 
systems proved to be challenging to study this disease. The most commonly used 
animal models to study DN are hypertensive rodents as hypertension is one of 
the contributing factors in renal morbidity (Kopp, 2013, Herrera and Coffman, 
2012). However studies of diabetic mice suggest that, like diabetes patients, mice 
can exhibit susceptibility to diabetes and also renal and cardiovascular diseases 
(Sugiyama et al., 2001, Paigen et al., 1987). The Animal Models of Diabetic 
Complications Consortium (AMDCC) defined criteria for validating murine models 
of human diabetes and diabetic complications: with more than 50% decline in 
GFR over the lifetime of the animal, more than 10-fold increase in albuminuria 
(when compared with controls from the same strain) and with distinct pathology 
of the kidneys (advanced mesangial matrix expansion, basement membrane 
thickening by more than 50% over baseline and tubulointerstitial fibrosis) 
(Brosius et al., 2009). 
1.5.1 In-vivo: rodent models 
In the current study three different mouse models of diabetes were used (Table 
1.5) in order to investigate early changes in organs and circulating cells caused by 
hyperglycaemia. Streptozotocin-induced (STZ-induced) diabetic mouse were 
used as a mouse model of T1D. The chemical structure of STZ is similar to 
glucose; therefore the compound is delivered to the cells through GLUT-2 
transporter. STZ specifically targets β-cells and causes cell necrosis through the 
depletion of ATP (King, 2012). Second mouse model of T1D were Prohibitin 2 
knockout mice (β-PhB2-/-) which represent a model of spontaneous diabetes 
progression, through a series of molecular events which appear after 3 weeks 
and not require administration of chemicals such as STZ (Supale et al.,2013). 
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Therefore, we used this spontaneous model of diabetes for an examination of 
the MtDNA content in the presence of hyperglycaemia in parallel to STZ-induced 
diabetic mice. The Lep ob/ob (ob/ob) recessive obese mice were also used in 
current study, as a mouse model of T2D. Ob/ob mice carry a mutation in the 
leptin gene which leads to uncontrolled appetite and quick weight gain (Chua et 
al., 1996). Detailed information about mouse models used is provided in chapter 
4. 
Table 1.5. Mouse models used in the study 
Acronym Type 1 diabetes Method of 
generation 
References 
STZ T1D Chemical (Rackham et al., 
2013) 
β-PHB2-/- T1D Knockout (Supale et al., 2013) 
ob/ob T2D Mutation selection (Ingalls et al., 1950) 
 
While in-vivo studies provide valuable information about the disease, since the 
changes are systemic, it makes it difficult to study individual pathways and 
establish direct effects of hyperglycaemia on single type of cells. Using in-vitro 
models of cultured renal cells allows the researcher to manipulate experimental 
conditions in a way it might not be ethically possible in the in-vivo experiments 
and study early stages of the disease. 
1.5.2 In-vitro: cultured kidney cells 
1.5.2.1 Mesangial cells 
Mesangial cells are specialised cells located around the glomerular capillaries 
within the renal corpuscle of the kidney. They have several functions, including 
carrying out the deposition of the matrix which results from increased 
glomerular filtration pressure. However, in DN, these cells contribute to the 
development of the disease, through expansion of the matrix into the capillary 
lumens and the secretion of pro-inflammatory cytokines (Wada et al., 2001) and 
are considered to be key mediators of glomerular inflammation and fibrosis 
(Wani et al., 2007). Progression of diabetic nephropathy is associated with 
structural changes in the kidney like thickening of the glomerulal basement 
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membrane and expansion of extracellular matrix with deposition of collagen type 
IV and VI, fibronectin and laminin (Wolf, 2004). The diabetic glomerulosclerosis is 
characterised  by mesangial accumulation of extracellular matrix proteins such as 
laminin, collagen IV and fibronectin genes (Tervaert et al., 2010). 
A number of in-vitro studies have suggested that hyperglycaemia can modify 
mesangial cell function and could contribute to changes observed in the DN. A 
study by Wolf et al., (1992) showed a different rate of proliferation in mouse 
mesangial cells exposed to high glucose (Wolf et al., 1992). Clarkson at el. (2002) 
by using a hybridization technique identified 200 genes differentially expressed 
in human mesangial cells incubated in high glucose. Most of the identified genes 
included modulators and products of extracellular matrix protein metabolism 
and regulators of cell growth and turnover (Clarkson et al., 2002). Many reports 
also showed an increased ROS and ROS-induced inflammatory pathways in 
mesangial cells in response to hyperglycaemia (Catherwood et al., 2002, Ha and 
Lee, 2003, Zhang et al., 2011, Al-Kafaji and Malik, 2010). These reports support 
the idea, that the alterations in pathways signalling in mesangial cells in response 
to hyperglycaemia may be involved in the development of DN. 
1.5.2.2 Tubular cells 
DN is often considered to be primarily a glomerular disease however 
glomerulopathy is only found in a one-third of a patients with T2D and 
microalbuminuria while other patients have a normal glomerular structure but 
present severe tubulointerstitial lesions (Gilbert and Cooper, 1999, Dalla Vestra 
et al., 2000). The progression of renal disease, characterized as pathogenic 
mechanisms that lead to progressive interstitial fibrosis, peritubular capillary loss 
and destruction of functioning nephrons due to the tubular atrophy (Eddy, 2005). 
Proximal tubule epithelial cells create the lining of the duct within nephrons 
leading to the Bowman's capsule. Although major pathogenic mechanisms in DN 
development involves glomerular fibrosis, through mesangial expansion, it is 
now known that tubular epithelial cells are also affected by inflammation (Bohle 
et al., 1991). 
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In addition to inflammation, interstitial fibrosis is a major determinant of 
progressive renal disease. For instance, albumin stimulated proximal tubular 
epithelial cells to produce TGF-β which is the most effective cytokine for renal 
fibrogenesis (Liu and Butow, 2006). Another study demonstrated increased 
expression of toll like receptor 4 (TLR4) via PKC activation in proximal tubular 
cells cultured in high glucose (Lin et al., 2012). Kidney injury molecule-1 (KIM-1) 
was demonstrated to be released from proximal tubular cells by the exposure to 
high glucose and AGE in parallel with increased ROS (Lim et al., 2014a). Lee at al., 
(2014) showed increased mitochondrial respiration and complexes activity in 
mitochondrial renal tubule cells from spontaneously hypertensive rats (Lee et al., 
2014). Peng at al., (2014) demonstrated activation of mitochondrial mediated 
apoptosis and ATP depletion in high glucose-conditioned renal 
proximal tubular cells (Peng et al., 2014). These studies support the view that 
tubular cells can also contribute to the development of DN. 
1.6 Background of the study 
A number of novel genes that are regulated by high glucose in rodent models of 
diabetes and mesangial cells grown in high glucose have been identified 
previously in our group, in an attempt to find novel therapeutic targets for DN.  
In 1997, using mRNA fingerprinting in rat model of diabetes, our group identified 
several genes that were up regulated in the kidney, during the development of 
diabetes. A number of changes in mRNA expression under hyperglycaemic state 
were detected in genes specific for mitochondrial genome (Table 1.6.) (Page et 
al., 1997). This led to further research and more focus on the possible 
correlations between mitochondria, progression of diabetes mellitus and 
development of DN. 
Further findings showed that patients with diabetes and proteinuria had 
elevated levels of MtDNA circulating in their blood, when compared to the 
healthy controls and patients with diabetes, but without proteinuria (Malik et al., 
2009). Also unpublished results from our group obtained from two experiments; 
a diabetic Goto-Kakizaki rat (GK-rat) study and in-vitro cultured renal cells 
suggested increased MtDNA copy caused by hyperglycaemia. MtDNA content 
was significantly increased in kidneys of diabetic animals, when compared to the 
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age matched controls (Malik and Al-Kafaji unpublished) and also significantly up-
regulated in renal cells cultured for 3 days in 25mM glucose (Malik unpublished). 
These results suggest there may be a correlation between mitochondrial 
biogenesis and development of kidney disease in diabetes. 
Table 1.6. Increased mitochondrial mRNAs in the diabetic rat kidney. cDNA fragments 
corresponding to mitochondrial genes up-regulated in hyperglycaemia in diabetic GK rat 









To date, very little is known about mitochondria biogenesis, replication and 
degradation and there are many discrepancies in the literature about MtDNA 
content in diabetes, probably due to the pitfall of the methodology used for the 
quantification (Lee et al., 1998, Rolo and Palmeira, 2006, Hsieh et al., 2011, Singh 
et al., 2007, Gianotti et al., 2008, Weng et al., 2009). A common method for 
measuring MtDNA content is by using real-time qPCR assay and mitochondrial 
encoded gene to nuclear encoded gene ratio. However there are several 
problems with using mitochondrial specific primers as mitochondrial genome is 
widely duplicated in the nuclear genome (Fig.1.10), therefore many of the 
commonly used MtDNA primers co-amplify homologous pseudogenes.  
Clone Identity 
CDK2 NADH ubiquinone oxidoreductase  42KD subunit precursor 
CDK110 mitochondrial cytochrome b 
CDK116 RM NADH dehrogenase subunit 
CDK117 RM cytochrome C oxidase subunit I 
CDK118 RM cytochrome C oxidase subunit I 
CDK120 RM cytochrome C oxidase subunit II 
CDK121 RM NADH dehrogenase subunit 5 
CDK123 RM cytochrome C oxidase subunit I 
CDK124 RM cytochrome C oxidase subunit I 
CDK125 RM cytochrome C oxidase subunit I 
CDK126 RM cytochrome C oxidase subunit I 
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Fig.1.10. Duplication of the mitochondrial genome in the nuclear genome: The 
mitochondrial genome sequence accession number NC-001807, was blasted against the 
reference sequence of the human genome using blast, the first 50 best matching 
sequences are shown, the top red line being an exact match to the mitochondrial 
genome, whereas the remaining 49 lines are regions of the nuclear genome showing a 
high degree of identity. The colour key for alignment scores is given at the top of the 
figure with red being the highest alignment score (A). Mitochondrial pseudogenes in the 
nuclear genome are shown as bars against the relevant human chromosome, the extent 
of the homology is shown as a colour code indicated in and the number of hits is shown 




Secondly, using regions from nuclear genes such as β-actin and 18S rRNA as 
experimental controls which are repetitive and/or highly variable leads to errors. 
Also errors during DNA extraction, dilution (the size difference of mitochondrial 
and nuclear genomes cause a ‘‘dilution bias’’ when template DNA is diluted) and 
storage may affect the results. A unique assay developed in our group previously, 
for assessing MtDNA content using mitochondrial genome specific primers and 
optimised preparation of the samples, allows avoiding bias in co-amplifying 
mitochondrial sequences, which are duplicated in the nuclear genome. The 
content of MtDNA is assesed as a ratio of mitochondrial to nuclear genome and  
Beta-2 microglobulin ( B2M) is used as a single copy gene for the nucelar control 
(Malik et al., 2011). 
A) B) 
51 | P a g e  
 
Hypothesis and Aims 
1.7 Hypothesis and Aims  
Although mitochondrial dysfunction has been proposed to be a key mechanism 
in the development of DN and diabetic complications, the main mechanisms 
leading to this are not fully understood. DN develops over decades of clinical 
silence and currently there are no biomarkers which allow detetction of the early 
clinically silent stages of DN. The main hypothesis that will be tested in this thesis 
is that hyperglycaemia/high glucose can cause early changes in mitochondrial 
DNA (content/quality) and that these changes can contribute to mitochondrial 
dysfunction.  
Aims and objectives: 
The major aim of this thesis is to test the hypothesis that glucose-induced 
changes in MtDNA contribute to mitochondrial dysfunction and that this process 
is involved in the damage to the kidney that results in development of DN. 
This aim will be met by undertaking the following objectives: 
1. I will examine whether hyperglycaemia can alter MtDNA content in 
cultured renal cells and whether any such changes are permanent. 
2. I will investigate, using in-vivo models of diabetes, whether 
hyperglycaemia can alter MtDNA content in organs and circulating cells of 
diabetic mice. 
3. I will examine whether glucose-induced changes in MtDNA occur in 
parallel with functional changes in mitochondria in cultured renal cells.  
4. I will examine whether glucose-induced changes in MtDNA occur in 
parallel with altered mitochondrial respiration in renal cells.  
 
The above specific objectives will be met using different experimental models 
(in-vitro and in-vivo) and a range of molecular/cellular biology and biochemical 
techniques to understand the relationship between MtDNA content and 
mitochondrial dysfunction and their contribution to early glucose-induced 
changes which may be involved in the development of DN. 
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Chapter 2 
2.1 Chemicals and reagents 
All chemicals and reagents used in this study were of molecular biology grade. A 
list of the chemical and reagents along with their suppliers are shown in table 
2.1.  
Table 2.1. List of chemicals, reagents and their suppliers 
Materials and kits Supplier 
Dulbecco’s modified eagle’s medium (DMEM),Penicillin-
Streptomycin, Ampicillin,  Trypsin, Chloroform, Transfer 
ribonuclease (tRNA), Bromophenol blue, Ethidium bromide, 
Trypan blue, Sodium dedeocylsulfate (SDS), Tris base (Tris-HCl), 
Ammonium persulphate, Glycine, Nonfat milk, Tween 20, Bovine 
serum albumine (BSA) 
Sigma-Aldrich Ltd (UK) 
Mouse polyclonal horseradish peroxidase conjugated (HRP) 
antibody, 
Santa Cruz  Biotechnology 
Inc. (UK) 
Hybond nitrocellulose paper, 3MM Chromatography papers Amersham Biosciences Ltd (UK). 
Insulin-transferrin-selenium (ITS), HEPES buffer, Foetal bovine 
serum (FBS), Phosphate buffer saline (PBS), L-glutamine, 
SeeBlue®Plus2 Pre-Stained Standard marker, Agarose, 
MitoTracker Orange CMTMRos, Countess cell counting chambers 
Invitrogen, Life 
Technologies  (UK) 
DreamTaq PCR master mix, 100 base pair DNA ladder, Molecular 
grade DNAse, RNAse free water, BCA kit 
Thermo Scientific 
DNeasy Blood or Tissue kit, RNeasy Mini kit , Proteinase K, 
Quantifast SYBR Master Mix (2x), Qiaquick gel extraction kit Qiagen (UK) 
Cell culture flask (25;  75; 162 cm2), 6-well cell culture cluster, 
Polypropylene conical falcon tube (15; 50 ml), sterile pipette (5; 
10; 25 ml), 0.22 mM sterile filters, 1 ml Cryo-vials 
Beckton Dickinson Ltd. 
(UK) 
Filter, Rnase, DNase free  tips, 1.5ml tubes STar Lab (UK) 
Molecular Biology Grade : Ethanol, Methanol, Isopropanol, 96-
well PCR plates 
VWR International 
Ltd.(UK) 
XFe96 FluxPak, XF Cell Mito Stress Test Kit Seahorse Bioscience Ltd 
HK-2 cells ATCC  
Total OXPHOX human WB antibody cocktail, β-actin antibody Abcam 
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2.2 Solutions and buffers 
All solutions and buffers were prepared according to the manufacturer’s 
instructions and were sterilized by autoclaving, except those supplied in kits. 
Table 2.2 shows the buffers and reagents that were prepared according to the 
manufacturer’s instruction.   
 
Table 2.2. preparation of reagents and buffers 
Solution Chemical components 
0.5 M EDTA pH 8.0/ 500 ml Disodium ethylenediaminetetra-acetate.2H2O 186.1 g 
(pH 8.0 adjusted with NaOH)   
10 X Tris-borate (TBE)/ 
1000ml 
Tris base 108 g, boric acid 55 g, 0.5 M EDTA (40 ml, pH 
8.0) 
10 X Tris-acetate /100ml Tris base 108 g, glacial acetic acid 11.42g, 0.5 M EDTA 
(20 ml, pH 8.0)  
1 M Tris/ 500 ml Tris-base 60.55 g pH 7.0, 70 ml HCl added 
10% SDS/ 500ml Electrophoresis-grade SDS 50 g, pH 7.2 with few drops 
of HCl 
 
2.3 Cell culture 
2.3.1  Culturing of renal cells 
Three types of human renal cells were used in the study, primary cultured 
human mesangial cells (HMCs, kindly provided by Prof Luigi Gnudi from 
Cardiovascular Division at KCL), human mesangial immortalised cells (HMCL, 
kindly provided by Dr Ruan Xiongzhong from Nephrology Department at UCL) 
and human cortex proximal tubular immortalized cells (HK-2, ATCC, LGC 
Standards). HMCL, HMCs and HK-2 cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) enriched with supplements. Complete growth medium 
was supplemented with: 10% of fetal bovine serum (FBS, Gibco), 1ml of Insulin-
Transferrin-Selenium (ITS, 5ug/ml, Life Technologies Ltd.) 1ml of Amphotericin B 
(0.25ug/ml, Life Technologies Ltd.), and 5ml of mixture of penicillin and 
streptomycin (100 units/ml, Sigma Aldrich, UK). Cells were cultured in 5ml or 15 
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ml of the complete growth medium in T-25 or T-75 culture flasks respectively; 
when 6-well plates dishes were used, cells were grown in 2 ml of media/well. 
Cells were cultured at 37°C in a humidified atmosphere containing 5% CO2 until 
80% confluent before passaging. Confluence was assessed under the inverted 
microscope. The growth medium was replaced every 2-3 days. 
2.3.2  Subculturing 
During routine culture complete growth media was renewed every 2-3 days and 
cells growth density was carefully inspected under the microscope. When cells 
reached approximately 80% of confluence, flasks were removed from the 
incubator and media was aspirated and discarded. Cell layer were then washed 
once with calcium free phosphate buffered saline (PBS, Sigma Aldrich ,UK) in 
order to remove any traces of FBS which has an inhibitory effect on Trypsin-EDTA 
(Sigma Aldrich, UK) solution used for cells’ detachment. Trypsin actively digests 
the anchorage sites between the cells and the growing surface, and EDTA binds 
to Ca2+ that is required for Ca2+-dependent adhesion due to its divalent ion 
chelating property. Between 2-5 ml of pre-warmed Trypsin-EDTA solution was 
added to the cells and incubated for approximately 3-5 min at 37°C to detach the 
cells from the flask. After 3 min of incubation cells were inspected under the 
inverted microscope in order to assess cell layer dispersion. 5ml of complete 
growth medium was then added to the flask to stop the digestion. Cell mixture 
was then gently aspirated and placed in a sterile 15 ml falcon tube and 
centrifuged at 100x g for 5min. To remove Trypsin-EDTA solution supernatant 
was discarded and the cell pellet resuspended in fresh 5.5mM of glucose 
complete growth medium and transferred the culture flask. A subcultivation 
ratio of 1:4 was used in all grown cell types. After plating cells were inspected 
under the inverted microscope and returned to the incubator. 
2.3.3 Counting the cells 
For the purpose of the experiments cells were counted and their viability 
assessed by using Countess Automated Cell Counter (Life technologies, Ltd.) 
which allowed accurate and reproducible assessment of cell number within 30 
sec. After trypsinisation, 10μl of cell suspension was thoroughly mixed with equal 
56 | P a g e  
 
Chapter 2: Methods 
volume of 0.4% trypan blue (Life technologies, Ltd.) and pipetted into Countess 
chamber. Reactivity of trypan blue is based on the fact, that it is negatively 
charged and does not interact with the cell unless the membrane is damaged.  
Therefore, all the cells which exclude the dye are viable. Total cell number and 
viability was assessed and cell solution was diluted in order to obtain required 
cell number per ml of growth media. Cells were next plated in 6- well culture 
plates at the density: 1x104 (HMCs and HMCL) - 1x 105 (HK-2) cells per well. 
Before the start of the experiments growth of the cells was arrested for 24h by 
culturing them in DMEM supplemented with 0.5% FBS only. This step helps to 
synchronize the growth of the cells before the start of the treatment. 
2.3.4 Freezing down and thawing the cells 
Cells which are in the logarithmic phase of growth and just approaching 
confluency (80-85%) were harvested as described above, and re-suspended with 
pre-warmed freezing medium containing: DMEM (10 %), DMSO (10%) and FBS 
(80%).  Cell suspension was dispensed in 1 ml aliquots into sterile freezer Cryo-
vials. The Cryo-vials were placed in a Nalgene Cryo freezing container filled with 
appropriate volume of isopropanol and placed at -80oC overnight (ideally, the 
temperature should decrease 1oC per minute).  Frozen vials were then stored in 
a liquid nitrogen for permanent storage.  To recover the cells, frozen cryo vials 
with cells were thawed in a 37˚C water bath, after partial defrosting, 500 ul of 
pre-warmed complete growth medium was added to the vials and cell solution 
was gently transferred to the sterile 15 ml falcon tube containing growth media. 
Cell mixture was then centrifuged at 100x g for 5 min. To remove any residue of 
DMSO which can be toxic to the cells, supernatant was discarded and the cell 
pellet was gently re-suspended in fresh 5.5mM of glucose complete growth 
medium and transferred the culture flask. Cells were inspected after under the 
inverted microscope and maintained under the same culture conditions as 
described previously.  
2.3.5 Culturing mesangial and tubular cells in the presence of high glucose 
 In order to perform in-vitro experiments cells were grown under four different 
conditions including: 5mM D-glucose (normal glucose-NG), 25 mM D-glucose 
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(high glucose-HG) and 5mM glucose plus 20mM D-mannitol (osmotic control, 
NGM) which served as an osmotic control. In one of the high glucose group 
medium was reverted to normal glucose (HG/NG). Before starting the 
experiment cells were counted and synchronized as described previously.  
Experiment was carried out in 6 replicates for 4-12 days, with medium changed 
every 2-3 days. After finishing the experiment, medium was aspirated and cell 
layers washed twice with ice cold PBS. Cells were then trypsinized, transferred 
into 1.5ml microcentrifuge tubes and centrifuged at 300xg for 3 min.  
Supernatants were removed and cell pellets were snap frozen in liquid nitrogen 
and stored at -80°C for further processing. 
2.4 Mouse tissue and peripheral blood samples  
2.4.1 Streptozotocin mouse model of type 1 diabetes 
STZ-diabetic mouse model was kindly provided by Dr Chloe Rackham from King’s 
College London. 8 week old male C57BL/6 mice were made diabetic with an 
injection of 180 mg/kg streptozotocin (STZ, Sigma Aldrich, UK) dissolved in citrate 
buffer (Citric Acid: 0.21g, 0.9% NaCl: 00ml at pH 4.5) and administered within 10 
minutes. To measure blood glucose, a needle prick was made at the end of the 
tail and blood glucose concentrations were determined using blood and an Accu-
Chek glucose meter and strips (Roche).  Islets were isolated from the pancreases 
of 8-10 week old male C57BL/6 mice using collagenase digestion followed by 
gradient purification, as described previously (King et al., 2007). Three days after 
STZ injection, diabetic mice (>15 mM) received a suboptimal islet graft of 150 
islets transplanted under the left kidney.  Islets were implanted into isoflourane 
anaesthetized mice using PE50 tubing and a Hamilton syringe (Rackham et al., 
2013). 1 week and 4 weeks after transplantation, kidneys were obtained from 
animals which had not been treated and thus remained diabetic throughout the 
study (blood glucose level > 15 mM) or from treated mice (blood glucose level < 
11.1 mmol/L for 4 weeks after transplantation). In addition, 12 week-old non-
transplanted, non-diabetic mice were used as controls (glucose level <11 
mmol/L). Tissues were removed and immediately frozen in liquid nitrogen, and 
stored at −80°C until further processed.  
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2.4.2  Prohibitin2 knockout mouse model of type 1 diabetes  
ß-Phb2-/-(beta-cell specific prohibitin 2 knockout) mice were bred from crossing 
of flox-Phb2-flox mice with Rat-Insulin promoter driven Cre mice so that PHB2 is 
specifically deleted in the pancreatic beta-cells. This spontaneous mouse model 
of T1D was kindly provided by Dr Sachin Supale and Prof Pierre Maechler from 
University of Geneva. These ß-Phb2-/-mice developed mild diabetes at the age of 
5-6 weeks and then became severely diabetic at 8-9 (Supale et al., 2013). Blood 
samples from control and diabetic mice were taken weekly between weeks 4 to 
11 and kidney samples were collected at week 11.  Tissues were removed and 
snap frozen in the liquid nitrogen, and stored at −80°C until further processed. 
2.4.3 Lep ob/ob mouse model of type 2 diabetes  
Lepob/ob (ob/ob) mice were used as a mouse model of T2D. The ob/ob mice were 
kindly provided by Dr Aileen King from King’s College London. Ob/ob mice have a 
mutation in the leptin gene which leads to uncontrolled appetite and quick 
weight gain. Mutants were discovered in the out-bred colony in the Jackson 
Laboratory in 1949 and later bred into C57BL/6 mice (King, 2012, Ingalls et al., 
1950). Ob/ob mice are a very good model for insulin resistance caused by obesity 
as they start gaining weight within 2 weeks following birth and develop 
hyperinsulinaemia and moderate hyperglycaemia after 4 weeks. Tissues were 
removed and snap frozen in the liquid nitrogen, and stored at −80°C until further 
processed. 
2.5 DNA extraction  
2.5.1 DNA extraction from human cells 
To prepare genomic DNA from the cell pellets a column base method (Qiagen 
DNeasy Blood and Tissue kit) was used according to manufacturer’s instructions. 
Following termination of the experiments cells were collected as described 
above.  Cell pellets were snap frozen in liquid nitrogen and stored at -80°C. 200µl 
of PBS was added to the cell pellets, followed by 20µl of proteinase K 
(>600mAU/ml, Qiagen, UK). All samples were vortex for about 30s in order to 
completely disperse cell pellets. Buffers AL, AW1, AW2 and AE were provided 
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with the DNeasy kit. To lyse the cells 200μl of lysis buffer (buffer AL, without 
added ethanol) was added and mixed by vortexing. Samples were then incubated 
at 56°C for 10 min. Following incubation, 200μl ethanol (96–100%) was added 
and mixed thoroughly by vortexing.  Lysates were transferred into the DNeasy 
Mini spin column placed in a 2 ml collection tube and centrifuged at 9300x g for 
1min. In order to wash the columns, 500μl wash buffer AW1 was added to the 
columns and spun down at 9300x g for 1 min. Wash step was repeated with 
500μl of buffer AW2 and columns were dried by spinning down at 12000x g for 3 
min. To elute the DNA, 30μl of elution buffer (buffer AE) was added directly onto 
the DNeasy membrane, incubated at room temperature for 1 min, and then 
centrifuged for 1 min at 9300x g. For maximum DNA yield, elution step was 
repeated once again in 30μl buffer AE to make 60μl of total volume. Between 1-
2μl of DNA was used to determine the concentration and quality of the DNA 
using the NanoDrop or equivalent instrument as described in section 2.6.3. 
2.5.2 DNA extraction from mouse tissue and mouse blood samples 
• DNA  extraction from mouse tissues 
To prepare genomic DNA from the tissues and whole mouse blood a column 
base method was used (Qiagen DNeasy Blood and Tissue kit), according to 
manufacturer’s instructions. Lysis buffers ATL, AL, wash buffers AW1 and AW2 
and elution buffer AE were provided with the kit (Qiagen).  First step in the total 
DNA extraction from mice tissues was the homogenisation of approximately 0.3-
0.5g of tissue in 180μl of ATL lysis buffer in 2ml microtubes (QIAGEN, UK) using 
Tissue lyser (Qiagen, UK) for 3-5 minutes at 20MHz. Following homogenisation, 
samples were briefly spun down and 20μl of proteinase K was added to each 
tube. Samples were then incubated at 56°C for 2-3h to allow complete lysis. 
Following incubation, 200μl ethanol (96–100%) was added and mixed thoroughly 
by vortexing.  Lysates were transferred into the DNeasy Mini spin column placed 
in a 2 ml collection tube and centrifuged at 9300x g for 1min. In order to wash 
the columns, 500μl wash buffer AW1 was added to the columns and spun down 
at 9300x g for 1 min. Wash step was repeated with 500μl of buffer AW2 and 
columns were dried by spinning down at 12000x g for 3 min. To elute the DNA, 
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50μl of elution buffer (buffer AE) was added directly onto the DNeasy 
membrane, incubated at room temperature for 1 min, and then centrifuged for 1 
min at 9300x g. For maximum DNA yield, elution step was repeated once again in 
50μl buffer AE to make 100μl of total volume. 
• DNA  extraction from mouse whole blood  
Between 10-50μl of blood samples was used and adjusted to 200μl with PBS 
buffer. 20μl of proteinase K (>600mAU/ml, Qiagen, UK) was added to the 
PBS/blood mixture and mixed for 15s.  To lyse the cells 200μl of lysis buffer 
(buffer AL, without added ethanol) was added and mixed by vortexing. Samples 
were then incubated at 56°C for 10 min. Following incubation, 200μl ethanol 
(96–100%) was added and mixed thoroughly by vortexing.  Lysates were 
transferred into the DNeasy Mini spin column placed in a 2 ml collection tube 
and centrifuged at 9300x g for 1min. In order to wash the columns, 500μl wash 
buffer AW1 was added to the columns and spun down at 9300x g for 1 min. 
Wash step was repeated with 500μl of buffer AW2 and columns were dried by 
spinning down at 12000x g for 3 min. To elute the DNA, 30μl of elution buffer 
(buffer AE) was added directly onto the DNeasy membrane, incubated at room 
temperature for 1 min, and then centrifuged for 1 min at 9300x g. For maximum 
DNA yield, elution step was repeated once again in 30μl buffer AE to make 60μl 
of total volume.  
Between 1-2μl of DNA was used to determine the concentration and quality of 
the DNA using the NanoDrop or equivalent instrument as described in section 
2.6.3. 
2.5.3 Pre-treatment/fragmentation of DNA  
 In order to avoid dilution bias, DNA template had to be sheared via sonication 
method.  Between 30-50μl of DNA was transferred into a clean 1.5ml micro 
centrifuge tube, placed in a Bath sonicator (Kerry, Pulsatron 55) which uses 38 
kHz +/- 10% and sonicated for 5 to 10minutes. After sonication, concentration of 
DNA was determined again and adjusted between 1ng/μl to 10ng/µl. Following 
the pre-treatment and dilution, samples were checked by amplifying hMito3 and 
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hB2M1 genes or mMito and mB2M using PCR method and specific primers given 
in table 2.3 and table 2.4.  
Following extraction and sonication, samples were stored at 4°C to avoid freezing 
for the duration of the study.  
2.6  RNA extraction 
There are four types of RNAs in living cells, messenger RNA (mRNA), transfer RNA 
(tRNA), ribosomal RNA (rRNA) and microRNA (miRNA). A good quality of total 
RNA is required to detect specific gene expression by complementary DNA 
(cDNA) amplification using polymerase chain reaction (PCR).  
2.6.1 RNA Extraction from human cells 
Total RNA was extracted from collected cell pellets according to manufacturer 
instruction by using RNeasy Mini kit (Qiagen,UK). Lysis buffer RLT, wash buffers 
RW1 and RPE were provided with the kit (Qiagen , UK). Renal cells were grown as 
monolayers in a 6-well plates and harvested by trypsinisation when reached 75-
80% confluency. Cell pellets were re-suspended in 600µl of lysis buffer (RLT) and 
briefly mixed by vortexing. Lysate was then transferred to into QiaShredder 
column in order to homogenize cell membranes and spun down for 3 min at 
12000x g. Following centrifugation, column was discarded and 600µl of 70% 
ethanol was added to the homogenised lysate. Following mixing by pipetting, 
700µl of homogenate was transferred to a RNeasy spin column and centrifuged 
for 15s at 12000x g. Flow through was discarded after the centrifugation and 
membrane with bounded RNA was washed with 700µl of washing RW1 buffer. 
Following another centrifugation step (15s, at 12000x g), membranes were 
washed with 500µl of RPE buffer. After final centrifugation step (2min, 12000x g), 
columns were transferred into new 1.5ml collection tubes. Extracted RNA was 
eluted with 50µl of the RNase-free water. RNA samples were stored at -80 °C.      
2.6.2  RNA extraction from mouse tissue 
Total RNA was extracted from mouse kidney tissues using Qiazol-based 
extraction method (Qiagen, UK) according to manufacturer guidelines. 
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Approximately 0.1-0.5g of tissue was homogenised in 2ml microtubes (QIAGEN, 
UK) the 800µl of Qiazol using Tissue lyser (Qiagen, UK) for 3 minutes at 20MHz. 
Following homogenization, RNA was separated from protein and DNA by adding 
200 µl of Chloroform (Sigma- Aldrich) and mixed vigorously for 15s. Next, 
homogenate was incubated at room temperature for 3 minutes. Samples were 
centrifuged for 15 min at 14500x g at 4 °C and the aqueous phase (approximately 
60% of the total volume) was transferred to a fresh nuclease-free tube. 500µl 
isopropyl alcohol (Sigma-Aldrich, UK) was added to the aqueous phase, inverted 
to mix and incubated at room temperature for 10 minutes. RNA pellets were 
recovered by centrifugation (14500x g, 20 min, 4 °C) and washed with 0.5ml of 
75 % chilled ethanol (Sigma-Aldrich, UK).  Pellets were re-precipitated by 
centrifugation (5000x g, 20 min, 4 °C) and left to air dry to remove the ethanol.  
RNA was re-suspended in 50 μl dH2O and stored at - 80 °C.      
2.6.3 Determination of RNA concentration  
Concentrations of RNA in the extracts were quantified using the ND1000 
spectrophotometer (Nanodrop). This device is able to measure 260 and 280nm 
absorbance from samples in only 1μl of extract. A260nm is automatically converted 
to give an accurate estimation of RNA content in ng/μl. Moreover, the ratio of 
A260nm/A280nm can be further used as an indication of RNA quality. A ratio of <1.6 
indicates contamination of samples with protein, phenol or other compounds 
which absorb at 280nm. Sample RNAs with A260nm/A280nm > 1.6 were stored at -
85˚C and used subsequently for complementary DNA (cDNA) synthesis. 
2.6.4 DNase-1 treatment of RNA 
No RNA isolation procedure can guarantee the complete removal of trace 
amount of DNA below the limit of detection by real-time qPCR. Therefore, to 
effectively remove the DNA contamination from RNA, a DNA inactivation kit 
based on DNase I treatment (Life Technologies-Ambion, UK) was used. A 50μl 
RNA was mixed gently with 5μl of DNase-1 buffer (10 X), DNase I enzyme (0.5μl) 
and incubated at 37 °C in a heat block for 30 min.  After this step, the RNA should 
be free from contaminating DNA. The DNase I must be now removed from RNA 
that will be subjected to RT-PCR because it could degrade DNA made in the PCR.  
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Consequently, the reaction was stopped by adding 5μl of DNase inactivation 
reagent and mixed by gentle flicking to disperse the DNase inactivation reagent 
in the reaction. Samples were incubated at room temperature for 2 min and 
were flicked once more to re-disperse the reagent.  The DNase inactivation 
reagent removes divalent cations introduced by the DNase-1 buffer and these 
cations can degrade RNA at temperature typically used for RNA denaturation 
prior to reveres transcription. To recover the RNA, samples were centrifuged at 
14,000 rpm for 1 min and the upper layer was carefully transferred to 1.5ml 
DNA-free microcentrifuge tube (with avoiding any transfer of the DNase 
inactivation agent). The treated RNA samples were then kept at -80 °C.     
2.6.5 cDNA synthesis 
Reverse transcription is a process, in which single-stranded mRNA is transcribed 
into complementary DNA (cDNA) using the reverse transcriptase enzyme. Equal 
amounts of the DNA-free RNA (2 µg) were reverse transcribed to cDNA using 
High Capacity RNA-to-cDNA KIT (Life-Technologies, Applied Biosystems, UK).   
According to the protocol provided with the kit, cDNA synthesis was carried out 
as following: 
Preparation of RNA: RT primer mix:  
11 μl of RT –mix (including Oligo-dT and random hexamer primers, RT buffer) 
was gently mixed with 9 μl of RNA and 1 μl of RT enzyme mix. The RNA:RT 
mixture was then incubated at 37 °C for 60 min. The cDNA samples were stored 
at -20°C. 
2.7 Assessment of the gene expression 
2.7.1 Polymerase chain reaction- PCR 
Polymerase chain reaction (PCR) technology was invented by Dr. Kary Mullis in 
1983 for which he received a Nobel Prize in chemistry in 1993. PCR is a technique 
to amplify DNA sequences of interest in-vitro (Fig.2.1).  
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Fig.2.1. Schematic illustration of PCR amplification. A)The double stranded cDNA is 
dissociated at 95˚C (melting) and cooled down to an appropriate temperature to allow 
binding of primers to complementary sequences within the template DNA (annealing). The 
primers serve as initiation points for DNA polymerase which, at 72˚C, extends the primers 
in the 5’ to 3’ direction thereby facilitating DNA synthesis (extending). B) As PCR cycles are 




DNA polymerase is required to synthesise specific regions of template DNAs. 
Pairs of sequence-specific oligonucleotide primers are essential to define 
replicating regions by binding to complementary sequences on the DNA 
template where amplification starts and stops. PCR amplifications are carried out 
in thermal cyclers in repeated cycles of three phases: denaturation of double 
stranded DNAs at 95˚C, annealing between primers and DNA templates at ~60˚C, 
and extension of newly amplified DNAs of interest at 72˚C (Fig.2.2.A). The 
annealing temperatures are usually determined by the percentage of guanosine 
and cytidine nucleosides in the DNA sequence of interest and by primer length.  
In the experiments described in this thesis, real time qPCR was performed with 
cDNAs of renal cells, and DNA extracted from cells and mouse kidneys and 
mouse blood samples. Specific sets of primers were designed and selected using 
the Roche Universal ProbeLibrary System technology (Roche, 2012) and used to 
amplify regions of interest. List of primers used in this thesis are shown in tables 
2.3 and 2.4. 
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Table 2.3.  Human oligonucleotide primers used in this study 
Gene Accession number Primers (5’->3’) 
Amplicon 
Length (bp) 
TFAM NM_003201.2 F:GAACAACTACCCATATTTAAAGCTCA 95 
R:  GAATCAGGAAGTTCCCTCCA 
PGC1a NM_013261.3 F:  ACTGCAGGCCTAACTCCACCCA 190 
R: ACTCGGATTGCTCCGGCCCT 








MFN1 NM_033540.2 F:GAGAAAATACAAAACAATTCAAAGCTC 96 
R:GCTTGAAGGTAGAAACTGCTTAGTAAA 
MFN2 NM_014874.3 F: AGCCACCAAGTCCAGCAG 117 
R: AACCTCAATTTTCTTGTTCATGG 
OPA1 NM_015560.2 F: GAGCCAGGTTACACCAAAACA 120 
R: GTTCCTGAATTCATGGTCTGC 
Pink1 NM_032409.2 F: CTTACAGAAAATCCAAGAGAGG 199 
R: CAGGGATAGTTCTTCATAACG 
Park2 NM_004562.2 F: GAGGATTTAACCCAGGAGAG 113 
R: ACAAACACTATCATGGTCAC 
Drp1 NM_012063.3 F: TCACGAGACAAGTTAATTCAGGA 344 
R: GCCTTTGGCACACTGTCTTG 
ND1  NC_012920.1 F: GAGCAGTAGCCCAAACAATCTC 140 
R: GGGTCATGATGGCAGGAGTAAT 
ND6  NC_012920.1 F: TGGGGTTAGCGATGGAGGTAGG 140 
R: AATAGGATCCTCCCGAATCAAC 
COX3 NC_012920.1 F: TCCTCACTATCTGCTTCATCCG 140 
R: CCCTCATCAATAGATGGAGACA 
β-actin NM_001101.3 F: GACGACATGGAGAAAATCTG 131 
R: ATGATCTGGGTCATCTTCTC 
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Table.2.4. Mouse oligonucleotide primers used in this study 
 
PCR reaction mixes was performed in 0.2 ml PCR tubes and a reaction mix was 
prepared by adding 12.5µl of DreamTaq PCR master mix, 0.5µl of forward and 
reverse primer (10 µM) and 10.5µl RNase free H2O. Between 1-2µl of DNA 
template was added and gently vortexed and spun down. DNA templates were 
amplified using a Thermal Cycler (Thermal Cycler, Bioer) using following 
conditions: initial denaturation at 94⁰C for 15 minutes  (1cycle), followed by 
denaturation at 94⁰C for 30 seconds, annealing at 60⁰C for 30 seconds and 
extension 72⁰C for 1 minute and 30 seconds (30 cycles). Final extension was at 
72⁰C for 7 minutes. Once the amplifications had been completed, 10μl of each 
PCR product were loaded into a 2% agarose gel, which was prepared using 2g of 
agarose (Invitrogen), 50ml of 0.5X TBE buffer and 10µl ethidium bromide (Sigma 
100ng/µl). The agarose was melted in a microwave oven (medium power, 5 min) 
and cooled to approximately 60°C. when it is cooled down, ethidium bromide 
(0.5 µg/ ml) was added.  Ethidium bromide stained gel was then cast to a 
thickness of 5 mm comb.  The gel was placed in horizontal gel electrophoresis 
apparatus and covered with 1X TBE buffer.  Loading buffer (2 µl) was added to 
each DNA sample (5-10 µl), mixed and loaded into the well of the agarose gel.  
Electrophoresis (50-100 V, 1-2 hrs) was carried out at to allow a sufficient 
separation of the DNA fragments.  Ethidium bromide stained agarose gels were 




Primers (5’->3’) Amplicon 
Length (bp) 
mMito NC_012387.1 F: CTAGAAACCCCGAAACCAAA 125 
R: CCAGCTATCACCAAGCTCGT 
mB2M NC_000068.7 F: ATGGGAAGCCGAACATACTG 177 
R: CAGTCTCAGTGGGGGTGAAT 
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2.7.2 Preparation of standards for absolute quantification 
• Purification of DNA from the gel band  
Following PCR amplification with the appropriate primers (see table 2.3 and 2.4) 
and gel electrophoresis of PCR products, DNA fragments were excised from the 
gel with a clean scalpel using a UV transilluminator (Transilluminator UVP) to 
visualise the bands. Excised agarose chunks with DNA were placed in a clean 
tube and QIAquick Gel extraction Kit was used, according to the manufacturer's 
protocol. The excised gel was weighed and three gel volumes of buffer QG was 
added to the gel. The gel was then incubated at 50°C for 10min to dissolve the 
gel, vortexing it every 2-3mins to mix the solution. One gel volume of 
isopropanol was then added and the solution was mixed by vortexing. 800µl of 
the sample mix was then added to a QIAquick spin column in a 2ml collection 
tube and centrifuged for 1min at 14500x g. The flow through was discarded, and 
the remaining sample was loaded and spun again repeatedly until all the sample 
had been used up. 500µl of buffer QG was added and centrifuged for 1min at 
14500x g. The sample mix was then washed with 750µl of buffer PE and 
centrifuged for 1min at 14500x g. The flow though was discarded and the sample 
was spun again. The QIAquick column was then placed in a 1.5ml microcentrifuge 
tube and the DNA was eluted by 30µl of the elution buffer EB added to the 
centre of the membrane and then the sample centrifuged for 4min at 14500x g. 
10µl of purified DNA was run on the 2% agarose gel, to ensure, that PCR product 
was purified successfully before proceeding to standards preparation.  
• Standards preparation  
It is essential that the dilution series from which the standard curve is generated 
be carefully prepared. To prepare standards for the generation of standard 
curves, PCR products were purified using the GFX PCR DNA and gel band 
purification kit as described above. Concentration of the purified DNA was 
assessed using NanoDrop instrument.  The exact DNA copy numbers of the 
purified PCR product were calculated using Avogadro’s number and the formula 
shown on Fig.2.2. A dilution series containing 107, 106, 105, 104, 103 and 102 
copies/μl of the gene to be quantified were prepared in the presence of carrier 
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transfer ribonucleic acid (tRNA, 10 mg/ ml; Sigma, UK) and used as a calibration 
curve in every run with the Roche LC480. Standards prepared for a target gene 
and a reference gene were used to establish standard curves by amplification in 
10-fold dilutions of PCR product of each gene to be quantified.  
 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴′𝑠𝑠 𝑐𝑐𝐴𝐴𝑐𝑐𝑠𝑠𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐
𝑀𝑀𝑀𝑀 𝑥𝑥 109 𝑥𝑥 𝐶𝐶𝐴𝐴𝑐𝑐𝑐𝑐𝐶𝐶𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝐶𝐶𝐴𝐴𝑐𝑐 = 𝑐𝑐𝐴𝐴𝑐𝑐𝐶𝐶𝐶𝐶𝑠𝑠/µ𝑙𝑙 
Avogadro’s constant = 6.02 x 1023 
MW = 330Da x 2 x template length (bp) 
Concentration of DNA = ng/µl 
Fig.2.2. Calculation of the copy number per µl of the PCR product. Following gel 
purification, DNA concentration was measured on NanoDrop and copy number of gene 
of interest per µl of extracted PCR product was calculated using the formula presented 
on a figure. 
 
 
2.7.3 Real time quantitative PCR -amplification of required product 
Quantitative real-time polymerase chain reaction is a sensitive and specific 
technique used to characterise gene expression patterns. Total RNA is extracted 
from tissues and cDNA is synthesised from the messenger RNA (mRNA) present 
in the total RNA using the reverse transcriptase enzyme. The target amplicon 
specific to the gene of interest in the cDNA is then amplified to detectable levels 
using PCR. The amplification process is monitored in real time by measuring the 
fluorescent signal emitted when SYBR Green binds to the double stranded DNA. 
The rate at which the fluorescent signal reaches a threshold level in the 
exponential phase correlates with the amount of original cDNA target sequence, 
which in turn reflects the original amount of mRNA in the starting material. We 
examined the mRNA expression of genes involved in mitochondrial biogenesis 
(TFAM, PGC-1α), fission (DRP1), fusion (MFN1 and MFN2; OPA1) and mitophagy 
(PINK1, PARK2). The mRNA expression of mitochondrial encoded subunits; ND1, 
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ND6 and COX3 was also measured. For mRNA quantification, following RNA 
extraction and reverse transcription, qPCR was carried out for the target gene 
and β-actin as a stably expressed reference gene in triplicate. Expression of 
several reference genes was tested by using GeNorm software (Vandesompele et 
al., 2002). For MtDNA quantification, following DNA extraction and template pre-
treatment qPCR was carried out in triplicates for a target mitochondrial gene and 
Beta-2 microglobulin (B2M, nuclear control). Absolute quantification was carried 
out in the presence of dilution standards for each gene. For each DNA or cDNA 
sample under investigation, the reaction was carried out in duplicate or 
triplicate.  
Real-time qPCR was carried put in a total volume of 10μl, containing 5μl of 
Quantifast SYBR Master Mix, 0.5μl of forward and reverse primer (500nM final 
concentration each), 2μl template DNA (sample or standard) and 2μl of RNase 
free-water.  
The reactions were performed in Roche LighCycler (LC) 480 instrument using the 
following program protocol: pre-incubation at 95°C for 5 minutes (1 cycle); 
denaturation at 95°C for 10 seconds, annealing and extension at 60°C for 30 
seconds (repeat denaturation and extension steps for 40 cycles), melting at 95°C 
for 5 seconds, 65°C for 60 seconds, and 95°C continues (melt curve analysis -1 
cycle) and the last step, cooling at 40°C for 30 seconds .In order to obtain copy 
numbers for tested samples the threshold was set up above the noise and on the 
linear/exponential part of amplification curves (example for hMito3 is shown on 
Fig.2.3A and for the rest of the genes see Appendix II). When running 10-fold 
dilutions standards and after setting up the values for each standard were 
plotted against their concentration, giving also values for reaction efficiency 
(recommended coefficiency of reaction [R2] is 1.0 (Fig.2.43.C, Appendix II). 
Specificity of the primers was also checked by using melt curve analysis; one 
clear peak was visible for each investigated PCR product (Fig.2.3.B, Appendix II). 
The mRNA copy numbers were calculated by dividing the mean values of target 
gene relative to the mean values of β-actin, MtDNA copy numbers were assessed 
as mitochondrial to nuclear gene ratio and B2M served as a nuclear control. 
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Fig.2.3.Amplification of hMito3 in 10-fold dilutions and standard curve generation. 
Dilution standards of hMito3 were prepared and 2ul of each standard was used in qPCR 
reaction and amplified. Fluorescence data was acquired once per cycle and amplification 
curve (A) was generated showing dilution series from 102 to 107 copies of hMito3. 
Melting point analysis (B) represents specificity of multiplied product as one single melt 
peak is visible at 83°C. (C) Standard curve showing the crossing point (Ct) for each of the 
10-fold dilutions plotted against a log concentration. Threshold line is shown in red.  
 
 
2.8 Western blot and detection of the OXPHOS proteins 
2.8.1 Protein extraction 
Mesangial cells were maintained as monolayers in 6-well plates up to 75% 
confluence. The cells were harvested by trypsinisation and washed with PBS. 
Lysis buffer (Table 2.5) supplemented with protease and phosphatase inhibitors 
to protect the proteins from being degraded and dephosphorylated, was added 
to mesangial cells, followed by sonication in the water bath for 3 min. Protein 
content of samples was quantified using 10μl of each cell lysate. The remaining 
protein extracts were kept at -80˚C. 
2.8.2 Determination of protein concentration 
To ensure equal loading for SDS-PAGE, protein concentration was determined by 
the bicinchoninic acid (BCA) assay kit (Pierce; distributed by Thermofisher 
Scientific, Cramlington, UK). This colorimetric method is based on the reduction 
of Cu2+ to Cu1+ by protein in an alkaline medium and the formation of a purple-
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coloured reaction product by the subsequent chelating of the reduced Cu1+ with 
BCA. The amount of protein in the sample is directly proportional to the amount 
of purple coloured reaction complex. 
Protein standard curve was made by a serial dilution of the stock solution (2 
mg/ml of BSA) to final concentrations of 0.25, 0.5, 0.75, 1.0, 1.5and 2.0 mg/ml. 
Protein lysates were further diluted 1:4 in the lysis buffer. The working reagent 
was prepared by mixing 50 parts reagent A (containing BCA in a 0.1 M sodium 
hydroxide solution) with 1 part reagent B (containing 4 % cupric sulphate). 
10µl of blank (lysis buffer), standards and samples were added in triplicate to the 
wells of a 96 well plate. 200µl working reagent was then added to each well. The 
plate was thoroughly mixed on a plate shaker for 30 s and incubated for 30 min 
at 37 oC. The plate was cooled to room temperature and the absorbance read at 
570 nm on a spectrophotometer (Chameleon microplate reader, Hidex). The 
absorbances of each standard point were plotted and the concentration in the 
unknown sample derived from the regression equation of the standard curve 
(Fig.2.4).  
 
Table 2.5. Preparation of cell lysis buffer.  
Reagent Amount for 100ml Final Conc. 
Tris-base 790mg 50mM 
NaCl 900mg 150mM 
NP-40 (10%)(v/v) 10ml 1% (v/v) 
Na-deoxycholate (10%) (v/v) 2.5ml 0.25% (v/v) 
EDTA (100 mM) 1ml 1mM 
 
Tris base and NaCl were first dissolved in 75ml DI H2O, the pH was adjusted to 7.4 with 
concentrated HCl followed by addition of NP-40, Na-deoxycholate and EDTA. DI H2O was 
then added to make up the final volume to 100ml. 
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Fig.2.4.Representative example of a BCA assay standard curve. Absorbance was plotted 
against total protein concentration of the BSA standards. Equations for the regression 
line and the goodness of fit (R2) value are shown. 
 
 
2.8.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE is a method commonly used to separate proteins across an electric 
field based on their molecular weight. SDS is a negatively charged detergent that 
binds to and unfolds the protein to its primary structure, and applies a net 
negative charge. In the presence of an electric field, the negatively charged 
proteins migrate towards the positive pole through a porous gel matrix of 
polyacrylamide. The amount of polyacrylamide determines the pore size, and 
effectively causes separation of the polypeptides according to their lengths. The 
NuPAGE Bis-Tris electrophoresis system was used in the experiments described 
in this thesis. Equal amounts of total protein from mesangial cell protein extracts 
were loaded on to a 10% Bis-Tris-HCl buffered (pH 6.4) polyacrylamide gels. The 
gel was arranged and placed in the Xcel Surelock mini cell apparatus, and the 
inner chamber, containing sample proteins was filled with antioxidant-
supplemented MOPS running buffer (Table 2.6). The outer chamber was filled 
with approximately 600ml of MOPS running buffer and the gel was run at 200V 
for 50min. A Rainbow® coloured protein molecular weight marker, labelled with 
chromophores for detection, was also loaded and run in parallel to the sample 
protein extracts for identification of sample protein molecular weights.  
BCA protein assay
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Table 2.6. Preparation of MOPS running buffer 
Reagent Amount for 500ml Final Conc. 
MOPS 104.6g 1M 
Tris Base 60.6g 1M 
SDS 10g 69.3mM 
EDTA 3g 20.5mM 
 
Reagents listed above were dissolved in 400ml DI H2O and adjusted to a final volume of 
500ml. The 20×MOPS running buffer was kept at 4˚C and diluted 1 in 20 (50ml 20×MOPS 
running buffer in 950ml DI H2O) before use.  
 
 
2.8.4 Western blot 
After SDS-PAGE, the separated proteins are usually transferred to a suitable 
membrane such as polyvinylidene difluoride (PVDF) to allow access of specific 
antibodies for immuno-detection of proteins of interest. The transfer process is 
carried out by sandwiching the polyacrylamide gel and PVDF membrane between 
layers of filter paper, pre-soaked in a Tris-based transfer buffer (Table 2.7) while 
an electric current is used to pull the proteins from the gel onto the PVDF 
membrane. 
After immunoblotting, the membrane was incubated in a protein-rich solution 
(5% w/v skimmed milk powder dissolved in TBS-Tween), for 1 hour at room 
temperature to block non-specific binding sites. Following the blocking process, 
the protein of interest was probed by incubating the membrane with a primary 
antibody raised against the target protein overnight at 4˚C. (The primary OXPHOS 
antibody cocktail antibody was diluted the ratio 1:2000 in 5% in w/v milk TBS-T 
to increase specificity.). After primary antibody incubation, the membrane was 
washed with blocking buffer (5% w/v milk in TBS-T/1× TBS-T, 15min each) 3 
times to remove unbound primary antibody. The membrane was then incubated 
for 1 hour in a horseradish peroxidase-conjugated secondary antibody solution 
(1:7500 dilution in 5% w/v milk TBS-T) at room temperature. After 5 washes with 
TBS-T (5min each), immunoreactive proteins were identified by 
chemiluminescent detection following addition of enhanced chemiluminescent   
reagents. Photographic film which detects light signals was used and protein 
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identification was carried out by comparing the immunoreactive bands with 
those of the Rainbow® markers loaded during SDS-PAGE.  
 
Table 2.7. Preparation of ×1 Transfer buffer.  
Reagent Volume 
DI H2O 849ml 
20× NuPAGE transfer buffer (Invitrogen) 50ml 




2.8.5 Semi-quantitative analysis using ImageJ 
To analyze protein expression, densitometry of both the protein of interest and 
reference protein was performed using ImageJ (version 1.43: National Institutes 
of Health; www.rsb.info.nih.gov/ij), a program that quantifies protein band 
intensity based on peak area. The amount of the protein of interest was 
expressed relative to the reference protein (β-actin) for each sample. 
2.9 Mitochondrial network visualisation 
2.9.1 Staining mitochondrial network with MitoTracker orange 
Cells were cultured in different medium condition as follow: 5mM (NG) and 
25mM (HG) glucose at various time points. To visualise mitochondria, 
MitoTracker (Invitrogen) fluorescent probes was added into the culture medium 
(100nM working concentration) and incubated at 37°C for 30 minutes. Cells were 
then washed three times with PBS and fixed by incubation with 
paraformaldehyde for 30 minutes at 4°C. After fixation, cells were rinsed three 
times with PBS and then visualized using the Nikon Eclipse Ti-E Inverted 
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Fig.2.5. Mitochondria stained with MitoTracker Orange. To visualise mitochondria, 
MitoTracker (Invitrogen) fluorescent probes was added into the culture medium (100nM 
working concentration) and incubated at 37°C for 30 minutes. Cells were then washed 
three times with PBS and fixed by incubation with paraformaldehyde for 30 minutes at 
4°C. Magnification 40x, Scale bar 10μm 
 
 
2.9.2 ImageJ analysis of mitochondrial morphology 
To visualise mitochondrial morphology, cells were grown in 96-well plates with 
clear bottoms, fixed with paraformaldehyde and visualized by staining with 
Mitotracker Orange (Invitrogen) according to the manufacturer's instructions. 
Cells were viewed under Nikon Eclipse Ti-E Inverted Microscope, using CFI S Plan 
Fluor ELWD  20x/0.45NA objective, at room temperature 25ᵒC, in PBS. Images 
were captured using a PhotometricsCoolsnap HQ CCD camera, and images were 
acquired using NIS Elements V4.20. The stained mitochondrial network was 
assessed using ImageJ software (version 1.47q: National Institutes of 
Health; www.rsb.info.nih.gov/ij) using an image-processing algorithm as 
described by Koopman at al. (Koopman et al., 2005). Briefly, after adjusting 
brightness and contrast, a spatial filter was applied and by adjusting the 
threshold, mitochondrial network was distinguished from the background. Two 
different parameters, formfactor F (calculated as a perimeter2/4Π*area) and the 
aspect ratio AR (ratio between major and minor axes) were used to quantify 
mitochondrial morphology. Both formfactorF and aspect ratio AR are 
independent of image magnification, and have a minimal value of 1. Formfactor 
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F is a measure of the length and degree of branching and aspect ratio AR is a 
measure of mitochondria length. 
2.10 Measurement of cell viability in human mesangial cells  
Cell viability was measured using CellTiter-Glo luminescence assay (Promega, UK) 
in the microplate reader (according to the manufacturer’s instructions). The 
assay detects number of viable cells, based on the measurement of ATP present, 
an indicator of metabolically active cells. 
2.11 Measurement of cellular ROS production 
Intracellular ROS in cultured cells was measured using cell-permeant 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) oxidation in the microplate 
reader (according to the manufacturer’s instructions). Cells well grown in various 
glucose concentrations in 6-well plates for 4 or 8 days. 4 days before the 
assessment cell were trypsinised and seeded in 96-well plates at the density of 
103cells/well. On a day of the assessment, cells were treated with H2DCFDA, 
washed 3 times with PBS and fluorescence signal was measured in the 
Chameleon microplate reader (Hidex) using excitation/emission: ~ 495/540 
filters. DCFDA is a fluorogenic dye that measures hydroxyl, peroxyl and other 
ROS activity within the cell. After diffusion in to the cell, DCFDA is deacetylated 
by cellular esterases to a non-fluorescent compound, which is later oxidized by 
ROS into 2’, 7’ –dichlorofluorescein (DCF), which is highly fluorescent.  
2.12 Mitochondrial DNA damage 
MtDNA damage was assessed using the PCR based elongase method (Furda et 
al., 2014).15 ng of genomic DNA isolated as described above was amplified using 
the primers 14841 and 5999 as described by Furda et al which amplifies an 8.9kb 
region of the mitochondrial genome. Cycling conditions used the standard 
program (following the hot start of 75°C for 2 min and the addition of the 
polymerase) includes an initial denaturation step at 94°C for 1 min followed by a 
variable number of cycles of 94°C for 15 seconds and a set annealing/extension 
temperature for 12 min, with a final extension at 72°C for 10 min (Hunter et al., 
2010). The thermocycler profile for the amplification of short DNA fragments 
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(127bp) includes an initial denaturation step at 94°C for 15 min, 21 cycles of 
denaturation at 94°C for 30 seconds, a specified annealing for 30 seconds, and 
72°C for extension for 1 minute, with final extension at 72°C for 7 min. PCR assay 
included treated DNA samples, positive control, 50% DNA positive control and a 
negative control. DNA damage is quantiﬁed by comparing the relative 
ampliﬁcation of large fragments (8.9 kb) of DNA from treated samples to those of 
controls and normalizing this to the ampliﬁcation of small (127 bp) fragments. 
2.13 Extracellular flux experiments using Seahorse XF e96 analyzer 
The metabolic profiles of cultured HMCs and HK-2 cells were assessed using the 
XFe96 Seahorse analyser and XF cell mito stress test kit and XF-FluxPaks 
containing 96-well plates and cartridges (Seahorse Biosciences, Fig.2.6). Oxygen 
consumption rate (OCR), a measurement of mitochondrial respiration, and 
extracellular acidification rate (ECAR) which correlates to amount of protons 
released from the cell with potential contribution from glycolysis and the Krebs 
cycle, were measured in the presence of specific mitochondrial activators and 
inhibitors.  
Oligomycin (ATP synthase blocker) was used to measure ATP turnover and to 
determine proton leak, the mitochondrial uncoupler FCCP (carbonyl cyanide 4-
[trifluoromethoxy] phenylhydrazone) was used to measure maximum respiratory 
function (maximal OCR). Reserve capacity was calculated as maximal OCR minus 
the basal respiration. At the end of the experiments, rotenone (inhibitor of 
complex I) and antimycin A (a blocker of complex III), were injected to 
completely shut the mitochondrial respiration down, to confirm that any changes 
observed in respiration were mitochondrial. In order to determine optimal cell 
number and drug concentration, optimisation experiments with a different cell 
seeding number and titration of  electron transport chain  activators and 
inhibitors were carried out to accurately assess OCR and ECAR  which are 
explained in details in chapter 6. HMCs were grown in 5mM glucose (NG), 25mM 
glucose (HG) and in 5mM glucose plus 20mM mannitol (osmotic control, NGM) 
for 4, 8 and 12 days. One day prior to the flux analysis, cells were seeded at the 
concentration of 35000cells/ well in 96-well assay plates in complete growth 
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medium containing NG, HG glucose and NGM. 1hr prior to the experiment the 
growth medium was removed, cells washed 3 times and then incubated in low 
buffered assay medium (Seahorse bioscience) supplemented with 5mM glucose 










Fig.2.6.Measurement of mitochondrial function (respiration and glycolysis) via 
Seahorse XFe96 analyzer. Seahorse XFe96 analyzer (A), Oxygen consumption rate (OCR), 
a measurement of mitochondrial respiration, and extracellular acidification rate (ECAR) 
which correlates to amount of protons released  from the cell with potential 
contribution from glycolysis and the Krebs cycle, were measured in the presence of 
specific mitochondrial activators and inhibitors (B), drug injection ports (C), 7µl volume 
transient micro chamber  allowing real-time  measurement of the mitochondrial 




The microplates were then assayed in the XF-96eanalyzer. For a measurement of 
steady basal respiration 4 to 5 measurements were taken before injecting ATP 
synthase inhibitor, oligomycin at 1μM (final concentration). Mitochondrial 
membrane uncoupler FCCP was then injected at 0.75μM. Finally a mixture of 
rotenone and antimycin A (1μM) was injected. Mitochondrial basal respiration, 
proton leak, spare capacity and maximal respiration were measured after 
correcting for non-mitochondrial respiration. After finishing the experiments 
20μl of cell lysis buffer [10mmM Tris, pH 7.4, 0.1% Triton X-100] were added per 
well and protein content measured by BCA assay (Fisher Scientific). OCR and 
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ECAR rates were normalised to the protein content and presented as 
pmolesO2/min/μg protein. 
 
Table 2.8. Preparation of protein lysis buffer for Seahorse flux analyzer experiments. 
Reagent Volume  Final concentration 
Tris-HCL 100mM 10 10mM 
Triton X-100 0.1 0.1% 
DI H2O 89 - 
 
100mM Tris-Hcl was prepared by adding 242mg of Tris-HCl powder (MW=121.14) to 
20ml of DI H2O.  
 
2.14 Statistical analysis 
All tests were performed using GraphPad analysis software. Data are presented 
as mean ± standard deviation (SD). Gaussian distribution of the data was tested 
using the Kolmogorov-Smirnov test if possible or by the assessment of scatter 
plots. If data didn't follow normal distribution a log10 function was performed 
and Kolmogorov-Smirnov test was run on samples again Student’s independent 
t- test or Mann-Whitney U-tests were used depending on the distribution of the 
data. When comparing means between more than 2 groups 1 way analysis of 
variance was used (1 way ANOVA) with post-hoc Tukey’s multiple comparison 
test. The null hypothesis was rejected where P <0.05. 




Hyperglycaemia-induced changes in mitochondrial 
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3.1 Abstract 
Background/Aims: The main hypothesis of this thesis is that 
hyperglycaemia/high glucose can cause early changes in mitochondrial DNA 
(content/quality) and that these changes can contribute to mitochondrial 
dysfunction. In the current chapter this theory was investigated using cultured 
renal cells.   
Methods: Human renal immortalised and primary cultured mesangial cells 
(HMCL, HMCs) and transformed tubular epithelial cells (HK-2) were cultured in 
5mM (NG) and 25mM (HG) glucose and in 5mM glucose plus 20mM mannitol 
(NGM). Total DNA was extracted and MtDNA content was determined as the 
mitochondrial genome to nuclear genome ratio using real time qPCR. Changes in 
MtDNA content in response to fluctuations of glucose concentration were also 
assessed. Moreover a reversal experiment was performed, where growth 
medium with HG was replaced with NG, and the effect of change on MtDNA copy 
number was measured. 
Results: Culture in HG had no effect on MtDNA copy number in immortalized 
cells (HMCL and HK-2). Contrary to the cell line data, in primary cultured 
mesangial cells, there was a highly significant, almost 3-fold higher up-regulation 
of MtDNA copy number in response to HG when compared to the control 
(P<0.01) after 4 days of culture. 8 days of the exposure to HG caused an 
alteration in the MtDNA copy number, but the result was no longer significant 
(P>0.05). Fluctuations of glucose concentration every 24 hours (HG/NG/HG), 
caused a significant increase in MtDNA copy number (P<0.05). In a reversal 
experiment, the change in MtDNA copy number was reversible after 2 days of 
culture in HG, followed by 2 days in NG, but was not reversible after longer 
exposure to HG.   
Conclusion: These results show that cellular MtDNA can be increased in response 
to hyperglycaemia in cultured primary mesangial cells. The functional 
consequences of this increase are unknown.  
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3.2 Introduction 
MtDNA exclusively codes for 13 proteins of the OXPHOS which are crucial for 
proper cell function (Falkenberg et al., 2007). The number of mitochondria in a 
particular cell type can change depending on many factors, including the stage in 
the cell cycle, the environment and redox balance of the cell, the stage of 
differentiation, and a number of cell signalling mechanisms (Michel et al., 2012; 
Rodriguez-Enriquez et al., 2009). It has been assumed, that cellular MtDNA 
content is proportionate to the mitochondrial function and respiratory complex 
activity, and can be regulated by the cellular energy demand and linked to the 
bioenergetic requirements of the cells (Hock and Kralli, 2009). However, work 
from our group and others has supported that in certain conditions of disease, 
MtDNA content can be altered. The work started in our laboratory led to the 
identification of genes that change at the mRNA level during the progression of 
hyperglycaemia. Using the technique of differential screening, Page et al., (1997) 
detected transcriptional changes in both, mitochondrial encoded and nuclear 
encoded mRNAs in the kidney during the development of diabetes in the GK rat 
(Page et al., 1997). These results led to further research on possible links 
between MtDNA content and changes in the kidneys caused by hyperglycaemia. 
Unpublished results from our group obtained from two pilot experiments; a 
diabetic GK-rat study and in-vitro cultured renal mesangial cells suggested 
increased MtDNA copy caused by hyperglycaemia. MtDNA content was 
significantly increased in kidneys of diabetic animals, when compared to the 
controls (Figure 3.1.) and also significantly up-regulated in renal cells cultured in 
high concentration of glucose (Figure 3.2.). These data suggest there may be a 
correlation between mitochondrial biogenesis and development of kidney 
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Fig.3.1. Mitochondrial DNA is up-regulated in diabetic rat kidneys. Goto Kakizaki (GK) 
rat study results. Diabetic rat kidneys contain more MtDNA per cell than control   







Fig.3.2. Mitochondrial DNA is increased by hyperglycaemia in human primary 
mesangial cells. HMCLs were cultured in 5mM (NG) and in 25mM (HG) for 6 days. 
Growth of mesangial cells in HG leads to increased MtDNA copy number. This increase 
can be reversed by removing the HG after 3 days. Data presented as median with range 
(Malik and Al-Kafaji, upublished). 
 
Several animal and human studies have described variations in MtDNA content 
in diabetes and diabetic complications, including DN, showing alterations in 
MtDNA in peripheral white mononuclear cells (Song et al., 2001, Khan et al., 
2011, Malik et al., 2009, Cormio et al., 2009), decrease in MtDNA copy number in 
blood vessel in patients with diabetic atherogenesis (Chien et al., 2012) and in 
skeletal muscle from patients with T2D (Kelley et al., 2002). The discrepancies 






























84 | P a g e  
 
Chapter 3: MtDNA content in in-vitro models of diabetes 
problems/variations with the methodologies used, including different methods 
of DNA extraction and accurate detection MtDNA content, without 
measurement of the pseudogenes (Malik et al., 2011).  
Although changes in the MtDNA levels were reported in patients with diabetes 
and diabetic complications (reviewed in the main introduction section), to date it 
is not known how glucose causes alteration in MtDNA levels, how these changes 
correlate with mitochondrial function and possible contribution to the disease 
development.  
While in-vivo studies provide physiological information about the disease, since 
the changes are systemic, it makes it difficult to study individual pathways and 
establish direct effects of hyperglycaemia on single cell types. Using in-vitro 
models provides valuable information and allows the researcher to manipulate 
experimental conditions in a way it might not be ethically or practically possible 
in the in-vivo experiments. Cells chosen in this study were human primary 
cultured mesangial cells (HMCs) and immortalised proximal tubule epithelial cell 
line (HK-2), as these two cell types are involved in the development of DN. 
Mesangial cells are specialised cells located around the glomerular capillaries 
within the renal corpuscle of the kidney. They have several functions, including 
carrying out the deposition of the matrix which results from increased 
glomerular filtration pressure. However, in DN, these cells contribute to the 
development of the disease, through expansion of the matrix into the capillary 
lumens (Wada et al., 2001). Proximal tubule epithelial cells create the lining of 
the duct within nephrons leading to the Bowman's capsule. Primarily, it was 
thought that major pathogenic mechanisms in DN development involves 
glomerular fibrosis, through mesangial expansion, but it is now known that 
tubular epithelial cells are also affected by inflammation and later fibrosis (Bohle 
et al., 1991).  
Both mesangial and tubular cells are highly energetic and contain many 
mitochondria due to the active filtration processes they are involved with (Brown 
and Breton, 1996, Hall et al., 2008). 
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3.3 Hypothesis and aims 
3.3.1 Hypothesis 
The main hypothesis under study in this work is that hyperglycaemia can cause 
early changes in mitochondrial DNA (content/quality) and that these changes can 
contribute to mitochondrial dysfunction. In the current chapter the first part of 
this hypothesis was investigated using cultured renal cells.   
3.3.2 Aims and objectives 
The main objective of this chapter was to demonstrate using cultured renal cells 
whether hyperglycaemia can alter MtDNA content in cells and whether any such 
changes are permanent. 
This aim will be met as follows:  
1. The effect of growth of renal cells in high glucose on MtDNA content will 
be evaluated.  
2. Time course experiments will be performed on renal cells which display 
glucose induced MtDNA changes. 
3. The effect of the reversing and oscillation of the glucose concentration on 
MtDNA content will be evaluated.  
The experimental strategy to carry out the above will be as follows: 
1. Three different renal cells will be used, immortalized mesangial and 
epithelial proximal tubular cells (HMCL and HK-2) and primary cultured 
mesangial cells (HMCs). 
2. Cells will be cultured in 5mM (normal, NG) and 25mM (high, HG) glucose, 
for various time points. 20mM mannitol in 5mM glucose (Man)  will be 
used as an osmolarity control. 
3. Following DNA extraction, MtDNA content will be measured as a 
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3.4 Results 
Changes in the MtDNA content were investigated in cells cultured in different 
glucose concentrations. Three different in-vitro models of hyperglycaemia were 
used, immortalized mesangial (HMCL) and tubular cells (HK-2), and primary 
cultured mesangial cells (HMCs). Cells were cultured in 5mM (NG) or 25mM (HG) 
glucose for 4 or 8 days. To exclude the possibility that change in MtDNA content 
occurs as a result of osmotic stress, cells were incubated in 5mM glucose plus 














Fig.3.3. Overview of chapter 3. Immortalized and primary mesangial cells (HMCL and 
HMCs) and tubular epithelial (HK-2) cells were cultured in DMEM containing 5mM (NG) 
or 25mM glucose (HG) and in 5mM glucose plus 20mM mannitol for the times shown. 
 
87 | P a g e  
 
Chapter 3: MtDNA content in in-vitro models of diabetes 
3.4.1 Does high glucose affect mitochondrial DNA copy number in renal 
cells cultured for 4 days? 
The aim of this experiment was to evaluate the effect of high glucose on MtDNA 
copy number in cultured renal cells.  Three types of human renal cells were used 
in the study; HMCs, HMCL and HK-2 cells. Following growth arrest in DMEM 
containing 0.5% FBS for 24 h to allow cell synchronisation, cells were cultured for 
4 or 8 days in DMEM containing 5mM (NG), 25mM (HG) or the 5mM glucose plus 
20mM D-mannitol (NGM). Total genomic DNA was extracted as described in the 
main methods section of this thesis (section 2.5.1), and template was sheared by 
sonication in order to avoid dilution bias [methods section 2.5.3. (Malik et al., 
2011)]. 
As shown in table 3.1, average concentration of DNA extracted from 
immortalized mesangial cells exposed to high glucose for 4 days was almost 2-
fold lower when compared to the controls (P<0.05). No statistically significant 
difference was observed in the average DNA yield extracted from HK-2 or HMCs 
cells cultured in media with different concentrations of glucose (table 3.1, 
P>0.05). 
To assess MtDNA content, ratio of mitochondrial to nuclear genome was 
measured using real-time qPCR. Oligonucleotides against human mitochondrial 
genome (hMito 3; accession number: NC_012920.1) and reference gene (hB2M1; 
accession number: NC_000015.10) were design and optimized previously in our 
group. These hMitoF3 (CACTTTCCACACAGACATCA) and hMitoR3 
(TGGTTAGGCTGGTGTTAGGG) designed against human mitochondrial genome 
(NC_012920) amplified a unique region of 127 bp, which is not duplicated in the 
nuclear genome (Fig.3.4.A). hB2MF1 (TGTTCCTGCTGGGTAGCTCT) and hB2MR1 
(CCTCCATGATGCTGCTTACA) designed against B2M precursor (NC_000015.10) 
amplified a 188 bp fragment (Fig.3.4.B). The specificity of the primers (one PCR 
product multiplied) was recognized as a single band when run on 2% agarose gel 
for both genes of interest (Fig.3.4.).  
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Table 3.1. DNA concentration extracted from human renal cells cultured in different 








Cells were cultured for 4 days in 5mM (NG), 25mM glucose (HG) and in 5mM glucose 
plus 20mM D-mannitol (NGM). Cells were washed in ice cold PBS, trypsinized and cell 
pellets collected for DNA extraction. NanoDrop instrument was used to determine DNA 
concentration in each sample. 5-6 observations of each condition were used in the study 
(HMCL) or 3-4 independent experiments (HK-2, HMCs). Data presented as Mean ± SD, 






Fig.3.4. Agarose gel electrophoresis of hMito3 and hB2M1 PCR products. The PCR 
products obtained from primers hMito F3and hMito R3 (Figure A) and primers hB2M F1 
and hB2M R1 (Figure B) electrophoresed on a 2% agarose gel. The 127bp hMito and 
189bp hB2M PCR products are indicated by the red arrows. Ladder bands are marked 
with white arrows and labelled with appropriate molecular weight sizes 
 
 
To detect copy number of mitochondrial and B2M gene fluorescence based qPCR 
assay and absolute quantification method were used as described in section 
2.7.2. Briefly 10 fold dilution of each transcript was used to create a standard 
curve (Fig3.5.A, 3.6A) and specificity of the primers was recognised as a single 
Cell type Treatment Average DNA concentration [ng/μl] 
HMCL 
NG 33 ± 12 
HG 18 ± 5 * 
NGM 30 ± 3 
HK-2 
NG 16 ± 13 
HG 14 ± 7 
NGM 16 ± 11 
HMCs 
NG 25 ± 8 
HG 18 ± 8 
NGM 30 ± 7 
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melt peak (Fig.3.5B, 3.6B). MtDNA content was determined as mitochondrial to 
nuclear gene ratio after extrapolating the values from the standard curves for 







Fig.3.5. Amplification of hMito3 in 10-fold dilutions. Dilution standards of hMito3 were 
prepared and 2ul of each standard was used in qPCR reaction and amplified. 
Fluorescence data was acquired once per cycle and amplification curve (A) was 
generated showing dilution series from 102 to 107 copies of hMito3. Melting point 
analysis (B) represents specificity of multiplied product as one single melt peak is visible 
at 83°C. (C) Standard curve showing the crossing point (Ct) for each of the 10-fold 









Fig.3.6. Amplification of hB2M1 in 10-fold dilutions. Dilution standards of hB2M were 
prepared and 2ul of each standard was used in qPCR reaction and amplified. 
Fluorescence data was acquired once per cycle and amplification curve (A) was 
generated showing dilution series from 102 to 107 copies of hB2M1. Melting point 
analysis (B) represents specificity of multiplied product as one single melt peak is visible 
at 79°C. (C) Standard curve showing the crossing point (Ct) for each of the 10-fold 
dilutions plotted against a log concentration. Threshold line is shown in red.  
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As illustrated on Fig.3.7. hyperglycaemia had no significant effect on MtDNA 
copy number in renal cell lines. MtDNA copy number seems to be lower in HMCL 
cells exposed to high glucose (293± 197) when compared to the control (478± 
281), in   contrary to H2-2 cells grown in high glucose, which MtDNA content was 
1.5-fold higher (430± 187) when compared to the control (298±178), but none of 
these results were significant (P>0.05, Fig.3.7). However in primary mesangial 
cells exposed to high glucose for 4 days, MtDNA content was approximately 2.5-
fold higher when compared to the control (717± 157 vs. 280±53, respectively 
P<0.01). MtDNA copy number detected in primary mesangial cells was similar to 
the one measured in tubular cells (280±53 vs. 298±178) but lower than in HMCL 
cells (478± 281), when cells were culture in normal glucose (Fig.3.7). Osmotic 








Fig.3.7.Mitochondrial DNA content in human renal cells cultured in different 
concentrations of glucose. Cells were synchronized FBS for 24hr and then cultured in 
DMEM containing 5mM (NG) and 25mM (HG) glucose for 4 days. 5mM glucose plus 
20mM mannitol (NGM) was used as an osmotic control. MtDNA copy number was 
assessed as a mitochondrial to nuclear gene ratio using real-time qPCR method. Data 
presented as a mean ± SD, n=5-6 observations for HMCL cells and n=3-4 independent 




The above data show, that exposure to hyperglycaemia had no significant effect 
on MtDNA content in any of the examined immortalized renal cells but did 
significantly affect the cell growth and resulted in lower DNA yield in mesangial 
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cell line. In the primary mesangial cells cultured in high glucose for 4 days MtDNA 
copy number was significantly up-regulated and no significant effect on cell 
growth was observed. 
3.4.2 Time course study of the effect of high glucose on mitochondrial DNA 
copy number in human primary mesangial cells 
As shown above, MtDNA copy number in HMCs was elevated after 4 days of 
culture in high glucose, therefore the aim of this experiment, was to assess 
MtDNA copy number in response to different exposure time to hyperglycaemia. 
HMCs were grown in NG and HG glucose for 1, 2, 3 and 4 days in order to assess 
effect of high glucose on MtDNA changes over time. 
MtDNA content was almost 2 fold higher after 24h of culture in HG (421 ± 112) 
when compared to time matched control (242 ± 47), but the difference was not 
significant (P>0.05). 72 and 96 h of high glucose treatment caused a significant 
up-regulation of MtDNA, when compared to the controls (537 ± 68 and 647 ± 32 







Fig.3.8. Time course study of mitochondrial DNA content in primary mesangial cells 
cultured in different glucose concentrations. HMCs were synchronized in 0.5% FBS  for 
24hr and then cultured in DMEM containing 5mM (NG), 25mM (HG) for 4 days. Samples 
were collected every 24 h. Following DNA extraction, MtDNA copy number was assessed 
as a mitochondrial to nuclear gene ratio using real-time qPCR method. Representative 
control for MtDNA content in cells cultured in NG for 4 days is shown. Data presented as 
a mean ± SD, n=3-4, Student’s t-test where, *P<0.05, **P <0.01  
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The above data show that MtDNA copy numbers in HMCs were up-regulated as 
quickly as within 24 h after the exposure to hyperglycaemia and this increase 
became statistically significant after 72 hours. 
3.4.3 Does mitochondrial DNA copy number remain up-regulated in 
human primary mesangial cells after 8 days of culture in high 
glucose? 
In order to see, if the increase in MtDNA content persists in HMCs exposed to 
high glucose for a longer period of time, cells were cultured in 25mM glucose for 
8 days. As there was no effect of the osmotic control observed on MtDNA copy 
number in the previous study, mannitol was not used in this part of the 
experiment. Although MtDNA content was still elevated in cells cultured in high 
glucose for 8 days, the difference was no longer statistically significant in cells 
grown in high glucose when compared to the control (792 ± 575 vs. 263 ± 120, 
P>0.05, Fig.3.9). No effect of passage on MtDNA in cells cultured in NG was 







Fig. 3.9. Mitochondrial DNA content in human primary mesangial cells after 8 days of 
culture. Cells were synchronized in 0.5% DMEM for 24hr and then cultured in 5mM 
(NG), 25mM (HG) glucose for 4 and 8 days. Following DNA extraction, MtDNA copy 
number was assessed as a mitochondrial to nuclear gene ratio using real-time qPCR 
method. Data presented as a mean ± SD, n=3 -4, Student’s t-test where, **P<0.01  
 
To summarize, MtDNA content in HMCs cultured for 8 days in high glucose was 
still increased but the difference was not significant.  
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3.4.4 Is glucose-induced up-regulation of mitochondrial DNA content in 
mesangial cells reversible? 
It was shown above, that exposure of HMCs to high glucose for 4 and 8 days 
increases MtDNA content. To assess if these changes were permanent or 
possibly reversible, a ‘rescue’ study was designed to examine MtDNA content in 
cells which were cultured in high glucose growth medium followed by low 
glucose. Three time points were chosen for 4 and 8 days respectively, as 
illustrated (Fig.3.10). 
 
       
 
 
Fig.3.10. Schematic representation of the experimental strategy. 5mM glucose (NG), 
25mM glucose (HG). HG/NG, growth medium reversed from HG to NG.   
As shown on Fig.3.11, short exposure to 25mM, following longer ‘recovery’ with 
5mM glucose medium (HG1/NG3), had no effect on MtDNA content (P>0.05, 
Fig.3.11. MtDNA copy number was significantly reduced in HG2/NG2 group when 
compared to the cells cultured in the HG for 4 days (218 ±40 vs. 936 ±383 
respectively, P<0.05).). 3 days exposure to 25mM glucose following 1 day of 
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treatment with 5mM glucose (HG3/NG1) did not significantly altered MtDNA 
copy number when compared to the control and cells cultured in HG (P>0.05, 
Fig.3.11). 4 days of the exposure to 25mM glucose significantly up-regulated 







Fig. 3.11. Glucose-induced mitochondrial DNA content change in human primary 
mesangial cells. Cells were synchronized in 0.5% DMEM for 24hr and then cultured in 
5mM (NG), 25mM (HG) glucose or in reversed conditions (HG/NG) for 4 days. Following 
DNA extraction, MtDNA copy number was assessed as a mitochondrial to nuclear gene 
ratio using real-time qPCR method. Data presented as a mean ± SD, n=3 observations, 
one way ANOVA with Tukey’s post hoc test where, *P<0.05 
 
 
After 8 days of culture and with media change, there was no difference between 
the groups as shown on Fig.3.12. MtDNA content seem to be dys-regulated in all 
groups in which cells were exposed to high glucose, but none of the results was 
significant, when one way ANOVA was performed (P>0.05, Fig.3.12).  
Short exposure to high glucose, following longer ‘recovery’ with medium with 
physiological glucose concentration (HG2/NG6), did not normalise MtDNA copy, 
which was almost two fold higher than the control (P>0.05, Fig.3.12 A, B).  
4 days exposure to high glucose flowing 4 days treatment with normal glucose 
did not significantly alter MtDNA copy number  in any of the experiments, but 
MtDNA  content in this group was almost 3 fold higher than in the control 
(P>0.05, Fig.3.12A, B). Prolonged, 6 days of the exposure to high glucose, 
following the media change to normal glucose for 2 days (HG6/NG2), had no 
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significant effect on MtDNA copy number, but there were contradictory results 
observed in this group between the two experiments (P>0.05, Fig.3.12). There 
was a stimulating effect (although not significant) of high glucose on MtDNA 
copy number observed in the experiment shown on Fig3.12A and no effect of 
hyperglycaemia observed in experiment illustrated on Fig.3.12B.  
 
A)                B)     





Fig. 3.12. Mitochondrial DNA content in human primary mesangial cells is not affected 
in glucose reversal experiment after 8 days. Cells were synchronized in 0.5% DMEM for 
24hr and then cultured in 5mM (NG), 25mM (HG) glucose or in reversed conditions 
(HG/NG) for 8 days in two independent experiments (A-B). Following DNA extraction, 
MtDNA copy number was assessed as a mitochondrial to nuclear gene ratio using real-
time qPCR method. Following DNA extraction, MtDNA copy number was assessed as a 
mitochondrial to nuclear gene ratio using real-time qPCR method. Data presented as a 
mean ± SD, n=3 observations per experiment, one way ANOVA where, P>0.05  
 
 
Pilot data from the 4-days glucose reversal experiment showed, that MtDNA 
content can be altered by reversing glucose concentration, but two independent 
experiments for 8 days proved to be inconclusive (Fig.3.12). Therefore, I have 
repeated the experiment on different batch of primary mesangial cells, choosing 
only two reversal time points for 4 and 8 days, in order to see if the MtDNA is still 
dys-regulated or if it can be normalised by a glucose concentration change. 
As illustrated on Fig.3.13, in cells, which were cultured in high glucose for 2 days 
and had the media changed to normal glucose for  2 days (HG2/NG2), MtDNA 
copy number was not significantly different when compared to the control 
(404±254 vs. 280±53, P>0.05, Fig.3.13). However, in the HG4/NG4 group MtDNA 
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copy number remained significantly higher when compared to the control 






Fig.3.13. Mitochondrial DNA content in human primary mesangial cells can be changed 
by reversing glucose concentrations. Cells were synchronized in 0.5% FBS for 24hr and 
then cultured in DMEM containing 5mM (NG), 25mM (HG) glucose or in reversed 
conditions (HG/NG) for 4 and 8 days. Following DNA extraction, MtDNA copy number 
was assessed as a mitochondrial to nuclear gene ratio using real-time qPCR method. 
Data presented as a mean ± SD, n=3-4, one way ANOVA with Tukey’s post hoc test 
where, *P<0.05  
 
 
In summary, data from the glucose reversal experiment showed that the increase 
in MtDNA copy number is dependent on the exposure time to high glucose, and 
that this increase cannot be reversed after 4 days of the high glucose treatment. 
3.4.5 Does oscillation of the glucose concentration in the growth medium 
affect MtDNA content in human mesangial cells? 
Primary mesangial cells were cultured for 4 or 8 days, and had their growth 
medium changed from high glucose to normal (HG/NG) or from normal to high 
glucose (NG/HG) every 1 day (HG1/NG1), or every 2 days (HG2/NG2) 
respectively. Two independent experiments for each of the selected times points 
were performed.  
Oscillation of the glucose concentration for 4 days, caused a significant, 2-4 fold 
up-regulation of MtDNA in HMCs, but only following the exposure to high 
glucose for the last 24 h before the cells collection when compared to the HMCs 
cultured in normal glucose (NG1/HG1, P<0.01, P<0.05, Fig.3.14A, B). When the 
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growth medium glucose levels were returned to physiological concentration, 
although there was still an up-regulation of MtDNA content, the result was no 
longer significant (HG1/NG1, P>0.05, Fig.3.14A, B). 
 
A)                                                                 B) 
 
Fig. 3.14. Mitochondrial DNA content in human primary mesangial cells grown for 4 
days in various glucose concentrations. Cells were synchronized in 0.5% FBS for 24hr 
and then cultured in DMEM containing 5mM (NG), 25mM (HG) glucose or in reversed 
glucose concentrations (HG1/NG1, NG1/HG1, medium changed every 1 day) for 4 days 
in two independent experiments (A,B). Following DNA extraction, MtDNA copy number 
was assessed as a mitochondrial to nuclear gene ratio using real-time qPCR method. 
Data presented as a mean ± SD, n=3 observations per experiment, one way ANOVA with 
Tukey’s post hoc test where, *P<0.05, **P<0.01 
 
 
Oscillation of the glucose concentration every two days for 8 days caused an 
increase in MtDNA copy number but result was not statistically significant in any 
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Fig.3.15. Mitochondrial DNA content in human primary mesangial cells grown for 8 
days in various glucose concentrations. Cells were synchronized in 0.5% DMEM for 24hr 
and then cultured in 5mM (NG), 25mM (HG) glucose or in reversed conditions 
(HG2/NG2, NG2/HG2, medium changed every 2 days) for 8 days in two independent 
experiments (A,B). Following DNA extraction, MtDNA copy number was assessed as a 
mitochondrial to nuclear gene ratio using real-time qPCR method. Data presented as a 
mean ± SD, n=3-4 observations per experiment, one way ANOVA 
 
In summary, oscillation of the glucose concentration in the growth medium for 4 
days significantly affected MtDNA content. Moreover, final glucose 
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3.5 Discussion 
Data from the current study show, that MtDNA content is positively regulated by 
hyperglycaemia in primary cultured human mesangial cells. No significant 
changes in MtDNA copy number were observed in any of the tested 
immortalised cell lines, HK-2 and HMCL. In addition increase in MtDNA content 
occurs as early as 24 hours following the exposure to high glucose. Changes in 
glucose concentration in the growth medium further contributed to MtDNA 
number dys-regulation. In the ‘rescue’ experiment when high glucose growth 
medium was substituted with a low-glucose one, after 4 days of cells exposure to 
high glucose, changes in the MtDNA were not reversible. 
The lack of any differences in the response to hyperglycaemia in  the 
immortalised cells, was surprising, but in the case of HMCL, the problem may be 
with the culture system, as this cell line already had a high passage number (>50) 
when used in these experiments and high passage has been shown to affect cell 
line’s characteristics over time (Chang-Liu and Woloschak, 1997). 
Tubular cells seem to have dys-regulated level of MtDNA, which was slightly 
higher than in controls, but limitation may be, not using the correct, fully 
optimised experimental time points, as these cells might be slightly more/less 
sensitive to the high glucose concentrations, therefore this experiment may need 
further optimising. Another reason for the lack of differences in the immortalized 
cells may be the different characteristics of the cell lines, which may lose some 
properties from the primary cells during the viral transfection and therefore 
respond differently to treatment. As immortalized cell lines are in-vitro 
equivalent of cancerous cells, they may not use their OXPHOS systems as much 
as the cells they were originated from and rely more on glycolysis. 
However, data obtained from primary mesangial cells clearly show MtDNA 
alteration, when cells were exposed to high glucose. Mesangial cells are the cells 
surrounding blood vessels in kidney and their excessive proliferation and 
production of extracellular matrix contribute to the pathophysiological 
mechanism during the development of DN (Wada and Makino, 2013). It is well 
established that these cells are susceptible to a high glucose environment and 
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when exposed to hyperglycaemia, the increased production of free radicals and 
activation of signalling pathways present in DN is observed (Henningsen et al., 
2003, Ha and Lee, 2005, Catherwood et al., 2002). Published data from our 
group, also suggested increased ROS in human mesangial cells when analyzed by 
confocal microscopy and flow cytometry in response to hyperglycaemia (Al-Kafaji 
and Malik, 2010).  
However, to my knowledge this is the first study showing up-regulation of 
MtDNA in human renal cells exposed to hyperglycaemia. In the presence of the 
oxidative stress, when the redox balance of the cells is disturbed, there might be 
an alteration in MtDNA copy number and MtDNA function. In healthy cells, 
mitochondrial mass is regulated through mitochondrial biogenesis and 
degradation via mitophagy, but in the case of cellular signalling dys-regulation, 
an adaptive response that leads to increased  mitochondrial mass can occur 
(Michel et al., 2012). MtDNA copy number was increased as early as 24 hours 
after the exposure to high glucose, which is not surprising, as MtDNA resemble 
bacterial DNA and can replicate in a very short time (Bogenhagen et al., 1979). 
Also, unlike nuclear DNA, MtDNA replication happens independently of the cell 
cycle (Sazer and Sherwood, 1990). Due to the lack of strict restriction in 
replication (Clayton, 1982), increases in MtDNA could be an adaptive response of 
cells, trying to cope with the nutrient overload by increasing number of the 
mitochondria, or a compensatory mechanism to high-glucose induced 
mitochondrial damage. Induction of the MtDNA might be some sort of a 'rescue 
mechanism’ that would help cells overcome free radical damage to their 
mitochondria. 
However, after 8 days exposure to high glucose, MtDNA was still up-regulated 
but the result was no longer significant. Possible explanations might be either 
technical issue with the experiments, or that cells removed the mutated MtDNA, 
and mitochondria by mitophagy process (Ma et al., 2013). Observed changes in 
MtDNA following the treatment with high glucose could also be transient and 
represent an early response of the cells to hyperglycaemia. 
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The theory of the compensatory mechanism of increased MtDNA content caused 
by the falling mitochondrial function is supported by a clinical study from 
Lindinger et al.,(2010). They reported an increase in MtDNA content in adipose 
tissue from obese patients and suggested that this up-regulation of MtDNA copy 
number in patients with severe obesity as a form of an adaptation to 
dysfunctional mitochondria (Lindinger et al., 2010). Wei et al. (2001), reported 
increased mitochondrial mass and MtDNA content in cybrid cells from skin 
fibroblasts carrying a 4977 bp deletion when compared to cybrids with wild type 
MtDNA only. Moreover the relative increase in MtDNA amount correlated 
positively with increased percentage of the mutated MtDNA content and by 
treatment with H2O2 (Wei et al., 2001). 
High glucose-increase in MtDNA copy number, which could not be reduced by 
normalizing glucose levels in a 'rescue' experiment' might imply epigenetic 
changes caused by glucose as suggested by El-Osta and Brownlee (El-Osta et al., 
2008). Results from those studies suggested that even transient exposure of 
vascular cells to high glucose, both in-vitro and in-vivo, can cause long lasting 
effects on gene expression and methylation (El-Osta et al., 2008).  
One of the limitations of the current study may be a low number of repeats for 
some of the experiments and not fully optimised experimental time points, 
especially for HK-2 cells.  Also the 'rescue' experiments in mesangial cells, 
showed some variability in MtDNA content after the exposure to hyperglycaemia 
and following normalization of glucose levels, therefore this experiment should 
be repeated with larger numbers. Furthermore, 8 day exposure caused an 
increase in MtDNA, but because of variability, it was no longer significant. An 
increased number of repeats would lower the observed variability and enable 
better definition of the changes in MtDNA replication in response to 
hyperglycaemia. Finally, extending the treatment time might provide valuable 
information about the long term effects of hyperglycaemia on the kidney cells. 
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In summary, I have shown that hyperglycaemia positively regulates MtDNA copy 
number in primary cultured human mesangial cells and that these were transient 
and may represent early compensatory response to the hyperglycaemia. 
 
  




Hyperglycaemia-induced changes in mitochondrial 
DNA in mouse models of diabetes 
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4.1 Abstract 
 
Background/Aims: The hypothesis that will be tested in this thesis is that 
hyperglycaemia/high glucose can cause early changes in mitochondrial DNA 
content and that these changes can contribute to mitochondrial dysfunction. In 
the current chapter, the effect of hyperglycaemia on MtDNA content in organs 
and circulating cells in different mouse models of diabetes was investigated. 
Methods: Tissue and whole blood samples were collected from 3 different 
mouse models of diabetes representing: T1D (STZ-induced and spontaneous β-
PhB2-/- mice) and T2D (Lepob/ob mice). Following DNA extraction, MtDNA content 
was determined as the mitochondrial genome to nuclear genome ratio using real 
time qPCR. 
Results: In the STZ-induced diabetic mice MtDNA content was increased by 4 fold 
in mouse blood after 7 days of induction of diabetes (P<0.05). After 4 weeks of 
hyperglycaemia, there was a significant decrease in MtDNA content in kidneys of 
STZ- mice. No significant difference between diabetic and control mouse heart, 
brain, lung and liver were observed (P>0.05) but an increase in MtDNA content in 
STZ-mouse islets was observed (P<0.05). In β-PhB2-/- mice, significantly increased 
MtDNA content was observed in circulating cells sampled weekly (P<0.05), but 
no significant change in the amount of MtDNA in the kidneys was observed 
(P>0.05). In the Lepob/ob there was a decline in MtDNA copy number in the 
kidneys, but result was not significant (P>0.05).  
Conclusion: These results show that hyperglycaemia leads to the increase in 
MtDNA content in circulating cells in the mouse models of diabetes. These data 
also suggest that there is a loss in MtDNA in diabetic mouse kidney, which may 
be a result of either leakage of kidney MtDNA into circulation or increased 
removal of the damaged mitochondria.  
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4.2 Introduction 
In the previous chapter, I have shown that MtDNA is elevated in renal cells 
cultured in 25mM glucose. In this chapter the focus is on changes in MtDNA 
quantity in tissues of three in-vivo mouse models of diabetes. It is generally 
assumed that MtDNA is differentially expressed in various organs and its level 
correlates with mitochondrial function (Hock and Kralli, 2009). Unpublished 
results from our group obtained from pilot experiments using diabetic GK-rat 
samples suggested increased MtDNA copy caused by hyperglycaemia in the rat 
kidneys (Malik, unpublished). Several animal studies have described variations in 
MtDNA content and mitochondrial dysfunction in diabetes, including decreased 
activity of respiratory enzyme complexes, depletion of mitochondrial membrane 
potential, and decreased ATP production in diabetic rat liver mitochondria (Chen 
et al., 2011). Another group investigated the role of mitochondrial dysfunction 
and insulin resistance by using two different mouse models of type 1 and type 2 
diabetes, and reported increased ROS and later oxidative stress having an 
inhibiting effect on mitochondrial function at the molecular, structural and 
functional level in mouse muscle tissue (Bonnard et al., 2008). Altered 
mitochondrial structure and lower membrane potential had been highlighted in 
ischemic kidney injury in the rat (Plotnikov et al., 2007). Brookes at al. (2009) 
using mice an in-vitro mouse proximal tubular cell cultures as models of acute 
kidney injury, observed changes in mitochondrial structure (increased 
fragmentation) and depleted mitochondrial function (Brooks et al., 2009).  
The specific hypothesis of this chapter will be addressjed using the following 
models: 
a) Chemically induced model of T1D: a streptozotocin-induced diabetic mouse 
model (STZ-diabetic mice). STZ chemical structure is similar to glucose; therefore 
the compound is delivered to the cells through GLUT-2 transporter. STZ 
specifically targets β-cells and causes cell necrosis through the depletion of ATP. 
Animals become diabetic within 3 days after the injection. (Rackham et al., 2013) 
(table 4.1). C57BL/6 mice are extensively used for studies of kidney disease 
which are typically made diabetic by an injection of STZ, as it results in the 
destruction of the pancreatic β-cells. In humans, diabetic nephropathy is 
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clinically characterized by the development of microalbuminuria and a decline in 
renal function. These clinical parameters are observed in the rodent models, 
although the renal dysfunction is less severe when compared with a patient with 
DN (Tesch and Allen, 2007). The STZ diabetic mice typically develop extreme 
hyperglycaemia and insulin deficiency which can be observed as quickly as 3 days 
following the acute injection of STZ (Rackham et al., 2013).  
However STZ can have a toxic effect on the kidney, especially the tubular 
epithelium. Also in humans, DN gradually develops in patients 15 to 25 years 
after the onset of diabetes (Caramori et al, 2000). Most of the studies of DN in 
animals, such as the progression of albuminuria and histopathologic changes 
have focused on the earlier indication of DN due to the cost and convenience 
and not openly used renal deficiency as an end point (Sharma et al, 2003). In the 
current study the effect of hyperglycaemia on mitochondrial biogenesis in mouse 
kidneys as an indication of early change in diabetes and DN is investigated.  
b) Knockout mouse model of T1D: prohibitin 2 knockout (β-PHB2-/-) mice. 
Prohibitins are conserved proteins found as heterodimers (built from subunits of 
prohibitin 1 and prohibitin 2), localised mainly in mitochondrial membranes. 
They are responsible for a cell cycle, apoptosis, and more importantly 
functionally associated with MtDNA and mitochondrial biogenesis (Artal-Sanz 
and Tavernarakis, 2009). β-PHB2-/- mice were generated as a crossbred between 
flox-PHB2-flox (PHB2fl/fl) mice and rat-insulin promoter driven Cre mice (RipCre). 
The mix of the two breeds causes deletion of the PHB2 gene exclusively in β-cells 
in the pancreas. PHB2 mutants spontaneously developed diabetes at 6 weeks of 
age (glucose levels > 11.1mM) and progressed to severe hyperglycaemia 
afterwards (glucose levels >25mM). Blood samples were collected weekly, 
starting from animals at pre-diabetic state (week 4), till the end the termination 
of the experiment (week 11, which was equal to 5 weeks of the duration of 
severe diabetes). This knockout mouse model of diabetes has proven to be quite 
severe, with mice not surviving more than 14 weeks due to severe diabetes 
(Supale et al., 2013). 
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This model represents a model of spontaneous diabetes progression, through a 
series of molecular events which appear after 3 weeks and does not require 
administration of chemicals such as STZ. Therefore, we used this spontaneous 
model of diabetes for an examination of the expression of our genes of interest 
in the presence of hyperglycaemia parallel to STZ-induced diabetic mice. 
c) Lepob/ob (ob/ob) mice are a mouse model of T2D. These animals have a 
mutation in the leptin gene which leads to uncontrolled appetite and quick 
weight gain. Mutants were discovered in the out-bred colony in the Jackson 
Laboratory in 1949 and later bred into C57BL/6 mice (King, 2012, Ingalls et al., 
1950). Ob/ob mice are a very good model for insulin resistance caused by obesity 
as they start gaining weight within 2 weeks following birth and develop 
hyperinsulinaemia and moderate hyperglycaemia after 4 weeks (King, 2012) 
(table 4.1). Although changes in renal structure and function in response to 
hyperglycaemia in the ob/ob mice are  relatively mild (Soler et al., 2012), Chua et 
al. (1996) observed increased mesangial matrix expansion in FVB ob mice (Chua 
et al., 1996). In the current study, ob/ob mice were used as a model of T2D the 
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4.3 Hypothesis and aims 
4.3.1 Hypothesis 
The main hypothesis under study in this work is that hyperglycaemia can cause 
early changes in mitochondrial DNA content and that these changes can 
contribute to mitochondrial dysfunction. In the current chapter this hypothesis 
was investigated using mouse models of diabetes.  
4.3.2 Aims and objectives 
The main aim of this chapter was to, investigate using in-vivo models of diabetes, 
whether hyperglycaemia can alter MtDNA content in organs and circulating cells 
of diabetic mice. 
This aim will be met as follows:  
1. The effect of hyperglycaemia on MtDNA content in various mouse organs 
and circulating cells will be evaluated in three different mouse models 
representing T1D and T2D. 
 
The experimental strategy to carry out the above will be as follows: 
 1. Three different mouse models of diabetes were used: 
a) Mice made diabetic using  STZ were used as a model of T1D.  
b) Prohibitin2 knockout mice (β-PhB2-/-) were used as a spontaneous 
model of T1D 
c) Leptin deficient ob/ob mice were used as a model of T2D 
2. Blood and tissue samples will be collected after 7 and 31 days of 
hyperglycaemia in STZ-model from control mice, normoglycaemic 
transplanted mice and diabetic transplanted mice. 
3. Blood samples will be sampled weekly and kidney tissues will be collected 
after 6 weeks of diabetes in β-PhB2-/- model. 
4.  Kidneys will be collected from 8-week old leptin deficient ob/ob mice.  
5. Following DNA extraction, MtDNA content will be measured as a 
mitochondrial to nuclear genome ratio using real-time qPCR. 
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4.4 Results 
In this chapter changes in MtDNA content in response to hyperglycaemia were 
investigated. Three different mouse models of diabetes were used; STZ-induced 
model of T1D, a β-PHB2-/- model of T1D and insulin resistant ob/ob mice as a 






Fig.4.1. Overview of chapter 4. 
 
To measure MtDNA content, total DNA extraction was performed as described in 
the methods section 2.5 and following template pre-treatment MtDNA assay was 
performed. Unique regions in the mitochondrial and nuclear genome were used 
to design an assay which does not co-amplify pseudogenes (Malik et al., 2011). 
Oligonucleotides against mouse mitochondrial genome (mMito; accession 
number: NC_012387.1) and a single copy reference gene (mB2M; accession 
number: NC_000068.7) were designed and optimized previously in Malik’s lab. 
These mMitoF1 (CTAGAAACCCCGAAACCAAA) and mMitoR1 
(CCAGCTATCACCAAGCTCGT) designed against mouse mitochondrial genome 
(NC_012387) amplified a unique region of 125bp (Fig4.2.D), which is not 
duplicate din the nuclear genome. mB2MF (ATGGGAAGCCGAACATACTG) and 
hB2MR (CAGTCTCAGTGGGGGTGAAT) designed against B2M precursor amplified 
a 177bp fragment (Fig.4.3D). Fluorescence based qPCR assay was used to detect 
copy number of mitochondrial and B2M gene (nuclear control) by absolute 
quantification method by applying 10 fold dilution of each transcript to create 
standard curve. The specificity of the primers (one PCR product amplified) was 
recognised as a single melt peak and single band when  run on 2% agarose gel for 
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both genes of interest (Fig. 4.2 and Fig. 4.3). MtDNA content was measured as 
mitochondrial to nuclear gene ratio. 
 
Fig.4.2. Mouse mitochondrial qPCR assay. Standard curve of mMito1 showing dilution 
series from 108 to 103, fluorescence data acquired once per cycle (A). Product melting 
temperature (Tm) representing the specificity of the multiplied product as one single 
melt peak at 79°C (B). Standard curve efficiency showing the crossing point for each of 
the 10-fold dilutions with efficiency: 1.96 and error = 0.037 (C). Agarose electrophoresis 
of PCR product run alongside 100bp marker. A single product of PCR reaction is shown 








Figure 4.3. Mouse B2M qPCR assay. Standard curve of B2M product showing dilution 
series from 107 to 102, fluorescence data acquired once per cycle (A). Product melting 
temperature (Tm) representing the specificity of the multiplied product as one single 
melt peak at 81°C (B). Standard curve efficiency showing the crossing point for each of 
the 10-fold dilutions with efficiency: 1.92 and error =0.14 (C). Agarose electrophoresis of 
PCR product run alongside 100bp marker.  Single product of PCR reaction (177bp) shown 
with red arrow (D).     
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4.4.1 Mitochondrial DNA content in the streptozotocin induced mouse 
model of type 1 diabetes 
The experimental design and detailed description of the groups used in the study 
are presented in the Fig.4.4 and table 4.1.  Three groups of mice were used; 
control untreated C57Bl/6 mice, diabetic (D) which had been injected with STZ 
and didn't cure after transplantation of islets and treated (T) mice in which 
hyperglycaemia was reversed by the transplant (Table 4.1). Kidneys and blood 
samples of these mice were collected after 1 week (T7, D7) and 4 weeks (T31, 
D31) post-transplantation and compared to samples collected from non-diabetic 
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Table 4.1. Experimental mouse groups used in STZ study. Groups were divided based 

















non treated animals, non-
diabetic  








streptozotocin, 3 days after 
injection islets were 
transplanted and mice 
were diabetic for 7 days 
(transplantation failed) 






streptozotocin, 3 days after 
injection islets were 
transplanted and mice 
were normoglycaemic for 7 
days (transplantation 
successful) 






streptozotocin, 3 days after 
injection islets were 
transplanted and mice 
were diabetic for 31 days  
(transplantation failed) 






streptozotocin, 3 days after 
injection islets were 




3 days <11.1 
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The glucose levels in the mice used for this experiment are shown in Fig.4.4. As 
can be seen, the controls remained normoglycaemic (<11mM glucose) for the 
duration of the experiment. The treated mice were diabetic (>20mM glucose) for 
3 days and following islets transplant had hyperglycaemia reversed to blood 
glucose concentration of <11mM, whereas the diabetic mice remained 











Fig.4.4. Schematic illustration of the treatment in the STZ model of diabetes used in 
this study. Mice were made diabetic by streptozotocin injection, three days after the 
injection diabetic mice received a suboptimal islet graft of 150 islets transplanted under 
the left kidney. Time points representative for 7 and 31 days of duration of the 
experiment. Control mice were not given any injections. 
 
 
• Mitochondrial DNA content in the kidneys of STZ-diabetic mice 
 
The aim of this experiment was to evaluate the effect of high blood glucose on 
MtDNA copy number in the kidneys of diabetic mice.  
MtDNA content was quantified by using real-time qPCR method in DNA 
extracted from kidney sections of the 3 groups, healthy controls, treated and 
diabetic mice as described in the methods section. MtDNA copy number was 
estimated at approximately 400 copies per nuclear genome in healthy control 
mouse kidneys (Fig.4.5). In the kidneys of mice treated with islets' transplant, 
and subsequently cured for 7 days, there was a reduction in the MtDNA copy 
number when compared to the controls (258±72 vs. 385±42 respectively, 
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P>0.05), and this trend remained after 31 days of treatment (283±71), but it was 
not significant. Mice which were diabetic for 7 days had reduced MtDNA levels 
(232±112), when compared to the control group (385±42), but result was not 
significant (P>0.05). After 31 days, the depletion in MtDNA content was greater 
than 2 fold  when compared to non treated controls in the diabetic mice 








Fig.4.5. Hyperglycaemia affects mitochondrial DNA copy number in diabetic mouse 
kidneys in streptozotocin induced model of diabetes. C57BL/6 mice were made 
diabetic by streptozotocin injection, three days after the injection; some of the diabetic 
mice received a suboptimal islet graft of 150 islets transplanted under the left kidney (T7 
and T31).Tissue samples were collected 7(D7) and 31 (D31) days after induction of 
diabetes in mice and also from healthy controls. Following DNA extraction, MtDNA 
content was assessed as a ratio of mitochondrial to nuclear gene using qPCR method. 
Data are shown as mean ± SD, n =3-6, one way ANOVA with Tukey’s post hoc test 
where, *P<0.05 vs. Control 
 
 
• Mitochondrial DNA content in the circulating cells in STZ-diabetic mice 
 
Peripheral whole blood samples collected from STZ-induced diabetic mice were 
used in order to assess MtDNA content in circulating cells. As shown on Fig.4.6, 
MtDNA content in circulating cells in control animals was approximately 200 
copies per nuclear genome. D7 group showed a highly significant, 4 fold increase 
in MtDNA copy number when compared to the healthy control group (854 ± 636 
vs. 202±96 respectively; P<0.01). After 31 days of diabetes, MtDNA content 
returned to the control levels (113± 53 copies of MtDNA) and was significantly 
down-regulated when compared to D7 group (P<0.05). There was no difference 
in treated mice after 7 (T7) and 31 days (T31), when compared to the control 
group (Fig.4.6, P>0.05).  
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Fig.4.6. Hyperglycaemia affects mitochondrial DNA copy number in circulating cells in 
mouse blood in streptozotocin induced model of diabetes. C57BL/6 mice were made 
diabetic after single injection of streptozotocin. Some of the diabetic mice received a 
suboptimal islet graft of 150 islets transplanted under the left kidney (T7, T31) .Blood 
samples were collected 7(D7) and 31 (D31) days after induction of diabetes and from 
healthy controls. Following DNA extraction, MtDNA content was assessed as a ratio of 
mitochondrial to nuclear gene using qPCR method. Data are shown as mean ± SD, n =2-
6, one way ANOVA with Tukey’s post hoc test where, **P<0.01 (D7 vs. Control), ##P<0.01 
(D7 vs. D31). 
 
 
• Mitochondrial DNA content in different organs in control and diabetic 
mice 
 
Having established that hyperglycaemia caused a reduction in MtDNA content in 
the diabetic mouse kidney (D31) and a transient increase in circulating cells (D7), 
the next aim was to assess levels of MtDNA in other organs in control and 
diabetic mice (31D), in order to assess if changes were organ specific or systemic. 
Following DNA extraction, MtDNA copy number was measured in various control 
(table 4.2 and Fig.4.7) and diabetic (table 4.3 and Fig.4.8) mouse tissues.  
 
The results from control mice showed that MtDNA levels were the highest in the 
heart (~600 copies), followed by the kidney (~400 copies) and lowest in the lung 
and islets (~40 copies) (table 4.2). A similar trend was observed in the diabetic 
mouse tissues after 31 days of hyperglycaemia, with the highest MtDNA levels 
detected in mouse heart (~700 copies) and lowest in the lung (~30copies) and 
islets (~60 copies) (table 4.3). 
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Table 4.2. Mitochondrial DNA copy number in healthy mouse tissues. 
 Lung Liver Heart Kidney Whole blood Brain Islets 
N 6 6 6 6 6 3 4 
        
Mean 38 290 577 385 199 131 44 
SD 16 46 406 41 102 67 8 
Minimum 9 234 156 331 79 80 32 





The tissues were collected from healthy, 8-12 weeks old C57BL/6 mice and following 
DNA extraction, MtDNA copy number was assessed via real-time qPCR method. 
 






The tissues were collected from diabetic C57BL/6 mice (D31) and following  














Fig.4.7. Mitochondrial DNA copy numbers in control mouse tissues. Tissue samples 
were collected from healthy control C57BL/6 mice. Following DNA extraction, MtDNA 
content was assesses as a ratio of mitochondrial to nuclear gene using real-time qPCR 
method. Data are shown as mean ± SD, n =3-6 
 
 
 Lung Liver Heart Kidney Whole blood Brain Islets 
N 3 3 3 3 5 4 4 
        
Mean 24 190 657 183 113 147 61 
SD 7 61 595 89 53 29 10 
Minimum 19 120 277 80 57 106 50 
Maximum 33 235 1473 237 190 170 75 
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Fig.4.8. Mitochondrial DNA levels in diabetic mouse tissues. C57BL/6 mice were made 
diabetic after single injection of streptozotocin. Tissue samples were collected 31days 
after the induction of diabetes in mice. Following DNA extraction, MtDNA content was 
assesses as a ratio of mitochondrial to nuclear gene using qPCR method. Data are shown 
as mean ± SD, n =3-6. 
 
 
Interestingly, when using independent Student’s t-test to compare the direction 
of changes in the MtDNA levels between control and diabetic mouse tissues, we 
observed a significant decrease in MtDNA in diabetic kidney (as reported above) 
and a significant increase in diabetic islets (P<0.05), after 31 days of diabetes 
duration. No other significant changes in any other tissues were observed. 
However, there was a decrease MtDNA content in diabetic liver, and although it 
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Table 4.4. Results from statistical analysis of changes in mitochondrial DNA content 
between control and diabetic mouse tissues. 
Diabetes was induced in mice by administration of STZ. Samples were collected from 
diabetic mice 31 days after induction of diabetes (D31) and from healthy controls (Ctr). 
Following DNA extraction, the mitochondrial DNA (MtDNA) copy number was assessed 
as a ratio of mitochondrial to nuclear gene via qPCR method. Student’s t-test was 
performed to assess the differences in the MtDNA content between Ctr and D31 mouse 
tissues.  The tissues tested were lung, liver, heart, brain, islets, kidney, and whole blood 
samples.  ↑, increased; ↓, decreased  
 
 
To summerize, these data show that MtDNA content was significantly reduced in 
STZ-diabetic mouse kidneys after 4 weeks of the duration of diabetes. Treatment 
of diabetes (T7, T31) appeared to prevent the depletion of MtDNA observed in 
D31 group.  
A transient increase in MtDNA content in peripheral blood samples after 7 days 
of hyperglycaemia, which was different to the results obtained from diabetic 
mouse kidney, where a slight reduction was seen. There was no significant 
difference in MtDNA content in circulating cells in the treated groups (T7 and 
T31). The above data show, that MtDNA copy number varies between different 
mouse tissues and hyperglycaemia had up-regulatory effect on MtDNA content 
in the mouse islets and a down-regulatory in the mouse kidneys after 31 days. 
No changes in the MtDNA copy number between any other diabetic and control 
tissues were detected, although there was a trend in the diabetic liver towards 















D31 Lung P=0.22 - - - - - - 
D31 Liver - P=0.05 - - - - - 
D31 Heart - - P=0.82 - - - - 
D31 Brain - - - 0.7 - - - 
D31 Islets - - - - ↑P=0.04 - - 
D31 kidney - - - -  ↓P=0.02  
D31 Blood       P=0.13 
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4.4.2 The effect of hyperglycaemia on mitochondrial DNA content in the β-
PHB2-/- mouse model of type 1 diabetes 
As STZ-diabetic mice are a chemically induced mouse model of T1D, to exclude 
any direct toxic effect of STZ on MtDNA content, a different mouse model of 
hyperglycaemia representing T1D, β-PHB2-/- mice was used (Supale et al., 2013). 
The aim of this part of the work was to determine if hyperglycaemia affects 
MtDNA content in kidney, heart and in circulating cells of β-PHB2-/-. 
• Mitochondrial DNA content in organs in control and β-PHB2-/- diabetic mice 
MtDNA copy number in kidneys of control animals was slightly lower to the one 
which was observed in C57BL/6 control mice and estimated at around 300 of 
copies of MtDNA per nuclear genome. There was no difference in the MtDNA 
content between control and β-PHB2-/- diabetic mouse kidneys (287 ± 174 vs. 
379 ± 192, respectively, Fig. 4.8A). The next goal was to look at the MtDNA copy 
number in the diabetic mouse hearts, as kidney and heart are organs with the 
highest MtDNA content therefore possibly with rapid changes in mitochondrial 
biogenesis in response to oxidative stress. No statistically significant changes in 
the levels of MtDNA copy number in control and diabetic hearts (821 ± 246 vs. 
765 ± 396, respectively) were observed. Mean MtDNA copy number in the 
control animals were measured at around 800 copies and were slightly higher to 
the number detected in C57BL/6 mice used in the STZ model (4.9B). 





Fig.4.9. Mitochondrial DNA content is not affected by diabetes in β-PHB2-/- mouse 
tissues. Kidney (A) and heart (B) samples were collected from 11-week old healthy 
control and β-PHB2-/- diabetic mice. Following DNA extraction, MtDNA content was 
assessed as a ratio of mitochondrial to nuclear gene using qPCR method. Data are shown 
as mean ± SD, n =6-8, Student’s t-test where, P>0.05. 
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• Mitochondrial DNA content in circulating cells in control and β-PHB2-/- - 
diabetic mice 
MtDNA content detected in the control mouse blood samples was similar to that 
observed in C57BL/6 mice, and estimated at approximately 200-300 of copies 
(Fig.4.10). There was no significant difference in MtDNA content between the 
knockout and control group at the beginning of the study (week 4). However, 
after β-PHB2-/- became hyperglycaemic (week 6), there was a significant 
difference in MtDNA content between control and diabetic group, the latter 
having a higher number of MtDNA in circulation (277 ± 172 vs. 898 ± 343, 
respectively, P<0.05). Diabetic mice sustained high levels of MtDNA content in 
the blood throughout the duration of the study. The MtDNA copy number was 
almost 3 fold higher when compared to age-matched healthy controls and 






Fig.4.10. Mitochondrial DNA content in circulating cells is affected by hyperglycaemia 
in β-PHB2 knockout mice. Blood samples were collected from weekly form healthy 
control and β-PHB2-/- diabetic mice. Following DNA extraction MtDNA copy number was 
measured as a ratio of mitochondrial to nuclear gene copy number by qPCR method.  
Data shown as a mean ± SD, n =3-4, Student’s t-test, where, *P<0.05 
 
 
These data show that unlike to the reduction in MtDNA content observed in STZ-
diabetic model no changes in MtDNA copy number in β-PHB2-/- diabetic kidneys 
were observed. No change in MtDNA content in diabetic heart was also 
observed. There was a clear and significant 3 fold increase in MtDNA copy 
number in circulating cells in diabetic β-PHB2-/- mice. 
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4.4.3 The effect of hyperglycaemia on mitochondrial DNA content in the 
Lep ob/ob mouse model of type 2 diabetes 
Both, β-PHB2-/- and STZ mouse models used in the study were highly 
hyperglycaemic (Rackham et al., 2013, Supale et al., 2013).  The aim of this study 
was to evaluate MtDNA levels in the kidneys of type 2 diabetic mouse model, 
with relatively moderate obesity and hyperglycaemia. Mice used in this study 
were 8 weeks old and contained approximately 10x more abdominal fat than 
their aged matched lean controls. As shown on figure 4.11 ob/ob animals were 
also two times heavier than their lean controls (43 ± 1.6 vs. 21 ± 0.4). Moreover 
ob/ob mutants also had bigger pancreas and kidneys (personal communication, 
Dr Aileen King). MtDNA copy number in kidneys of control mice was also lower 
to the one which was observed in C57BL/6 control mice (approx.400 copies per 
nuclear gene) and controls in the knockout study (approx.300 copies per nuclear 






Fig.4.11. Ob/ob mutant mice are heavier than the lean controls. Body weights were 
taken from 8-weeks old C57BL/6 lean control and ob/ob mice. Data shown as a mean ± 
SD, n =4, Student’s t-test where,*** P<0.001 
 
 
As presented on Fig.4.12, MtDNA copy number was reduced by almost a half in 
the diabetic, obese mice when compared to the lean controls (63 ± 22 vs. 140 ± 
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Fig.4.12. Insulin resistant ob/ob mice seem to have less mitochondrial DNA content in 
the kidneys. Following DNA extraction MtDNA copy number was measured as a ratio of 
mitochondrial to nuclear gene copy number using qPCR technique. Data shown as a 
mean ± SD, n =4, Student’s t  test where, P<0.05 
 
These data suggest a trend towards down-regulation of MtDNA copy number in 
ob/ob mouse model of T2D, however a major limitation was the sample size 
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4.5 Discussion 
Three different mouse models of diabetes were used in this chapter to study the 
effect of hyperglycaemia on MtDNA content in circulating cells and tissues. Two 
models of T1D (chemically induced by STZ, and by using β-PHB2-/- mice), and one 
model of T2D were used. Healthy, non diabetic mice were used as a controls.  
In the STZ-induced diabetic model, lower MtDNA content was found in the 
kidneys of diabetic mice after 7 days, and this reduction became statistically 
significant after 31 days of the duration of diabetes. MtDNA content in 
circulating cells was increased after 7 days and returned to normal levels after 31 
days. As shown in Fig.4.3 the treated groups (T7and T31), which received STZ 
injection, also seem to have slightly reduced MtDNA content in the kidney, but 
this reduction was not statistically significant. STZ is a toxic compound, which 
specifically targets β-cells and causes cell necrosis through the depletion of ATP. 
This complex acts via ROS and when is transported to the cells causes DNA 
damage and activation of poly-ADP-ribosylation, NAD+ depletion, which causes a 
reduction in ATP produced (Szkudelski, 2001). The main controversy in using this 
chemically induced model of diabetes is that STZ is a broad spectrum toxin, 
which can also affect other organs. Lee at al. (2010) reported changes in protein 
levels of cytochrome P450(CYP) proteins in various rat tissues, showing up-
regulation of the CYP in the kidney, and dys-regulation in the liver, brain and 
intestines (Lee et al., 2010). On the other hand, Sandler and Swenne (1983) 
reported STZ-induced DNA repair in isolated mouse islets (Sandler and Swenne, 
1983). Additionally, glucose measurement data from our lab suggest, that in 
treated animals, glucose levels tend to oscillate between normal and diabetic 
levels, especially within the first week after transplantation of the islets (Dr Chloe 
Rackham, personal communication). This could explain why there seem to be 
(although not significant) dys-regulation of the MtDNA content in the treatment 
groups.  
In contrast to the kidney, circulating cells showed a significant up-regulation of 
MtDNA after a short duration of diabetes (7 days), and MtDNA content returning 
to normal after 31 days of hyperglycaemia. These results suggest possibly, an 
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increased mitochondrial biogenesis in response to hyperglycaemia, or leakage of 
MtDNA into the circulation from the tissues. Increased biogenesis is supported 
indirectly by the findings in the previous chapter, where up-regulation of MtDNA 
copy number in HMCs exposed to HG for 4 days was observed (Fig.3.6, chapter 
3). Also recent work of a Taiwan group assessed MtDNA content in leg muscle, 
blood vessels and peripheral leukocytes in type 2 diabetic patients in comparison 
to the healthy controls (Hsieh et al., 2011). Their results also showed 
discrepancies between the level of MtDNA in different tissues, with significant 
increase of MtDNA in blood cells, decrease in muscle tissue and no variation in 
MtDNA content in blood vessels, between diabetic and healthy patients, 
suggesting a varying effect of hyperglycaemia on different type of cells (Hsieh et 
al., 2011). 
Decreased MtDNA content in diabetic mouse kidneys, which is observed in this 
study in the STZ-diabetic mice and also in the ob/ob mice, correlate with data 
reported by others. Fedorova et al. (2013), using a proteomics approach in a 
partially nephrectomised rat model of chronic kidney disease (CKD), showed 
dysregulation of proteins involved in metabolism in rat kidney cortexes. They 
observed a 50% reduction in mitochondrial OXPHOS and structural proteins and 
approximately 30% reduction in the MtDNA content (Fedorova et al., 2013).  
The possible mechanism behind the reduction of the MtDNA amount in diabetic 
mouse kidneys might be damage of MtDNA by increased ROS. It has also been 
reported that in insulin resistant mice fed with high fat diet, there was an 
induction of MtDNA damage in mouse muscle and liver due to the dys-regulation 
of the repair enzyme, which eventually contributes to increased ROS production 
by mitochondria, dysfunction in OXPHOS and induction of apoptosis (Yuzefovych 
et al., 2013). However Dugan at el. (2013) by using in-vivo real-time 
transcutaneous fluorescence observed decreased oxygen production in diabetic 
mice kidneys by mitochondria and this result correlated with decreased 
mitochondrial function and biogenesis. By using STZ model they also observed a 
reduction in both, mitochondrial biogenesis and mitochondrial glucose oxidation 
(Dugan et al., 2013).  
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On the other hand, Ruggiero at al., (2011) reported increased mitochondrial 
bioenergetics in diabetic mouse kidneys as an adaptive response to oxidative 
stress. By using C57BL/6 mice fed on high fat diet, they reported structural 
changes in mouse kidneys (fibrosis and hypertrophy), which correlated with 
increased ROS production and pro-inflammatory markers. Increased levels of 
mitochondrial superoxide dismutase (MnSOD) and increased mitochondrial ATP-
linked respiration in animals kept for 12-weeks, which was not present at later 
stages, suggesting that there is an adaptive phase to the nutrient overload, but 
over time, mitochondria became exhausted and their function starts to fail 
(Ruggiero et al., 2011).  
In humans DN is characterised by different stages with hyperfiltration occurring 
first, followed by a decline in the filtration and lesion in the kidney (Mogensen et 
al., 1983). This could explain various reports from animal studies regarding 
mitochondrial biogenesis and function. Reduction in MtDNA levels, which was 
observed in two different diabetic mouse models used in current study may 
reflect adaptive mechanism in which excessive glucose load inhibits proximal re-
absorption of the glucose. Glucose is actively reabsorbed from the blood , 
through NA+/K+ pumps which require constant energy provided by mitochondria 
ATP (Vallon, 2011).  
The lack of changes in the kidneys observed in the knockout mice might be 
caused by slightly different mechanisms. In STZ-induced diabetic model we 
observed changes in circulating cells very quickly (after 7 days), and after 4 
weeks they return to normal levels. In the β-PHB-/- mice a constant induction of 
MtDNA in blood samples collected weekly was observed, and no difference in 
the kidney or heart tissues. Interestingly elevated MtDNA content, which we 
observed in circulating cells in the knockout animals correlates with the time 
when they develop diabetes (week 6). This data is supported by a study of 
Bonnard et al. (2008), in which diabetes-induced structural and functional 
changes in mitochondria in mouse muscle tissue were shown. A reduction in 
both MtDNA content and protein expression of mitochondrial transcription 
factor PGC-1α in two different mouse models of diabetes was also observed. 
Interestingly, in this report no changes in MtDNA content when animals were at 
126 | P a g e  
 
Chapter 4: MtDNA content in in-vivo models of diabetes 
pre-diabetic state were observed, but only at fully developed disease state. The 
in-vitro study showed that hyperglycaemia induced changes in mitochondrial 
function could be reverted by antioxidant treatment, suggesting that 
mitochondrial dysfunction was due to the increased oxidative stress also 
observed in experimental animals (Bonnard et al., 2008). 
I also compared MtDNA content in other tissues from the control and diabetic 
mice, and in both groups, tissues with the highest number of MtDNA were heart 
and kidney. Lowest MtDNA content was determined in the lung tissue. These 
findings correlate with results reported by others in human (Mercer et al., 2011) 
and in rat tissues (Fernandez-Vizarra et al., 2011), which confirm the MtDNA 
content test reliability. Islets proved to be among the organs with one of the 
lowest levels of MtDNA content, which might suggest they are particularly 
susceptible to the toxic effects of chronic hyperglycaemia. In this study, there 
was a significant increase of MtDNA in diabetic islets, when compared to the 
controls, which is in contrast to the findings reported by Lu et al. (2010), who 
observed no changes in MtDNA in beta-cells after the onset of diabetes and a 
decline during the progression of the disease in diabetic knockout mice (Lu et al., 
2010). However, we measured MtDNA after only 31 days of the onset of 
diabetes, therefore our results may suggest and adaptive response of the islets 
to their failing function. 
This study could be criticized for not using a specific animal model of diabetic 
nephropathy. However my aim was to examine the effect of hyperglycaemia on 
MtDNA levels in mouse organs and circulating cells. To date there are no ideal 
animal models of DN, since it takes approximately 15-20 years in humans to 
develop kidney disease, this makes it difficult to study the disease using animal 
models. Another limitation of this study is the lack of measurement of oxidative 
stress and enzyme activities. It was shown by others that mitochondrial 
biogenesis correlates with function in diabetic animal models, therefore falling 
levels of MtDNA in our study in the kidney tissues, suggest reduced mitochondria 
function in these animals. A further limitation may be use of relatively young 
animals. Some of the sample number used in the study was low, especially in the 
ob/ob mouse model and some of the groups in the STZ-model. In the kidneys of 
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ob/ob mice as the result was approaching significance and might become 
significant if a larger sample size was used.  
In summary, I have observed increased MtDNA level in circulating cells in the in-
vivo diabetic mouse models, and this increase preeceded changes observed in 
the mouse kidneys. To my knowledge this is the first report of altered levels of 
MtDNA in circulating cells in diabetic mouse models. Increased MtDNA content 
in circulation may be an adaptation to the nutrient overload or may be a cellular 
free MtDNA released from tissues. Decrease in MtDNA in diabetic mouse kidneys 
may be a sign of the failing mitochondrial function and cell death. 




Functional consequences of hyperglycaemia 
 in kidney cells  
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5.1 Abstract 
Background/Aims: The hypothesis that will be tested in this thesis is that 
hyperglycaemia/high glucose can cause early changes in mitochondrial DNA 
(content/quality) and that these changes can contribute to mitochondrial 
dysfunction. In the current chapter functional consequences of the altered 
MtDNA were examined in human mesangial cells. 
Methods: RNA was extracted from: human mesangial cells (HMCs) cultured in 
DMEM containing 5mM (NG) and 25mM (HG) glucose. Following reverse 
transcription, quantitative measurement of genes involved in mitochondrial life 
cycle (biogenesis and mitophagy) and mitochondrial encoded mRNAs were 
measured using real-time qPCR. ROS production and cell viability were also 
assessed in HMCs grown in normal and high glucose using fluorescence and 
luminescent assays. Moreover high glucose-induced mitochondrial DNA damage 
in renal cells was assessed using PCR. Mitochondrial morphology and protein 
content were assessed using MitoTracker staining and Western blot respectively. 
Results: Growth of HMCs in HG resulted in 2-fold higher TFAM (P<0.05). The 
expression of two mitochondrial genome encoded mRNAs was reduced (P<0.05) 
in parallel with increased MtDNA damage, cellular ROS and apoptosis (P<0.05) in 
HMCs exposed to HG. Mitochondrial length and degree of branching were 
reduced in HMCs cultured in HG (P<0.01, P<0.001). NF-κB and MYD88 expression 
were up-regulated in HMCs exposed to HG (P<0.05). 
Conclusion: These data suggest that exposure to hyperglycaemia caused a dys-
regulation between mitochondrial DNA content and mitochondrial transcription 
and translation. Moreover high glucose-induced stress caused damage to 
mitochondrial DNA, which suggest that although as previously shown 
mitochondrial DNA is up-regulated, it is not functional. Changes in mitochondrial 
morphology and network which occurred very quickly after the exposure to high 
glucose may also contribute further to mitochondrial dysfunction in the renal 
cells. 
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5.2 Introduction  
In this chapter the focus is on changes in MtDNA quality, morphology and 
expression of nuclear-encoded transcription factors and on the assessment of 
cellular ROS and apoptosis in human mesangial cells cultured in high glucose. It 
has been shown in the previous chapters, that MtDNA is elevated in renal cells 
cultured in high glucose and also in peripheral blood in diabetic mice but 
decreased in the diabetic mouse kidneys.  
Free radicals serve as intracellular messengers and can also stimulate the same 
pathway as glucose e.g. activation of protein kinase C (PKC); but excessive 
activation of PKC leads to tissue injury trough activation of transforming growth 
factors and also NF-κB, which then activates inflammatory response within the 
cells (Pugliese et al., 1994). Lee et al (2003) demonstrated that culturing renal 
cells under high glucose conditions augments production of ROS and that this 
stimulation of free radicals generation can be effectively blocked by PKC 
inhibitors (Lee et al., 2003). Catherwood et al., (2002) using in-vitro cultured 
porcine mesangial cells, showed also high glucose-induced impaired antioxidant 
activity including mitochondrial superoxide dismutase (MnSOD) (Catherwood et 
al., 2002). Nishikawa et al, (2000) had shown that culturing bovine endothelial 
cells in 30mM glucose induces ROS production and by using mitochondrial 
complex I and II inhibitors and uncoupler (CCCP) they were able to abolish 
stimulating effect of hyperglycaemia on free radicals production (Nishikawa et 
al., 2000). An adaptive response of mitochondria to oxidative stress might be to 
increase mitochondrial biogenesis via replication of the mitochondrial genome 
and increasing mitochondria mass. However, it has been shown that under 
persistent oxidative stress, mitochondrial DNA mutations ratio increases (Xie et 
al., 2008, Wei and Lee, 2002). 
Mitochondrial biogenesis is regulated by the nuclear transcription factors like 
mitochondrial transcription factor A (TFAM) and Peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) (Hock and Kralli, 2009). 
Mitochondria are not static organelle and they are frequently undergoing 
processes called fusion and fission; non-functional mitochondria are removed by 
a process called mitophagy. Fusion is maintained by mitofusin 1 and 2 (MFN1 
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and MFN2) and optic atrophy gene 1 (OPA1) and mitochondrial fission by 
mitochondrial fission protein 1 (FIS1), mitochondrial fission factor (MFF) and 
dynamin-related protein 1 (DRP1) (Twig and Shirihai, 2011). Non-functional 
mitochondria are removed during the mitophagy process which is orchestrated 
by PTEN induced putative kinase 1 (PINK-1) and parkin (PARK2), but it is not 
know how the faulty mitochondria are selected for disposal [reviewed in (Ashrafi 
and Schwarz, 2013)]. One possibility is a membrane potential, as by the fusion 
process some mitochondria can rescue their falling membrane potential. 
Mitochondrial fusion and fission occurs every 20 minutes which possibly allows 
mitochondria recover their membrane potential by fusing with mitochondria 
with the higher membrane potential (Twig and Shirihai, 2011).  
The mitochondrial mitophagy and fusion proteins are also important for the 
MtDNA maintenance (Chen and Chan, 2009). Moreover it has been reported that 
mutation in the OPA1 gene caused MtDNA deletion (Hudson et al., 2008). A 
disturbance in mitochondrial cycle, caused by oxidative stress might have a 
detrimental effect for the proper function of the cells, which have been shown in 
several studies. In mouse neuronal cells exposed to the oxidative stress, induced 
secondary ROS production was shown, as well as changes in mitochondrial 
morphology which also correlated with decreased mitochondrial function, 
measured as a membrane potential (Grohm et al., 2010). Makino at al., (2010) 
using cultured endothelial cells extracted from diabetic mice also reported an 
increased fragmentation of mitochondria which was reverted by a treatment 
with antioxidant which suggest effect of oxidative stress on mitochondrial 
morphology (Makino et al., 2010).  
Diabetic nephropathy is a complex disease associated with induced inflammation 
(Wada and Makino, 2013). Inflammation has been reported to be up-regulated 
through the AGE production and activations of the AGE-receptor (RAGE), which 
then induces NF-κB cascade and cytokine production (Mosquera, 2010). NF-κB is 
a regulatory switch for more than 400 genes involved in the inflammatory 
response, including cytokines, and pro-inflammatory enzymes (Sethi et al., 2008). 
MtDNA can also contribute directly to pathology in acquired diseases such as 
diabetic complications because, like bacterial DNA, it is un-methylated and 
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initiates immune responses via the intracellular Toll like receptor 9 (TLR9) 
(Barbalat et al., 2011, Sparwasser et al., 1997). 
 In overall, the main aim of this chapter is to assess functional changes in 
mitochondrial life cycle caused by hyperglycaemia in order to see if they 
correlate with increased MtDNA in renal cells. Mitochondrial transcription 
factors and the expression of the NF-κB and Myeloid differentiation primary 
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5.3 Hypothesis and aims 
5.3.1 Hypothesis 
The main hypothesis under study in this work is that hyperglycaemia can cause 
early changes in mitochondrial DNA (content/quality) and that these changes can 
contribute to mitochondrial dysfunction. In the current chapter hyperglycaemia-
induced functional changes in mitochondria and cells were investigated. 
5.3.2 Aims and objectives 
The main aim of this chapter is to demonstrate, using cultured renal cells, 
whether glucose-induced changes in MtDNA occur in parallel with functional 
changes in mitochondria and renal cells.  
This aim will be met as follows:  
1. The effect of culture of renal cells in high glucose on mitochondrially 
encoded mRNAs will be measured. 
2. The effect of hyperglycaemia on the nuclear control of MtDNA replication 
in the human mesangial cells will be determined. 
3. The effect of hyperglycaemia on the mRNAs expression of the genes 
involved in mitochondrial life cycle will be assessed in renal cells.  
4. The effect of hyperglycaemia on the activation of inflammatory 
associated mRNAs will be measured in renal cells. 
5. The effect of hyperglycaemia on cell viability and ROS production in 
human mesangial cells will be measured. 
6. MtDNA damage in human mesangial cells exposed to hyperglycaemia will 
be assessed. 
7. The effect of glucose-induced changes in mitochondrial protein levels and 
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The experimental strategy to carry out the above will be as follows: 
1. Primary mesangial cells will be cultured in 5mM (normal, NG) and 25mM 
(high, HG) glucose for 4 and 8 days.  
2. Following RNA extraction and reverse transcription, mitochondrial and 
nuclear encoded mRNAs will be measured using real-time qPCR following 
normalization to β-actin. 
3. Following protein extraction protein content will be assessed using 
Western blotting technique. 
4. Following staining of mitochondria and by using fluorescent microscopy 
and ImageJ software, mitochondrial morphology and network structure will 
be measured. 
5. Cellular ROS and cell viability will be assessed using fluorescence and 
luminescence assays. 
6. Following DNA extraction MtDNA damage will be assessed by using PCR 
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5.4 Results 
In this chapter, hyperglycaemia-induced functional changes in mitochondria and 





























Fig.5.1. Overview of chapter 5. 
 
5.4.1 The effect of hyperglycaemia on mitochondrial mRNAs in human 
mesangial cells 
HMCS were cultured as described in the main methods section 2.3. Cells were 
seeded at an equal density (1x105/well) in 6-well plates in DMEM containing 
either 5mM (normal, NG) or 25mM (high, HG) glucose for 4 and 8 days. To assess 
copy number of the investigated mRNAs, RNA was extracted, reversely 
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transcribed and real time qPCR was performed as describe in method section 
2.7. β-actin was selected for normalization by using GeNorm software. 
To examine whether glucose induced MtDNA content in HMCs correlated with 
changes in transcription of the mitochondrial genome, mRNAs for three 
mitochondria genome coded OXPHOS subunits were measured, ND6, ND1 and 
COX3. As illustrated on Fig.5.2, exposure to hyperglycaemia had significantly 
down-regulated expression of mitochondrial ND6 and COX3 after 4 days of 
culture, but had no effect on the expression of ND1.  
Expression of ND1 remained at the same level throughout the culture time and 
was not significantly affected by 25mM glucose (P>0.05, Fig.5.2.B). ND6 
expression was significantly decreased after 4 days of exposure to high glucose 
when compared to the control (64 ± 20 vs. 156 ± 8 respectively, P<0.01 
Fig.5.2.A). Similar trend was observed in COX3 expression, as there was a highly 
significant down-regulation of COX3 mRNA expression in HMCs exposed to high 
glucose for 4 days when compared to the control (285 ± 88 vs. 633 ± 44 
respectively, P<0.01, Fig.5.2.C). 
No significant differences between the groups were observed after 8 days of 
treatment (P>0.05, Fig.5.2). However, when the mRNA expressions of the 
controls were compared there was also observed a trend towards down-
regulation of ND6 expression in NG between 4 and 8 days of culture, but results 
was not significant (P>0.05) (Fig.5.2A). Moreover there was a trend (however not 
significant), towards the reduction of COX3 in cells cultured in NG for 8 days, 
when compared to the cells culture in normal glucose for 4 days (P>0.05, Fig. 5.2 
C), which may suggest an effect of sub-culturing on mitochondrial mRNAs in 
HMCs. 
 
In summary, the increased MtDNA in response to high glucose is not acting as a 
template for mitochondrial encoded mRNAs, as there was either no change or 
reduction of the mitochondrial encoded mRNAs.    
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Fig.5.2. The effect of hyperglycaemia on mitochondrial encoded mRNAs in human 
mesangial cells. After glucose synchronization with 0.5% FBS in DMEM, HMCs were 
cultured in DMEM containing 5mM (NG) and 25mM (HG) for 4 and 8 days. Following 
RNA extraction and reverse transcription, copy numbers of ND6 (A), ND1 (B), and COX3 
(C) were determined using real-time qPCR. mRNA copy numbers for each gene were 
determined relative to 1000 copies of reference gene β-actin. Data presented as a mean 
± SD, n=3,  Student’s t-test where, **P<0.01 vs. NG 
 
 
To determine whether hyperglycaemia affects the mRNA expression of genes 
involved in the mitochondrial life cycle, the mRNAs genes involved in 
mitochondrial biogenesis (TFAM and PGC-1α) in HMCs grown in normal and high 
glucose for 4 and 8 days were examined.  
As seen on Fig.5.3, the relative expression of TFAM in HMCs was 100 times 
higher, when compared to the detected levels of PGC1-α. TFAM expression was 
significantly increased in high glucose at 4 days when compared to the control 
(44±23 vs. 19±5, P<0.05, Fig.5.3.A). After 8 days of exposure to high glucose, 
TFAM expression was still elevated when compared to the control (32±11 vs. 
20±8) and the result was approaching significance (P=0.07, Fig.5.3 A). The levels 
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of the PGC-1α did not show a statistically significant change in high glucose when 







Fig.5.3. The effect of hyperglycaemia on mRNA expression of mitochondrial 
transcription factors in cultured primary human mesangial cells. After being 
synchronized, HMCs were cultured in DMEM containing 5mM (NG) and 25mM (HG) 
glucose for the times shown. Following RNA extraction and reverse transcription, copy 
numbers of TFAM (A) and PGC-1α (B) were determined using RT-qPCR. mRNA copy 
numbers for each gene were determined relative to 1000 copies of reference gene β-
actin. Data presented as a mean ± SD, n=5-6, Student’s t-test where, *P<0.05  
 
 
These data show that there is an up-regulation of TFAM in HMCs after 4 days of 
culture in HG. The increase in TFAM is taking place at the same time as the 
increase in MtDNA (Fig.3.7), but PGC-1α does not show a significant increase 
during this time.  
 
5.4.2 The effect of hyperglycaemia on fusion, fission and mitophagy 
mRNAs in human mesangial cells 
mRNA expression of the genes involved in mitochondrial dynamics was assessed 
in HMCs cultured in 5mM and 25mM glucose. Expressions of MFN1, MFN2, OPA1 
and DRP1 (as the candidate genes of mitochondrial fusion and fission) and PINK1 
and PARK2 (genes involved in mitophagy) were assessed using real-time qPCR 
and primers listed in table 2.4 in the methods chapter. There was no significant 
difference (P>0.05) in mRNA expression of any of the investigated genes involved 
in mitochondrial fusion (Fig.5.4 A-C), fission (Fig.5.5) and mitophagy (Fig.5.6A, B) 
between the groups (P>0.05).  
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Fig.5.4.Hyperglycaemia has no effect on the expression of mRNAs involved in 
mitochondrial fusion in cultured primary human mesangial cells. After being 
synchronized, HMCs were cultured in 5mM (NG) and 25mM (HG) glucose for 4 and 8 
days. Following RNA extraction and reverse transcription, copy numbers of MFN1 (A), 
MFN2 (B), and OPA1 (C) were determined using real-time-qPCR. mRNA copy numbers 
were determined relative to 1000 copies of reference gene β-actin.  Data presented as a 
mean ± SD, n=3, Student’s t-test where, P>0.05  
 
 
There was also no effect of the duration of the culture as the expression levels of 
MFN1, MFN2, OPA1, DRP1 in cells cultured in 5mM glucose for 4 and 8 days did 
not differ  (P>0.05, Fig 5.4 and Fig 5.5). Although no significant difference in the 
expression of the genes involved in mitophagy was observed, expression of 
PARK2 was up-regulated by 4-fold, in HMCs exposed to high glucose for 8 days, 
when compared to the control (0.04 ± 0.06 vs. 0.01 ± 0.005, P>0.05, Fig. 5.6 B). 
Expression of PINK1 did not vary between the treatments (P>0.05, Fig.5.6 A). 
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Fig.5.5. Hyperglycaemia does not affect mRNA involved in mitochondrial fission in 
cultured primary human mesangial cells. After being synchronized, HMCs were cultured 
in DMEM containing 5mM (NG) and 25mM (HG) glucose for 4 and 8 days. Following RNA 
extraction and reverse transcription, copy numbers of DRP1 were determined using real-
time qPCR and relative to 1000 copies of reference gene β-actin.  Data presented as a 









Fig.5.6. Hyperglycaemia does not affect mRNAs involved in mitophagy in cultured 
primary human mesangial cells. HMCs were cultured in DMEM containing 5mM (NG) 
and 25mM (HG) glucose for 4 and 8 days. Following RNA extraction and reverse 
transcription, copy numbers of PINK1 (A) and PARK2 (B) were determined using real-
time qPCR and relative to 1000 copies of reference gene β-actin.  Data presented as a 
mean ± SD, n=4-6, Student’s t-test where, P>0.05  
 
 
Therefore, there was no difference in the mRNA expression of the genes involved 
in mitochondrial life cycle, including fusion, fission and mitophagy. 
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5.4.3 The effect of hyperglycaemia on ROS production, viability and 
mitochondrial DNA damage in primary cultured human mesangial 
cells. 
Since nuclear encoded mRNAs involved in the mitochondrial life cycle did not 
respond to hyperglycaemia in the time frame in which the MtDNA increase is 
seen, intracellular ROS, cell viability and MtDNA damage were examined. Briefly, 
HMCs were cultured in DMEM containing 5mM (NG) and 25mM (HG) glucose, as 
previously described. Following trypsinisation, cell pellets were collected and 
MtDNA damage was assessed using the PCR based elongase method (Furda et 
al., 2014) as described in the main methods chapter (2.12). Data were kindly 
provided by Ms Chandani Kiran Parsade. Intracellular ROS in cultured cells was 
measured using cell-permeant 2',7'-dichlorodihydrofluorescein diacetate 
(H2DCFDA) and viability by using Celltiter-Glo reagent in the microplate reader 
(as described in methods sections 2.10 and 2.11). Briefly, cells grown in different 
glucose concentrations were seeded in 96-well opaque plates. Viability assay 
detects number of viable cells, based on the luminescence signal proportional to 
the amount of ATP present, an indicator of metabolically active cells. For ROS 
measurement, on a day of the assessment, HMCs were treated with H2DCFDA 
reagent and fluorescence signal from cleavage of the acetate groups by 
intracellular esterases was measured.  
There was a significant increase in intracellular ROS in HMCs grown in HG for 4 
(50% increase, P<0.001) and 8 days (30% increase, P<0.01, Fig.5.7). In parallel to 
the increased ROS, cell viability was significantly reduced by almost 2-fold in 
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Fig.5.7. Hyperglycaemia induces cellular ROS in human mesangial cells. After being 
synchronized, HMCs were cultured in DMEM containing 5mM (NG) and 25mM (HG) 
glucose for 4 and 8 days. H2DCFDA reagent was used to detect intracellular ROS by 
measurement of the fluorescence from cleavage of the acetate groups. Data presented 











Fig.5.8. Hyperglycaemia decreases cell viability in human mesangial cells. After being 
synchronized, HMCs were cultured in DMEM containing 5mM (NG) and 25mM (HG) 
glucose for 4 days. CellTiter Glo luminescence reagent used to detect intracellular ATP as 
a measurement of metabolically active cells. Data presented as mean ± SD of % of 
control, n=17-21 observations, Student’s t-test, where, **P<0.01  
 
Increase in ROS and reduced viability in parallel with reduction in MtDNA 
transcription suggest that ROS might damage MtDNA. Therefore the next aim 
was to assess MtDNA damage in HMCs cultured in high glucose, by using a PCR 
based elongase method. 
MtDNA damage was significantly increased in HMCs exposed to high glucose for 
4 days (P<0.05 Fig.5.9) and increased by almost 2-fold after 8 days, although 
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Fig.5.9. Hyperglycaemia-induced mitochondrial DNA damage in mesangial cells. After 
being synchronized, HMCs were cultured in DMEM containing 5mM (NG) and 25mM 
(HG) glucose for 4 and 8days. Long elongase PCR method was used to amplify 8.9kb and 
127 fragment of MtDNA. Following agarose gel electrophoresis of the long and short 
fragments, bands intensity was measured and ratio calculated. Data presented as mean 
± SD of % of control, n=3-6, Student’s t-test, where, *P<0.05 
 
 
The above data show that growth of HMCs in high glucose results in increased 
ROS and apoptosis, and in parallel increased damage to MtDNA. 
 
5.4.4 Does high glucose activate inflammatory pathways in human 
mesangial cells? 
HMCs were grown in normal and high glucose as previously described. 
Expression of the NF-κB and MYD88 mRNAs was assessed using absolute 
quantification method and real-time qPCR and primers listed in table 2.4 in 
methods section. Both NF-κB and MYD88 were significantly increased after 4 
days of incubation in high glucose by almost two fold when compared to the 
control (0.21±0.01 vs. 0.73±0.08 and 0.52± 0.12 vs. 0.98±0.3 respectively, P<0.05, 
Fig.5.10.A, B).  
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8 days of exposure to high glucose also resulted in the increase of NF-κB and 
MYD88 expression but result was not significant (0.13±0.03 vs. 0.80±0.6 and 






Fig.5.10. Hyperglycaemia-induced activation of toll like receptor 9 pathway. After 
being synchronized, HMCs were cultured in DMEM containing 5mM (NG) and 25mM 
(HG) glucose for 4 and 8days. Following RNA extraction and reverse transcription, copy 
numbers of Nf-kB (A) and MYD88 (B) were determined using real-time qPCR. mRNA copy 
numbers for each gene were determined relative to 1000 copies of reference gene β-
actin. n=3, Student’s t-test where, ***P<0.001, **P<0.01  
 
 
5.4.5 Is mitochondrial protein mass affected by high glucose treatment in 
human mesangial cells? 
Measurement of the mitochondrial OXPHOS protein levels in HMCs cultured in 
5mM (NG) and 25mM (HG) for 4 and 8 days, was performed using Western blot 
method, as described in the main methods section 2.9. Briefly, following SDS-
PAGE and a cocktail of primary antibodies against five different subunit of 
complex I-V (dilution 1:2000) were used to detect protein expression in HMCs 
cultured in different conditions. HRP conjugated anti-mouse secondary antibody 
(dilution 1:10000) was used to detect protein content via ECL method. 
Densitometry and ImageJ was used to quantify the expression levels of OXPHOS 
proteins, β-actin (dilution 1:5000) was used as a loading control. 
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As illustrated on Fig.5.11, there was no significant difference in the protein levels 




















Fig.5.11. Mitochondrial protein content in human mesangial cells culture for 4 and 8 
days. HMCs were incubated in DMEM containing 5mM glucose (NG) and 25mM glucose 
(HG) for the times shown. Western blotting of the mitochondrial respiratory complexes 
I–V in HMCS cultured in different conditions. Relative intensities of bands were 
quantified by densitometry and β-actin served as a loading control. CI, complex I (A); CII, 
complex II (B); CIII, complex III (C); CIV, complex IV (D); CV, complex V (E). 
Representative western blot (F). Data shown as mean ± SD, n=3, Independent student’s 
t-test, where, P>0.5 
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5.4.6 The effect of hyperglycaemia on mitochondrial morphology and 
network in human mesangial cells 
To visualise mitochondrial morphology, following culture in 5mM (NG) and 
25mM (HG) glucose HMCs were fixed with paraformaldehyde and visualized by 
staining with Mitotracker Orange (as decribed in method section 2.9) and viewed 
under Nikon Eclipse Ti-E Inverted Microscope. The stained mitochondrial 
network was assessed using ImageJ software using an image-processing 
algorithm as described by Koopman at al. (Koopman et al., 2005). HMCs were 
incubated in high glucose for the times shown in Fig.5.12 and Fig.5.13. Culture 
time had no effect on mitochondrial morphology as shown in summary  data 
shown on Fig.5.12, 1st and 2nd panel. 
To quantify mitochondrial network and morphology, two different parameters, 
formfactor F, a measure of the length and degree of branching and the aspect 
ratio AR, a measure of mitochondrial length, were used. (Fig.5.13, Fig.5.14). In 
HMCs grown in normal glucose medium, mitochondria were visualised as long, 
tubular networks throughout the cytoplasm (Fig.5.12 two left panels, Fig.5.13 
top panel). As illustrated on Fig.5.13 mitochondrial morphology and connection 
were not affected after short exposure to hyperglycaemia (2h), but extended 
exposure to hyperglycaemia (1-8 days) affected mitochondrial structure. More 
rounded and not connected mitochondria were visible after cells were cultured 
in high glucose for 8 days (Fig.5.13 left and middle panels). Plotting aspect ratio 
AF versus formfactor F clearly showed decreasing values for both parameters, 
correcting with increasing time of cells' exposure to HG (Fig.5.13 right panel).  
When calculated individually, both formfactor F and aspect ratio AR were highly 
significantly down-regulated in HMCs after 24h of incubation in high glucose 
(P<0.01, Fig.5.14A, B). These results became ever more significant after 4 days of 
incubation in the high glucose (P<0.001, Fig.5.14A, B) and the values for both 
factors showed a progressive reduction with increased time of the high glucose 
exposure (Fig.5.14A, B). 
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Fig.5.12. Mitochondrial morphology in mesangial cells incubated in high glucose. HMCs 
were cultured in 96-well plates in DMEM containing 5mM glucose (NG) and 25mM 
glucose (HG) for the times shown. Mitochondria were labelled with MitoTracker Orange 
CMXRos and images were captured at magnification x20. (A) Representative images of; 
time culture controls shown 1st and 2nd panel, cells cultured in Hg in 3rd and 4th panel.   .  
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Fig.5.13. High glucose affects mitochondrial morphology in mesangial cells. HMCs were 
cultured in 96-well plates in 5mM glucose in DMEM containing (NG) and 25mM glucose 
(HG) for the times shown. Mitochondria were labelled with MitoTracker Red CMXRos 
and images were captured at magnification x20. (A) Representative images of each 
condition shown in left panel. Mitochondrial length (Aspect ratio -AR), was plotted 
against mitochondrial degree of branching (Formfactor F) and shown on the right panel 
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Fig.5.14. High glucose affects mitochondrial length and degree of branching. HMCs 
were cultured in 96-well plates in 5mM glucose (NG) and 25mM glucose (HG) for the 
times shown. Mitochondria were labelled with MitoTracker Red CMXRos and images 
were captured at magnification x20. Mitochondrial length (Aspect ratio -AR), was 
plotted against mitochondrial degree of branching (Formfactor F). Quantitative analysis 
of aspect ratio AR (% of the control) (A). Quantitative analysis of formfactor F (% of the 
control) (B). Data are presented as mean ±SEM, n=10-14 cells, Kruskal-Wallis with 
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5.5 Discussion 
A key finding of current study is the demonstration that although exposure to 
high glucose leads to a rapid increase in renal mesangial cell MtDNA (as shown in 
Chapter 3), this does not correlate with increased mitochondrial encoded mRNA 
transcripts or mitochondrial mass. In contrast a decrease/unchanged  
transcription of mitochondrial encoded mRNAs and little change in the nuclear 
encoded mitochondrial mRNAs in renal cells, with the exception of glucose 
induced up-regulation of TFAM mRNA was observed. There was no difference in 
mitochondrial complexes’ protein content, but there was a change in 
mitochondrial network morphology with increased fragmentation occurring as 
early as 24 hours of the cells' exposure to high glucose. In parallel, there was an 
increase in MtDNA damage, increased ROS, decreased viability after 4 days of 
treatment with high glucose, these results correlated with the activation of TLR9 
pathway. 
When mitochondria are not meeting ATP demand , the number of mitochondria 
should eventually increase, as in the balanced environment  MtDNA content is 
proportionate to mitochondrial genome transcription level with a dose 
dependent effect (Williams, 1986, Hock and Kralli, 2009). Result from 
mitochondrial encoded mRNAs experiment suggest, that although MtDNA is 
increased (as shown in chapter 3), it is not functional and there is a disconnect 
between MtDNA and the mitochondrial transcription/translation.  A similar 
disconnect was reported in a study investigating the mechanisms of insulin 
resistance in muscle, with increased MtDNA but not increased mitochondrial 
content in myotubes (Aguer et al., 2013). Simultaneously Aguer et al., 
demonstrated increased MtDNA damage in parallel with reduced ATP levels 
(Aguer et al., 2013). Also, a report from Gao group (2010), demonstrates a 
disconnect in MtDNA replication and transcription in conditions of oxidative 
stress.  Although no changes in DNA copy number in adipose cells cultured in 
high glucose and also in fatty acid conditions were reported, there was a change 
in mitochondrial morphology and reduced levels of mitochondrial transcription 
factors in response to oxidative stress (Gao et al., 2010). Ballinger et al., (2000) 
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reported decreased synthesis of mitochondrial proteins in vascular endothelial 
and smooth muscle cells caused by ROS in dose dependent manner, which 
supports our observation of no changes in the protein level (Ballinger et al., 
2000). Xie et al., (2008) also showed a decrease in mitochondrial encoded 
OXPHOS subunit in human retinal cells following 6 h incubation in 30mM glucose 
(Xie et al., 2008b).  
In the current study no changes in the expression levels with any of the mRNAs 
involved in mitochondrial life cycles were observed with the exception of the 
glucose induced up-regulation of TFAM mRNA, which has been previously 
reported in rat muscle cells (Choi et al., 2004). This is contrary to the report by 
Bonnard et al. (2008), in which diabetes-induced structural and functional 
changes in mitochondria were shown in parallel with reduction in both, MtDNA 
content, and protein expression of PGC-1α in mouse muscle tissue of two 
different mouse models of diabetes (Bonnard et al., 2008). However, Shrepper et 
al. (2012) reported decreased OXPHOS complex activities, which didn’t correlate 
with any changes in mRNA expression of genes involved in mitochondria 
biogenesis (Schrepper et al., 2012).  However, it has been shown using a 
transient over-expression of TFAM in cultured human embryonic kidney (HEK) 
cells, that only small increase of TFAM protein can have stimulatory effects on 
mitochondrial transcription, and high levels of TFAM have an inhibitory effect on 
the MtDNA transcription rate (Maniura-Weber et al., 2004), which might explain 
8 days results with non significant changes in the MtDNA levels and 
mitochondrial transcription factors. No changes were observed in the nuclear 
encoded mitochondrial mRNAs in diabetic mouse kidney (data not shown), it 
might suggest there is a dys-regulation between nuclear and mitochondrial 
control of MtDNA replication (especially in STZ-induced mice), or possibly 
expression of the mitochondrial protein content should be measured, as both 
TFAM and PGC-1α mRNAs have been reported to have a short life time (Lai et al., 
2010).  
There were no significant changes in the mRNA expression of genes involved  in 
mitochondrial life cycle in renal cells, but interestingly mitochondrial morphology 
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in renal cells exposed to high glucose changed very quickly, with more short, 
rounded mitochondria which start losing their network connection within 24 
hours of the exposure to the high  glucose. Change in the mitochondrial 
morphology after the exposure to high glucose also suggests a dysfunction in 
fusion and fission processes, which are necessary to sustain healthy 
mitochondria (Twig and Shirihai, 2011). Results from current study are in 
accordance with reports by Molina et al., (2009), where almost complete 
fragmentation of the mitochondrial network was shown in beta cells within 1 
hour of exposure to 20mM glucose with 0.4mM palmitate  (Molina et al., 2009) 
and by Trudeau group (2010), which has shown increased mitochondrial 
fragmentation in rat retinal cells incubated for 6 days in high glucose (Trudeau et 
al., 2010). Although most the studies suggest oxidative stress playing a major role 
in mitochondrial network and motility, publication by Nowak et al. (2003), 
reported persistent  mitochondrial fragmentation in primary tubular cells which 
could not be abolished by the antioxidant treatment (Nowak et al., 2011). This 
loss in the connection between mitochondria might have  a detrimental effect on 
mitochondria coping with increased oxidative stress, as during constant fusion 
and fission mitochondria can actively exchange MtDNA [reviewed in (Chen and 
Chan, 2009)]. In the current study increased ROS and significantly reduced cells 
viability was also observed in HMCs incubated in high glucose. These results have 
been previously reported in the mesangial cells (Al-Kafaji and Malik, 2010, 
Catherwood et al., 2002).  
Moreover in the current report, MtDNA damage was also observed in cells 
incubated in high glucose. This result might explain the disconnection between 
MtDNA copy number and amount of mitochondrial encoded mRNA and suggest 
that most of the detected MtDNA molecules are not functional. MtDNA is very 
susceptible to damage due to its proximity to ETC (Ma et al., 2009). Publication 
of  Xie et al.,(2008) has shown that in the human retinal cells, first signs of  
damage to MtDNA can occur within 3 hours and turn into severe changes after 2 
days of the exposure to hyperglycaemia (Xie et al., 2008b). 
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I have also measured expression of the NF-κB mRNA as a marker of glucose-
induced inflammation, which is known to be induced by hyperglycaemia in, in-
vivo (Romeo et al., 2002), and in-vitro systems (Hattori et al., 2000).  
Mitochondria per se can contribute to the systemic inflammation through direct 
increase and release of the MtDNA. MtDNA resemblance bacterial genome and 
therefore can be recognised as a pathogen molecule by the system through toll 
like receptors (TLRs) because it’s un-methylated (Rutz et al., 2004). In the in-vitro 
study the expression of both, NF-κB and MYD88, as downstream signalling 
molecules of TLR-9 were examined. mRNAs expression of both NF-κB and MYD88 
were up-regulated in mesangial cells exposed to high glucose. As there was up-
regulation of MtDNA, increased ROS production, decreased mitochondrial 
transcription and increased rate of the MtDNA damage, taken all together these 
data might support the theory of damaged MtDNA acting as a danger molecule 
which by escaping autophagy activates inflammatory pathways via TLKR-9 
receptor (Oka et al., 2012).  
One of the major limitations of this study is lack of the data from protein 
expression for each of the investigated mRNAs. Results from mitochondrial 
staining in HMCs implicate possible changes in mitochondrial proteins 
responsible for the fusion, fission and mitophagy.  
In summary, in the current study we have observed functional changes in 
mitochondrial cycle following the exposure to high glucose, including induced 
intracellular ROS and damaged MtDNA, disconnection in mitochondrial 
transcription in translation (which may affect cellular response to oxidative 
stress) and also activation of the inflammatory pathways which may contribute 
further to the toxic effect of hyperglycaemia. 
  




Hyperglycaemia-induced changes in the bioenergetic 
profile of kidney cells 
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6.1 Abstract 
Background/Aims: The hypothesis that will be tested in this thesis is that 
hyperglycaemia/high glucose can cause early changes in mitochondrial DNA 
(content/quality) and that these changes can contribute to mitochondrial 
dysfunction. In the current chapter mitochondrial respiration in renal cells 
exposed to high glucose was examined.  
Methods: Primary cultured mesangial cells (HMCs) and tubular epithelial cell line 
(HK-2) were cultured in 5mM (normal) and 25mM (high) glucose and in 5mM 
glucose and 20mM mannitol (NGM) at various time points. Cellular bioenergetics 
was assessed in Seahorse XFe96 analyzer in cells cultured in NG, HG, NGM and in 
HMCs and HK-2 cells subjected to the treatment with hydrogen peroxide and 
acute 20mM glucose treatments. Mitochondrial basal, ATP-linked and maximal 
respiration in parallel with proton leak and non-mitochondrial respiration were 
assessed. Moreover a reversal experiment was performed, where growth 
medium with HG was replaced with NG, and the effect of change of glucose 
concentration on mitochondrial respiration was measured. 
Results: In HMCs cultured in high glucose, maximal respiration and reserve 
capacity did not change at 4 days, and were significantly reduced at 8 days 
(P<0.05) and at 12 days (P<0.001). No changes were seen at any of the time 
points in the NGM or in cells cultured in NG. No changes were also seen in 
glycolysis (ECAR) at 4, and 8 days of culture (P>0.05), but a significant decrease 
was observed at day 12 at basal level (P<0.05) and after the addition of 
oligomycin (P<0.01) in HMCs.  In HK-2 cells, basal, ATP-linked and maximal 
respiration were significantly down-regulated as early as 4 days of culture in HG 
(P<0.001, P<0.01). Acute treatment of HK-2 with H2O2 caused a significant 
decrease in mitochondrial respiration (P<0.05) and in basal and oligomycin-
induced glycolysis. Acute injection of 20mM glucose to HMCs, which were 
cultured in NG media, caused a ‘metabolic switch’ from OXPHOS respiration to 
the glycolysis but had no effect on cells pre-cultured in HG. Toxic effect of 
hyperglycaemia on cellular bioenergetics was reverted by correcting the glucose 
levels; however the outcome was dependent on the time of exposure of the cells 
to HG prior to media change.  
Conclusion: Hyperglycaemia significantly reduced mitochondrial respiration in 
the HMCs and HK-2 cells. Tubular cells seem to be more sensitive with more 
profound changes on their OXPHOS function that mesangial cells. Toxic effect of 
hyperglycaemia in mitochondrial respiration can be reverted; however the result 
is dependent on the time of exposure. These results show that hyperglycaemia 
leads to the decrease in energy metabolism in renal cells by down-regulation of 
their respiratory function. 
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6.2 Introduction 
It was shown in the Chapter 3 of this thesis, that MtDNA copy number was 
elevated in mesangial cells cultured in 25mM glucose. To my knowledge this is 
the first report showing increased MtDNA level in human mesangial cells in 
response to hyperglycaemia. The next question was related to mitochondrial 
function, and if changes which we observed on molecular level would correlate 
with altered mitochondrial respiration system. High glucose is known to be a 
contributing factor in the development of DN, and both clinical and experimental 
studies have shown, that high concentration of glucose inside the cells directly 
and indirectly activates a series of complex overlapping pathways. These include 
induction of oxidative stress and inflammatory responses, inhibition of 
antioxidant defence, formation of advanced glycation end products and 
activation of protein kinase C (Brownlee, 2005, Brownlee, 2001). There is also 
growing evidence that oxidative stress produced by dysfunctional mitochondria 
is a major contributor in the development of DN [reviewed in (Forbes et al., 
2008, Sivitz and Yorek, 2010)]. 
 Generation of reactive oxygen through metabolic processes leads to thickening 
of glomerular basement membrane, extracellular matrix accumulation in the 
mesangial cells and interstitial fibrosis which eventually will lead to kidney failure 
(Brownlee, 2005, Ha and Lee, 2003). Moreover glucose derived metabolites like 
pyruvate and NADH (created in the process of glycolysis), when transported to 
mitochondria for further utilization also contribute to ROS production. Pyruvate 
enters the mitochondrial membrane and after being metabolized, increases the 
ATP/ADP ratio consequently enhancing ROS/RNS formation. Increased levels of 
glucose and later pyruvate as a substrate may lead to increased oxidative 
phosphorylation, but this process is limited and can be ablated due to the 
changes in ETC caused by nutrient overload and toxic effect of superoxide ions 
which are produced as side effects of the OHPHOS system (Szabadkai and 
Duchen, 2009). 
The differences in energy demand and the way cells respond to nutrient 
concentration could explain why changes observed in diabetic complication 
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mainly involve certain types of cells like retinal, endothelial, tubular, neuronal 
and mesangial cells (Brownlee, 2005). This process could occur primarily due to 
the fact that these cells cannot cope with increased levels of glucose which is not 
removed efficiently and therefore glucose piles up inside the cells. It has been 
shown that there are differences in energy demands between different organs 
and cell types within organs in the body. Kidneys are organs requiring large 
amounts of energy in form of ATP due to the re-absorption processes and 
although their mass account of less than 1% of total body mass, they use almost 
10% of oxygen consumption which is then utilized in cellular respiration (Berg et 
al., 2002). Mercer et al., (2011) by using deep sequencing observed differences in 
the amount of each mitochondrial mRNA complexes between tissues and cells, 
with kidney mitochondrial mRNAs profiling showing one of the highest levels of 
mitochondrial transcripts, after colon, muscle and heart (Mercer et al., 2011). 
This data is not surprising, as eukaryotic cells, especially the ones with high 
energy demands rely mostly on ATP generated through OXPHOS, which is 15 
times more productive than the amount produced by aerobic glycolysis (Alberts 
et al., 2002). In the kidney, during the filtration processes glucose is re-absorbed 
from plasma and actively co-transported with help of NA+/K+ pumps which 
require constant source of ATP (Vallon, 2011). Moreover, different cells have 
different amount of mitochondrial transporters, with kidney proximal tubules 
mitochondria containing more types of transporters than other cell types 
especially with higher glutamate transporter levels, necessary in glutamine 
metabolism and formation and excretion of ammonia (Schoolwerth and LaNoue, 
1985). 
 In the current study, I investigated two types of kidney cells involved in the 
development of DN, primary mesangial cells and transformed proximal tubular 
cells. Both cell types are known to mostly use ATP through their OXPHOS system 
and proximal tubules are also known to have limited anaerobic glycolytic 
capacity (Wirthensohn and Guder, 1986). 
The current methodology used to measure mitochondrial function includes a 
variety of techniques including measurement of: mitochondrial physiology 
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(measurement of OXPHOS enzymes activity (Fernandez-Vizarra et al., 2011), 
assessment of proteins via western blotting (Sheng et al., 2012), northern blot 
analysis (Veltri et al., 1990), mitochondrial network structure via electron or 
fluorescent microscopy (Medeiros, 2008, Rodriguez-Enriquez et al., 2009) and 
also measurement of the oxygen consumption rate (Silva and Oliveira, 2012, 
Perry et al., 2013). The idea of the measurement of oxygen consumption as an 
indicator of mitochondrial health emerged from Clark oxygen electrode method. 
Clark electrode, developed by Leland Clark, enables accurate measurement of 
changes in oxygen levels present in the solution after the addition of 
mitochondrial extract mixture and mitochondrial activators and inhibitors (Silva 
and Oliveira, 2012, Clark et al., 1953). Although accurate, this technique requires 
optimisation and is not suitable for high throughput assessments.  The need of 
high throughput and standardise method to measure mitochondrial function, 
which could also be used directly on patient cells, lead to the development of 
extracellular flux analyzers like Seahorse XF analyzer (Ferrick et al., 2008).  
Due to allowing more experimental replicates and smaller samples sizes for 
analysis, Seahorse XF analyzer became a more popular method for the 
assessment of mitochondrial function in many samples including cell culture, 
whole mitochondria extracts (Brand and Nicholls, 2011), and also patients’ 
peripheral blood mononuclear cells (PBMCs) for a direct a quick measurement of 
mitochondrial respiration (function) in healthy and disease state (Chacko et al., 
2013, Shikuma et al., 2008, Caimari et al., 2010). By utilizing plate system and 
fibre optic probes, Seahorse technology assess the levels of O2 and H+ ions in 2-
7μl micro chamber created over the monolayer of cells. Two different probes 
allow simultaneous measurement of two aspects of mitochondrial bioenergetics: 
oxidative phosphorylation /oxygen consumption rate (OCR) and extracellular 
acidification rate /amount of H+ ions (ECAR) in intact cells in a plate format 
(Ferrick et al., 2008, Brand and Nicholls, 2011). 
The Seahorse analyzer allows measurement of the oxygen consumption from 
fundamental parameters of mitochondrial function: mitochondrial respiration 
(basal, maximal and ATP-linked respiration), glycolysis, and non-mitochondrial 
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respiration. In order to assess these factors cells are injected with mitochondrial 
respiration inhibitors and uncoupler such as oligomycin, antimycin A, rotenone 
and FCCP (Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone) (Fig.6.1.). 
Oligomycin (ATP synthase blocker) is used to observe ATP turnover and to 
determine if there is any difference in proton leak. In oxidative phosphorylation 
research, it is used to prevent state 3 respiration. Oligomycin inhibits ATP 
synthase (complex V) by blocking its proton channel (F0 subunit), which is 
necessary for oxidative phosphorylation of ADP to ATP (Brand and Nicholls, 
2011). The inhibition of the ATP synthesis by oligomycin will significantly reduce 
electron flow through the ETC; however, electron flow will not be stopped 
completely due to a process known as proton leak or mitochondrial uncoupling. 
This process is due to the facilitated diffusion of protons into the mitochondrial 
matrix through UCPs (uncoupling proteins) (Affourtit and Brand, 2008). After 
blocking ATP production through the OXPHOS system, cells tend to switch to 
glycolysis to balance their ATP levels. FCCP (mitochondrial uncoupler) is used to 
measure maximum respiratory function. It is called an uncoupling agent because 
it disrupts ATP synthesis by transporting hydrogen ions through a cell 
membrane against proton gradient (Schraufstatter et al., 1985). Rotenone 
(inhibitor of mitochondrial complex I) and antimycin A (blocker of ubiquinol 
phosphorylation) are used to completely shut mitochondrial respiration down to 
prove the changes in respiration were mainly in mitochondria. Use of these 
inhibitors gives us also indication of non-mitochondrial respiration, term used to 
asses amount of oxygen used by cellular oxidases, like NADPH dependent 
oxidases (Brand and Nicholls, 2011). 
To date there are no published reports describing cellular bioenergetics of 
human renal cells after the exposure to hyperglycaemia. Published poster data 
from Chacko et al., (2010) reported down-regulation of the mitochondrial 
function in primary mouse mesangial cells exposed to hyperglycaemia for 14 
days  (Chacko et al., 2010a). There are however reports about different cells 
types in response to hyperglycaemia, Trudeau at al., (2010) assessed 
mitochondrial bioenergetics in rat retinal endothelial cells cultured for 3 and 6 
days in 30mM glucose and also observed a decline in mitochondrial function. In 
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contrary, Fink at al., (2012) did not observed any changes in the bovine aortic 
endothelial cells and human platelets cultured in high glucose for 18 hours (Fink 










Fig.6.1. Key parameters of mitochondrial function measured by seahorse flux analyzer. 
The main parameters measured by using cell XF mito stress test kit are: basal 
respiration, ATP turnover, proton leak, maximal respiration and reserve capacity. In 
order to assess these factors cells are injected with mitochondrial respiration inhibitors 
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6.3 Hypothesis and aims 
6.3.1 Hypothesis 
The main hypothesis under study in this work is that high glucose can cause early 
changes in mitochondrial DNA (content/quality) and that these changes can 
contribute to mitochondrial dysfunction. In the current chapter the 
mitochondrial respiration was investigated in primary cultured renal mesangial 
cells.  
6.3.2 Aims and objectives 
The main aim of this chapter was to demonstrate using cultured renal cells 
whether glucose-induced changes in MtDNA occur in parallel with altered 
mitochondrial respiration in renal cells.  
This aim will be met as follows:  
1. The effect of hyperglycaemia on the bioenergetic profile in the renal cells 
will be measured.  
2. The effect of acute glucose load on the on mitochondrial respiration in 
renal cells will be determined. 
3. The effect of acute oxidative stress on the mitochondrial respiration in 
renal cells will be determined. 
4. The effect of the reversing of the glucose concentration on mitochondrial 
bioenergetic profile will be evaluated in renal cells.  
 
The experimental strategy to carry out the above will be as follows: 
1. Two different renal cell types will be used, primary cultured mesangial 
cells (HMCs) and immortalized proximal tubular cells (HK-2) cells 
2.  Cells will be cultured in 5mM (normal, NG) and 25mM (high, HG) glucose, 
for various time points. 20mM mannitol in 5mM glucose (Man) will be 
used as an osmolarity control. 
3. Bioenergetic profile will be assessed by using a Seahorse XFe96 analyzer 
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4. To measure acute effect of high glucose on mitochondrial respiration 
20mM glucose will be injected during respiration assessment. 
5. To determine effect of direct oxidative stress on metabolic profile of renal 
cells, HMCs and HK-2 will be treated with 1μM or 5μM H2O2 for 15 min 
prior the respiration assessment. 
 
6.4 Results 
In this chapter we investigated changes in bioenergetic profiles in human renal 
cells cultured under normal (5mM) and high (25mM) glucose. 5mM glucose plus 
20mM mannitol was used as an osmotic control (Man). 
Two different types of human renal cells were used, transformed tubular cells 
(HK-2) and primary cultured mesangial cells (HMCs). A simplified overview of the 






















Fig.6.2. Overview of results in chapter 6. 
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6.4.1  Cell XF mito stress test assay optimization. 
In order to define optimal conditions for the use of ‘XF cell mito stress test’ kit 
with human primary mesangial and transformed tubular cells, a series of 
optimization experiments were performed. The parameters which were tested 
included: a) cell density, b) concentration of ATP-synthase blocker-Oligomycin, c) 
concentration of mitochondrial uncoupler- FCCP. Rotenone and antimycin A are 
mitochondrial respiration blockers and usually do not require optimization, in 
these series of experiments optimal 0.5μM final concentrations were used. 
First, a titration experiment with different cell seeding density was performed. 
Cells were trypsinized and counted using Countess Cell counter. Human primary 
mesangial cells (HMCs) and human transformed tubular cells (HK-2) were re-
suspended at different densities (ranging from 10 000 to 40 000 cells) in 80μl of 
complete growth media and seeded in assay plates 24 h prior to OCR 
assessment. On the day of the assessment, media was changed to assay media 
containing 5mM glucose and 1mM sodium pyruvate, and basal OCR for both cell 
types were assessed using Seahorse XFe96 analyzer. Optimal cell density was 
evaluated based on the OCR values (200-350 pmol/min are considered optimal). 
As expected there were a significant differences in the OCR values depended on 
cell density, e.g. 10 000 and 15 000 of cells gave very low reading of basal OCR 
for both, HMCs (OCR: 55-94 pmol/min) and HK-2 cells (OCR: 50-94 pmol/min) 
(Fig.6.3). With increasing number of cells an increase in basal OCR was observed. 
For HMCs optimal cell number based on OCR readings (225-311 pmol/min) was 
assessed in the range of 25-40 000 cells and 35 000 of cells/ well was chosen 
(Fig.6.3.A). For HK-2 cells, 20-40 00 cells/ well gave optimal OCR reading (180-270 
pmol/min)  and 25 000 cells/ well was chosen (Fig.6.3.B).  Higher number of cells 
caused cell detachment during the washing steps, and this occurrence was 
observed in both HMCs and HK-2 cells.  
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Fig.6.3. Optimization of the cell number. Basal respiration in absolute rates (OCR in 
pmoles/min) was assessed in: (A) HMCs, harvested from the same culture flask, and 
seeded at five different densities, (B) HK-2 cells, harvested from the same culture flask, 
and seeded ad four different densities, as shown on the individual panels on the right. 
Six measurement of basal respiration were taken, followed by an injection of oligomycin 
(1μM final). To assess maximal respiration, FCCP was injection at the 0.5μM working 
concentration. Rotenone and Antimycin A(AA) were injected to completely bloc 
mitochondrial respiration. OCR show increasing absolute rates with increased cell 
density. Data shown as a mean ±SD, n=6 observations  
 
 
Cell seeding density directly impacts not only absolute rates, but also 
concentration of the injected compounds. Therefore, after estimation of the 
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concentration of mitochondrial uncoupler and blockers. Figure 6.4 represents 
optimization data for oligomycin for HMCs (A) and HK-2 cells (B). HMCs and HK-2 
cells were harvested and seeded at same density overnight (35 000 and 25 000 
cells/ well respectively). On the day of the experiment growth media was 
changed to assay media (as described previously) and absolute rate (OCR) were 
assessed. Oligomycin, ATP synthase blocker, causes drop in respiration trace, 
which gives an indication of amount of oxygen used for ATP production. 
Oligomycin was loaded and injected at three different concentrations (n=6 for 
each concentration), and drop in oxygen consumption was assessed as an 
indicator of drug concentration efficiency. After injection of 0.3µM and 0.6µM of 
oligomycin, there was observed a decline in OCR, however the response wasn’t 
rapid for both, HMCs (Figure 6.2 A) and HK-2 cells (Fig.6.4 B). 1µM of oligomycin 
proved to be sufficient to block ATP-synthase within 3 minutes from injection, 
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Fig.6.4. Optimization of the oligomycin concentration. Basal respiration in absolute 
rates (OCR in pmoles/min) was assessed in Seahorse analyzer in: (A) HMCs, (B) HK-2 
cells. Cells were seeded at the same density within one plate and six measurement of 
basal respiration were taken, followed by a three different injections of oligomycin (0.3-
1µM final concentration). OCR shows a decline in absolute rates with increased 
oligomycin concentration. Data presented as a mean ±SD, n=6 observations 
 
 
In the final set of the optimization experiments, the concentration of the FCCP, 
which is an ETC accelerator, was estimated. Figures 6.5 and 6.6 represents 
graphic optimization data for FCCP for HMCs (Fig.6.5A and 6.6A) and HK-2 cells 
(Fig.6.5B and 6.6.B). Cells harvested from the same flask were seeded at the 
same density overnight (35 000 and 25 000cells/well respectively). On a day of 
experiment growth media was changed to assay media (as described above) and 
absolute rate (OCR) were assessed. When FCCP is injected to the wells, it 
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disrupts mitochondrial membrane potential by bringing protons ions inside the 
mitochondria against the proton pump. This causes mitochondrial uncoupling 
and increase in OCR. FCCP was loaded and injected at six different 
concentrations (n=6 for each concentration), and maximal respiration (maximal 
increase in oxygen consumption) was assessed. OCR values rose with increasing 
low concentrations of FCCP (0.15µM and 0.3µM), but after reaching the peak, it 
declined with higher concentrations of the FCCP, in both HMCs and HK-2 cells 














Fig.6.5. Optimization of FCCP concentration. Basal respiration in absolute rates (OCR in 
pmoles/min) was assessed in: (A) HMCs, (B) HK-2 cells. Cells were seeded at the same 
density within one plate and OCR was assessed in Seahorse analyzer. Three 
measurement of basal respiration were taken, followed by an injection of oligomycin 
(1uM final). To assess optimal concentration of FCCP, cells were next injected with six 
different concentration of FCCP, ranging from 0.15 -1.25μM (colours corresponding to 
different concentrations of FCCP shown on the legend on the right upper corner). Data 
shown as a mean ±SD, n=6 observations 
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As ETC accelerator is the most sensitive compound in the kit to concentration 
changes, and high concentration proved to be toxic to the cells, it is really 
important to assess correct concentration peak. Therefore, maximal respiration 
rates obtained in the experiment shown in the figure 6.5.A and 6.5.B were 
calculated as a % maximal OCR and plotted against different concentration of 
FCCP in µM. 0.3µM final concentration of FCCP caused 40% increase in OCR in 
both HMCs (Fig.6.6 A) and HK-2 cells (Fig.6.6 B). Additional increase in FCCP 










Fig.6.6. FCCP dose response. Cells were seeded at the same density within one plate 
and maximal OCR dependent on FCCP concentration was assessed in Seahorse analyzer, 
in HMCs (A) and HK-2 cells (B).  OCR values rose with increasing low concentrations of 
FCCP, peak optimal concentration is highlighted by dotted red circle. Data were plotted 
as % of basal respiration, n=6 
 
6.4.2 Bioenergetic profile of human primary mesangial cells in normal and 
high glucose  
HMCs were grown in 5mM (NG), 25mM (HG) and 5mM glucose [plus 20mM 
mannitol (NGM) for 4, 8 and 12 days and determination of OCR and ECAR in real-
time was measured by using XF flux analyzer (Seahorse bioscience). Cell seeding 
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density and mitochondrial inhibitors concentration had been determined in a 
series of optimization experiments (as shown above). Oligomycin, FCCP, 
rotenone and antimycin A were injected sequentially through ports in the XF 
Assay cartridges to final concentrations of 1μM, 0.3μM, 0.5μM and 0.5μM 
respectively. Upon completion of the experimental run, assay media was 
removed and cells were treated with 20μl of lysis buffer (content of the buffer is 
shown in the methods section 2.13) for normalization purposes, therefore all 
values are presented as pmoles O2/ min/μg protein. 
• Bioenergetic profile of human mesangial cells cultured in high glucose for 
4 days 
After 4 days of culture in NG, HG and NGM, there was no difference in any of the 
assessed parameters (Fig.6.7 and 6.13). Basal respiration of HMCs cultured in NG 
and HG was around 250 pmoles/min/μg protein (Fig.6.7). Following the injection 
of oligomycin there was a 60% decline in OCR in all conditions and it did not 
differ significantly between treatments (Fig. 6.7 and 6.13.B). Maximal respiration 
measured after the injection of FCCP resulted in approximately 40% increase in 
respiration (from 250 to ~ 360 pmoles/min μg/protein) in cells grown in NG, HG 
and NGM (Fig.6.7 and 6.13C). No significant difference in reserve capacity was 
observed (Fig.6.7 and 6.13D). There was no difference in proton leak (Fig.6.13E); 
and although non-mitochondrial respiration was reduced in cells cultured in HG 
(56 ± 19) when compared to control (39.6 ± 8), it was not statistically significant 
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Fig.6.7. Bioenergetic profile of human mesnagial cells cultured in different conditions 
for 4 days. HMCs were grown in DMEM containing 5mM (NG), 25mM (HG) and 5mM 
glucose plus 20mM mannitol (NGM) for 3 days. Day before the assessment, cells were 
trypsinized, counted and seeded at density of 35 000 cells/well in different media. 
Following media change, OCR was assessed in seahorse analyzer. Four measurement of 
basal respiration were taken, followed by an injection of oligomycin (1μM final). To 
assess maximal respiration, FCCP was injection at the 0.3μM working concentration. 
Reserve capacity, measured as a difference between maximal and basal respiration, is 
presented via brackets. Data shown as a mean ±SD, n=6-7 observations 
 
No difference in glycolysis (ECAR) based on the measurement of the 
concentration of protons released into media was observed (Fig.6.8 and 
Fig.6.14A). The osmotic control- NGM showed a similar bioenergetic profile to 







Fig.6.8. Glycolytic profile of human mesangial cells cultured in different conditions for 
4 days. HMCs were grown in 5mM (NG), 25mM (HG) and 5mM glucose plus 20mM 
mannitol (NGM) for 3 days. Day before the assessment, cells were trypsinized, counted 
and seeded at density of 35 000 cells/well in different media. Following media change, 
ECAR was assessed in Seahorse XF96e analyzer. Data shown as a mean ±SD, n=6-7. 
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• Bioenergetic profile of human mesangial cells cultured in high glucose for 
8 days 
In HMCs cultured for 8 days in NG, HG and Man, there was a slight decline in 
basal respiration in cells cultured under HG when compared to the NG control 
(260 ± 21 vs. 272 ± 14 respectively), but the difference was not significant 
(P>0.05, Fig 6.9 and 6.13A). ATP-linked respiration did not differ between 
treatments and proton leak and non-mitochondrial respiration remain the same 
in cells cultured in NG, HG or in NGM (P>0.05, Fig. 6.13B and 6.13E-F 
respectively). Although no changes were observed in basal respiration and 
respiration used for ATP turnover,  cells grown in 25mM glucose had significantly 
decreased maximal respiration when compared to the controls (375±24 vs. 
415±3, respectively, P<0.05, Fig.6.9 and Fig. 6.13C). Reserve capacity, calculated 
as a maximal minus basal respiration, was also significantly reduced (by 20%) in 








Fig.6.9. Bioenergetic profile of human mesangial cells grown in different conditions for 
8 days. HMCs were grown in 5mM (NG), 25mM (HG) and 5mM glucose plus 20mM 
mannitol (NGM) for 7 days. Day before the assessment, cells were trypsinized, counted 
and seeded at density of 35 000 cells/well in different media. Following media change, 
OCR was assessed in Seahorse analyzer. Four measurement of basal respiration were 
taken, followed by an injection of oligomycin (1μM final). To assess maximal respiration, 
FCCP was injection at the 0.3μM working concentration. Reserve capacity, measured as 
a difference between maximal and basal respiration, is presented via brackets. Data 
shown as a mean ±SD, n=8 observations 
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No statistically significant difference in ECAR based on measurement of the 
concentration of protons released into media was observed at basal level or after 
the injection of oligomycin (Fig.6.10 and 6.14B, P>0.05). Mannitol had no effect 








Fig.6.10. Glycolytic profile of human mesangial cells cultured in different conditions for 
8 days. HMCs were grown in 5mM (NG), 25mM (HG) and in 5mM glucose plus 20mM 
mannitol (NGM) for 7 days. Day before the assessment, cells were trypsinized, counted 
and seeded at density of 35 000 cells/well in different media. Following media change, 




• Bioenergetic profile of human primary mesangial cell cultured in high 
glucose for 12 days 
 
Chronic, 12-day exposure to HG glucose decreased basal oxygen consumption in 
HMCs by more than 50% when compared to control (226±11 vs. 111±4 
respectively, P<0.0001 Fig.6.11 and 6.13A).  After the injection of oligomycin, 
cells cultured in HG had their ATP levels reduced by 2.5 fold when compared to 
cells cultured in NG (151±20 vs. 60±18 respectively, P<0.0001, Fig.6.11 and 
Fig.6.13B).  There was no difference in proton leak and in non-mitochondrial 
respiration (P>0.05, Fig.6.11 and Fig.6.13E, F). As described previously, maximal 
respiratory capacity of cells after injection of FCCP, was significantly lower in the 
cells cultured for 8 days in HG when compared to the controls, and this reduction 
became highly significant (P<0.0001) after 12 days of culture in HG, with 3 fold 
173 | P a g e  
 
Chapter 6: Hyperglycaemia affects bioenergetic profile of human renal cells 
reduction of maximal OCR when compared to the controls (128±29 vs. 365±47 
respectively, P<0.0001, Fig.6.11 and Fig.6.13C). There was also a 4 fold reduction 
in reserve capacity in cells grown in HG after 12 days when compared to cells 










Fig.6.11. High glucose affects bioenergetic profile of human mesangial cells after 12 
days of culture. HMCs were grown in 5mM (NG), 25mM (HG) and in 5mM glucose plus 
20mM mannitol (NGM) for 11 days. Day before the assessment, cells were trypsinized, 
counted and seeded at density of 35 000 cells/well in different media. Following media 
change, OCR was assessed in Seahorse analyzer. Four measurement of basal respiration 
were taken, followed by an injection of oligomycin (1μM final). To assess maximal 
respiration, FCCP was injection at the 0.3μM working concentration. Reserve capacity, 
measured as a difference between maximal and basal respiration, is shown on the right. 
Data shown as a mean ±SD, n=8 observations 
 
 
When glycolysis was assessed in these cells, there was a significant reduction in 
glycolysis at basal level (P<0.05) and also after the addition of oligomycin (which 
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Fig.6.12. Glycolytic profile of human mesangial cells cultured in different conditions for 
12 days. ECAR (glycolysis) was assessed in the Seahorse XFe96 analyzer. Data shown as a 

















Fig.6.13. High glucose affects metabolic profile of human mesangial cells. Human 
mesangial cells were grown in 5mM (NG), 25mM (HG) glucose and 5mM glucose plus 
20mM mannitol. for 4, 8 and 12 days. OCR was assessed in Seahorse XFe96 analyzer. 
Basal oxygen consumption rate (OCR) (A). ATP linked respiration (B). proton leak (E). 
Maximal respiration (C). Reserve capacity, measured as a difference between maximal 
and basal respiration, is shown on the figure D. All the parameters were calculated by 
subtracting non-mitochondrial values for each sample (F). Data shown as a mean ±SD, 
n=8 observations,One way ANOVA with Tukey’s post hoc where,  *P<0.05, ***P<0.001 
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Fig.6.14. Glycolytic profile of human primary mesangial cells cultured in different 
conditions. Human mesangial cells were grown under 5mM (NG), 25mM (HG) for 4 days 
(A), 8 days (B) and 12 days (C). Day before the assessment, cells were trypsinized, 
counted and seeded at density of 35 000 cells/well in different media. Basal ECAR and 
ECAR after injection of the oligomycin (1μM final) were assessed in XFe96 Seahorse 
analyzer. Data shown as a mean ±SD, n=6-8 observations, Student’s t-test where, 
*P<0.05, ** P<0.01 
 
 
In summary, these data show, that 4 days exposure to HG had no effect on any 
of the measured parameters involved in mitochondrial respiration or glycolysis in 
HMCs. 8 days exposure of HMCs to HG significantly decreased cells’ 
mitochondrial maximal respiration and reserve capacity but did not affect any 
other mitochondrial respiration parameters. 12 days exposure of HMCs to HG 
significantly affected cells’ mitochondrial respiration and glycolytic capacity. 
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Reduction in both glycolysis and OXPHOS function in cells grown in HG may 
suggest that cells became energetically inactive. 
6.4.3 The ratio of glycolysis and oxidative phosphorylation in mesangial 
cells 
Another parameter allowing assessment of the metabolic profile of cultured cells 
is the ratio of OCR and ECR. Glycolysis and OXPHOS are likely to be integrated 
during the cellular response to oxidative stress. The OCR and ECAR for a cell is 
related to the flux through pathways used to generate ATP. The response of both 
pathways to cellular stress can be assessed by plotting OCR against ECAR at a one 
time-point, usually at basal level or after injection of the compound of interest as 
shown in Fig.6.15 A-C which represents metabolic profile of cells grown in 5mM 
and 25mM glucose for 4, 8 and 12 days respectively. Mean basal ECAR versus 
OCR ratio didn’t change in cells grown under different conditions for 4 and 8 days 
(Fig.6.15A, B). After 12 days of culture, HMCs cultured in NG and NGM had high 
ECAR and OCR values (Fig.615 C). Chronic, 12 days exposure of cells to HG, 
caused a shift in their bioenergetic profile showing that the cells became 
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Fig.6.15. The oxygen consumption rate (OCR) and glycolysis (ECAR) of human primary 
mesangial cells. The mean basal OCR vs. basal ECAR in cells grown in different 
conditions for 4 days (A), 8 days (B) and 12 days (C). Arrow points a metabolic shift in 
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6.4.4 The effect of hydrogen peroxide and acute glucose load on the 
bioenergetic profile of human mesangial cells 
HMCs were grown for 12 days in normal glucose (5mM), and exposed for 15 
minutes to two different concentrations of H2O2. In the second part of this 
experiment, acute 20mM high glucose was injected into the wells during the 
Seahorse run. Day before the assessment, mesangial cells were seeded in XF 
assay plates as described before (35 000 cells/well), and on the day of the 
experiment were treated with different concentrations either 1μM or 5μM H2O2 
for 15min in complete growth media with 5mM glucose. Higher than 5μM 
concentrations of H2O2 and longer than 15 minutes treatment proved to be toxic 
to the cells and caused cell detachment during the media change. HMCs were 
then washed with XF assay media, and allowed to equilibrate at 37°C for 1 h in a 
non-CO2 incubator. Mitochondrial function was then assessed as described 
above using activators and inhibitors of ETC. 
• The effect of H2O2 on  bioenergetic profile of human mesangial cells  
The aim of these experiments was to assess if oxidative stress have the same 
effect on mitochondrial function as chronic (12 day) exposure to HG. As shown in 
Figure 6.16, basal OCR was increased in response to H2O2 in HMCs when 
compared to the control, but this result was not significant (Fig.6.16A). This 
occurred due to an increase in both, ATP-Linked OCR (10% increase) and proton 
leak (15% increase), but none of these results were significant (P>0.05, Fig. 6.16B 
and Fig.6.16F). After the addition of FCCP the OCR didn’t change and there was 
no difference in maximal OCR or reserve capacity P>0.05, (Fig.6.16C and 
Fig.6.16D). Interestingly, there was no increase in non-mitochondrial OCR, 
indicating there is little additional ROS production beyond the H2O2 the cells 
were exposed to initially, however treatment with higher concentrations of H2O2 
seem to reduce non-mitochondrial respiration which might suggest activation of 
antioxidant defences (P=0.09 when compared to NG).  
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Fig.6.16. Acute oxidative stress does not change bioenergetic profile of human primary 
mesangial cells. Human mesangial cells were grown in DMEM containing (NG), 25mM 
(HG) glucose for 12 days. Day before the assessment, cells were trypsinized, counted 
and seeded at density of 35 000 cells/well in different media. Some of the cells grown in 
NG were treated with 1μM or 5μM H2O2 for 15min before the OCR was assessed in 
Seahorse analyzer. Four measurement of basal OCR were taken, allowing measuring 
basal respiration (A). Following the injection of oligomycin (1μM final) assessment of 
ATP- linked respiration (B) and proton leak (F) were taken. To assess maximal respiration 
(C), FCCP was injected at the 0.3μM final concentration. Reserve capacity, measured as a 
difference between maximal and basal respiration, is shown on the figure D. All the 
parameters were calculated by subtracting non-mitochondrial values for each sample 
(E). Proton leak is presented on figure F. Data shown as a mean ±SD n=6 for NG and HG 
and n=3 observations for H2O2 treatment,One way Anova with Tukey’s post hoc test 
where, ***P<0.001 vs.NG12 
 
 
Basal glycolysis rate in cells treated with H2O2 was significantly increased by 
almost 50% when compared to the basal in cell cultured in NG (180±36 vs. 
104±21, P<0.01) and this increase was not dose dependent (Fig.6.17). Also after 
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Fig.6.17. Acute oxidative stress affects glycolysis in primary cultured human mesangial 
cells. Human mesangial cells were grown in DMEM containing 5mM (NG), 25mM (HG) 
glucose for 12 days. Day before the assessment, cells were trypsinized, counted and 
seeded at density of 35 000 cells/well in different media. On the day of the experiment 
of some the cells grown in NG were treated with 1μM or 5μM H2O2 for 15min before the 
basal ECAR was assessed in Seahorse analyzer. Data shown as a mean ±SD, n=6 for NG, 
HG and n=3 observations for H2O2 groups respectively, Kruskal Wallis test with Dunn’s 
post hoc where, *P<0.05, ** P<0.01 vs. NG basal, # P<0.05 vs. NG oligomycin 
 
 
• The effect of acute glucose injection on bioenergetic profile of human 
mesangial cells cultured in 5mM glucose 
The aim of these experiments was to assess if acute oxidative stress have the 
same effect on mitochondrial function as chronic (12 day) exposure to HG. Basal 
respiration rate was measured in the cells in which HG was injected into the 
wells during the Seahorse run, to assess effect of acute treatment with 25mM 
glucose.  
Cells were grown in 5mM glucose for 12 days and day before the assessment 
seeded in XF assay plates in the complete growth media. On the day of the 
experiment growth medium was change into assay media which contained 5mM 
glucose. After 3 measurements of basal OCR, glucose was injected into the well 
and consecutive measurements of basal OCR were taken followed by a standard 
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injection of oligomycin, FCCP and rotenone and antimycin A at concentrations 
described previously.  
Basal OCR significantly decreased after HG injection (from 180±27 to 80 ±50 
pmol/min), and the reduction was based on decreased ATP-linked OCR (from 
140±20 to 43±52) as there was no difference in the proton leak (Fig.6.19 A). 
Acute HG glucose injection caused slight but not significant increase in maximal 
respiration and increase in reserve capacity which was close to reach the 
significance (P=0.051). HG injection significantly increased non-mitochondrial 
OCR when compared to control (46±9 vs. 71±12 pmol/min respectively) 
suggesting other cellular processes involved in glucose processing which involve 








Fig.6.18. Acute injection of high glucose has an effect on the bioenergetic profile of 
human primary mesangial cells. HMCs were grown in DMEM containing 5mM (NG) 
glucose for 11 days. Day before the assessment, cells were trypsinized, counted and 
seeded at density of 35 000 cells/well in different media. Following media change, OCR 
was assessed in Seahorse analyzer. Three measurements of basal respiration were 
taken, followed by injection of 20mM glucose and another five consecutive 
measurements of basal OCR. To measure ATP-linked OCR, oligomycin was injected a 
1μM final. To assess maximal respiration, FCCP was injection at the 0.3μM working 
concentration. Data shown as a mean ±SD, n=4 for acute glucose injection, n= 6 
observations for NG, data are representative for one experiment 
 
Measurement of the ECAR (glycolytic rate) was carried out at the same time.  
Basal ECAR after the injection of acute 20mM glucose and ECAR after the 
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injection of oligomycin, were measured. As expected, drop in basal OCR 
described previously caused the switch in metabolism to glycolysis. After the HG 
injection, basal glycolytic rate significantly increased by more than two fold, 
when compared to cells injected just with the assay media (248±60 vs. 100±20 
mpH/min respectively). After the injection of oligomycin, the fold increase in 
ECAR rate was not as high as in cells injected with assay media. This data suggest 
that cells acutely treated with 20mM glucose could reach their maximal 














Fig.6.19. Acute injection of high glucose has an effect on the bioenergetic profile of 
human primary mesangial cells. HMCs were grown in 5mM (NG) for 12 days. Day before 
the assessment, cells were seeded at density of 35 000 cells/well in different media. 
Some of the cells grown in the NG were injected with assay media (-) or 20mM glucose 
(+) during the assessment in Seahorse analyzer. OCR (A) and basal ECAR and ECAR after 
the injections of oligomycin (B) were assessed in XF96 Seahorse analyzer. Data shown as 
a Mean ±SD Data shown as a mean ±SD, n=4-8 observations, data are representative for 
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• The effect of acute glucose injection on bioenergetic profile of human 
mesangial cells cultured in 25mM glucose 
HMCs were cultured for 12 days in 25mM glucose and bioenergetic assessment 
was carried out in Seahorse XF analyzer as described previously. After 3 
measurements of basal OCR, glucose was injected into the well and consecutive 
measurements of basal OCR were taken followed by a standard injection of 
pligomycin, FCCP and rotenone and antimycin A (Fig.6.20) at concentrations 
described previously. As illustrated on Fig.6.21.A cells pre-cultured in high 
glucose did not reduced their mitochondrial respiration after the 20mM glucose 
injection as there was no difference in any of the measured parameters of the 









Fig.6.20. Acute injection of high glucose has no effect on the bioenergetic profile of 
preconditioned human primary mesangial cells. HMCs were grown in DMEM containing 
25mM (HG) glucose for 11 days. Day before the assessment, cells were trypsinized, 
counted and seeded at density of 35 000 cells/well in different media. Following media 
change, OCR was assessed in Seahorse analyzer. Three measurements of basal 
respiration were taken, followed by injection of 20mM glucose and another five 
consecutive measurements of basal OCR. To measure ATP-linked OCR, oligomycin was 
injected a 1μM final. To assess maximal respiration, FCCP was injection at the 0.3μM 
working concentration. Data shown as a mean ±SD, n=4 for acute injection, n=8 for HG, 
data are representative for one experiment. 
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Basal glycolytic rate did significantly increase after the glucose injection by 
almost 2 fold when compared to cell injected with assay media only (P<0.01). 
After the injection of oligomycin, the fold increase in ECAR rate was not 













Fig.6.21. Acute injection of high glucose affect only glycolysis in human primary 
mesangial cells preconditioned in high glucose. Human mesangial cells were grown in 
DMEM containing 25mM (HG) glucose for 12 days. Day before the assessment, cells 
were trypsinized, counted and seeded at density of 35 000 cells/well in different media 
and assessment of OCR (A) and ECAR (B) was performed. Some of the cells grown in the 
HG for 12 days were injected with assay media (-) or 20mM glucose (+) during the 
assessment in Seahorse analyzer. To measure ATP-linked OCR and proton leak, 
oligomycin was injected a 1μM final. To assess maximal respiration, FCCP was injected at 
the 0.3μM final concentration. Reserve capacity was measured as a difference between 
maximal and basal respiration. Non-mitochondrial respiration was subtracted from all 
the values presented in the graph (A).  Basal ECAR and ECAR after the injection of 1μM 
of oligomycin was assessed in HG and in acute HG group (B). Data shown as a mean ±SD, 
n=4-6 replicates, data are representative for one experiment, Student’s t-test 
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These data show, that after the acute 20mM glucose injection, HMCs which were 
cultured in NG, switched their metabolism to glycolysis as basal glycolytic rate 
significantly increased by more than two fold, and basal and ATP-linked OCR was 
reduced. HMCs which were exposed to chronic hyperglycaemia lost their 
flexibility to respond to nutrient load, as they can increase their glycolytic rate 
but at the same time mitochondrial respiration remains the same which suggest 
they cannot balance their energy production. 
 
6.4.5  Is inhibiting effect of hyperglycaemia on mitochondria respiration in 
mesangial cells reversible? 
It was shown in the previous paragraph that exposure of HMCs to high glucose 
for 8 and 12 days significantly affects cells’ mitochondrial respiratory function, 
especially maximal respiration and reserve capacity. To assess if these changes 
were permanent or possible reversible, study was design to test mitochondrial 
respiration in cells which were cultured in DMEM with different glucose 
concentrations (HG media was substituted with low NG one). Two time points 
were used, cells were grown for 7 days in HG and the media was changed to NG 
glucose media for 1 day (HG7/NG1) and in the second time point, cells were 
grown under HG for 8 days and had the media reversed to normal glucose for 4 
days (HG8/NG4). In control groups cells were cultured in 5mM glucose for 8 and 
12 days. To compare the groups, one-way ANOVA was performed and analysis of 
variance proved to be significant (P=0.0005). Tukey's Multiple Comparison Test 
show no difference in basal or ATP-linked respiration (P>0.05) between HG 8 
days, NG 8 days and HG7/NG1 groups (Fig.6.22A and Fig.6.23A). As described 
previously cell cultured in HG for 4 days had the same OCR profile as control 
groups, but 8 day culture in HG had significantly decreased maximal respiration 
and reserve capacity (Fig.6.13). This trend was still observed in cells cultured in 
HG for 7 days with media change for one day to 5 mM glucose (Fig 6.22A and 
Fig.6.23A). Maximal respiration didn’t get back to normal levels and was still 
highly significantly lower when compared to NG group (P<0.001). Interestingly 
reserve capacity in HG7/NG1 group was significantly lower than in cells cultured 
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in HG for 8 days (P<0.05) and highly significantly lower when compared to the 
controls (P<0.001, Fig.6.23A). However, when cells were cultured for 8 days in 
HG and then reverted to normoglycaemia for 4 days, there was observed a 
beneficial effect of reversed conditions. Tukey's Multiple Comparison Test 
showed no difference in maximal respiration and reserved capacity between NG 
and HG8/NG4 groups. Also basal, ATP-linked and non-mitochondrial OCR which 
were significantly down regulated by 12 day treatment of HG returned to control 












Fig.6.22. Reversing the culture conditions affects bioenergetic profile of human 
primary mesangial cells. HMCs were grown in DMEM containing 5mM (NG), 25mM (HG) 
glucose for 11 days and in reversed conditions: HG7/NG1 (A) and HG8/NG4 (B). Day 
before the assessment, cells were trypsinized, counted and seeded at density of 35 000 
cells/well in different media. Following media change, OCR was assessed in Seahorse 
analyzer. Three measurements of basal respiration were taken, followed by the injection 
of oligomycin a 1μM final in order to measure ATP-linked OCR. To assess maximal 
respiration, FCCP was injection at the 0.3μM working concentration. Data shown as a 
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Fig.6.23. Reversing the culture conditions changes metabolic profile of human primary 
mesangial cells. Mesangial cells were grown either in DMEM containing 5mM (NG), 
25mM (HG) for 8 days (A) or in NG and HG for 12 days (B). During the 8 day culture in 
HG, medium was changed to low glucose after 7 days for 24hr (A). During 12 day culture, 
after 8 days HG medium was replaced by 5mM one for 4 days (B). Day before the 
assessment, cells were trypsinized, counted and seeded at density of 25 000 cells/well in 
different media. OCR was assessed in Seahorse analyzer. Four measurement of basal 
OCR were taken, allowing measuring basal OCR. Following the injection of oligomycin 
(1μM final) assessment of ATP- linked respiration and proton leak were taken. To assess 
maximal respiration, FCCP was injected at the 0.3μM final concentration. All the 
parameters were calculated by subtracting non-mitochondrial values for each sample. 
Data shown as a mean ±SD, n=6-8 observations, One way ANOVA with Tukey’s post hoc 
test where, *P<0.05, ***P<0.001 
 
 
Basal ECAR and ECAR after the injection of oligomycin were also assessed in 
reversal groups. There was no difference in basal glycolysis and after the 
induction of oligomycin in HG7/NG1 group when compared to NG and HG groups 
(Analysis of variance, P>0.05, Fig.6.24A). However when the basal levels and 
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response to oligomycin was assessed in HG8/NG4 group, Tukey's multiple 
comparison test showed a significant difference between basal ECAR in cells 
cultured in HG for 12 days and basal ECAR in HG8/NG4 group, (P<0.05). 
Glycolysis levels in HG8/NG 4 was significantly increased at basal and after the 
injection of oligomycin, when compared to HG group (P<0.01) and seem to 













Fig.6.24. Glycolytic profile of human primary mesangial cells cultured in reversed 
conditions. Human mesangial cells were grown in DMEM containing 5mM (NG), 25mM 
(HG)glucose and HG/NG conditions for 8 (A) and 12 days (B). Basal ECAR and ECAR after 
injection of oligomycin were assessed in Seahorse XF96e analyzer. Data shown as a 
mean ±SD, n=6 for NG, HG and n=8 observations for Hg7/NG1, HG8/NG4 respectively, 
One way ANOVA with Tukey’s post hoc test where, *P<0.05, ** P<0.01 
 
 
Mean basal ECAR versus OCR ratio didn’t change in cells grown under HG7/NG1 
(Fig. 6.25A). However prolonged period of normoglycaemia in HG8/NG4 group, 
ECAR HG8/NG4
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proved to have a beneficial effect of media reversal on OCR/ECAR ratio. After 
extended NG treatment there was observed a shift in cells bioenergetic profile 













Fig.6.25. The oxygen consumption rate (OCR) and glycolysis (ECAR) of human primary 
mesangial cells cultured in reversed conditions. The mean basal OCR vs. basal ECAR in 
cells grown in 25mM glucose (HG) for 7 days (A)and 8 days (B). Cells grown in HG have 
their media glucose levels reversed to NG for 1 day (A) and for 4 days (B). Arrow points a 
metabolic shift in energy in cells grown in HG and then when media was reversed to NG. 
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6.4.6 Bioenergetic profile of human transformed tubular cells cultured in 
high glucose 
Mesangial cells are central to the development of DN through their role in the 
development of glomerulosclerosis but tubular cells are the second type of the 
cells taking part in the development of diabetic nephropathy. During the process 
of the development of the disease, these cells undergo epithelial to 
mesenchymal transition. Therefore, the aim of this part of the study was to 
assess bioenergetic profile of human transformed tubular cells (HK-2) cells grown 
for 4 and 8 days in 5mM (NG), 25mM (HG) and in osmotic control (NGM, 20mM 
mannitol + 5mM glucose). Determination of oxygen (OCR) and proton (ECAR) 
concentration in real-time was measured by using XF analyzer (Seahorse 
bioscience), as described above. Mitochondrial inhibitors and uncoupler 
concentrations were set up in a series of optimization experiments (as shown 
above in section 6.4.1). HK-2 cells were grown under HG for 3 and 7 days in 
different media, day before the experiment cells were trypsinized, counted using 
Countless Cells counted and seeding in the density of 25 000cells/ well. 
Oligomycin, FCCP, rotenone and antimycin A were injected sequentially through 
ports in the XF Assay cartridges to final concentrations of 1μM, 0.3μM, 0.5μM 
and 0.5μM respectively. Basal respiration of HK-2 cells cultured in was measured 
at around 200-250 pmoles/min/μg/protein (Fig.6.26). 
• Bioenergetic profile of human transformed cell cultured in high glucose 
for 4 days 
Contrary to HMCs cells, in which bioenergetic profile was not affected by HG 
after 4 days of culture, in HK-2 cells, we observed a significant decrease in most 
of the assessed parameters (Figure 6.26 and Fig.6.30). Basal OCR was 
significantly lower in cells cultured in HG (101±22, N=14) when compared to cells 
grown in NG (130±18, N=17, P<0.001, Fig. 6.30A). ATP-linked respiration 
measured as a drop in OCR, following the injection of oligomycin was also 
significantly lower by approximately 25% in cells cultured in HG when compared 
to the controls (P<0.001 Fig.6.30B). Independent students t-test and one way 
ANOVA showed a significant decrease (more than 50%) of maximal respiration 
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and reserve capacity in HK-2 cells grown in HG for 4 days  when compared to NG 
and osmotic controls (P<0.001, Fig.6.30C-D). There was no difference in proton 
leak between the treatment group and controls (Fig.6.30F); conversely non-
mitochondrial respiration was significantly reduced in cells cultured in HG (29±9) 








Fig.6.26. Bioenergetic profile of human tubular cells cultured in high glucose for 4 
days. HK-2 cells were grown in DMEM containing 5mM (NG), 25mM (HG) glucose and 
osmotic control  for 4 days. Day before the assessment, cells were trypsinized, counted 
and seeded at density of25 000 cells/well in different media. Following media change, 
OCR was assessed in Seahorse XF 96e analyzer. Four measurement of basal respiration 
were taken, followed by an injection of oligomycin (1μM final). To assess maximal 
respiration, FCCP was injection at the 0.3μM working concentration. Reserve capacity, 
measured as a difference between maximal and basal respiration, is shown on the right. 
Data shown as a mean ±SD, n=14 for NG and n=17 observations for HG 
 
 
As shown in Fig. 6.27 and 6.31A basal ECAR was significantly increased by  in HK-
2 cells exposed to HG for 4 days when compared to cells cultured in NG (132±11 
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Fig.6.27. Glycolytic profile of human tubular cells cultured in high glucose for 4 days. 
HK-2 cells were grown in DMEM containing 5mM (NG), 25mM (HG) glucose and osmotic 
control for 4 days. ECAR (glycolysis) was assessed in Seahorse XF e 96 analyzer. Data 
shown as a mean ±SD, n=14 for NG and n=17 observations for HG 
 
 
• Bioenergetic profile of human transformed tubular cells cultured in high 
glucose for 8 days 
4 days of HG treatment caused dramatic changes in mitochondrial respiration 
parameters in HK-2 cells but there was still reserve capacity left, therefore we 
extended period of treatment to 8 days. As shown in figure 6.28 extended period 
of culture in 25mM glucose had more toxic effect on mitochondrial respiration 
when compared to HK-2 cells grown in different media for only for 4 days. HG 
significantly reduced basal OCR by approximately 60% (P<0.01, Fig.6.30A) and 
ATP-linked respiration by approximately 70% (P<0.001, Fig.6.30B). Similar to 4 
days treatment there was no significant difference in the proton leak between 
groups cultured for 8 days (P>0.05, Fig.6.60F) and non-mitochondrial respiration 
was significantly decreased in HG when compared to the control (P<0.05, 
Fig.6.30E). Interestingly HK-2 cells cultured in HG lost their ability to increase 
maximal respiration after the injection of FCCP when compared to NG (P<0.01, 
Fig.6.30D). 
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Fig.6.28. Bioenergetic profile of human tubular cells cultured in high glucose for 8 
days. HK-2 cells were grown in DMEM containing 5mM (NG), 25mM (HG) glucose and 
osmotic control for 4 days. Following media change, OCR was assessed in Seahorse 
analyzer. Four measurement of basal respiration were taken, followed by an injection of 
oligomycin (1μM final). To assess maximal respiration, FCCP was injection at the 0.3μM 
working concentration. Reserve capacity, measured as a difference between maximal 
and basal respiration, is shown on the right. Data shown as a mean ±SD, n=6 
observations. 
 
After 8 days of culture basal ECAR was significantly increased in the HG group 
when compared to control (P<0.05, Fig.6.29 and Fig.6.31B respectively). 
Moreover in cells grown in NG, there was almost 2 fold increase in basal ECAR 









Fig.6.29. Glycolytic profile of human tubular cells cultured in high glucose for 8 days. 
HMCs were grown in DMEM containing 5mM (NG), 25mM (HG) glucose and osmotic 
control for 4 days. ECAR (glycolysis) was assessed in Seahorse XF e 96 analyzer. Data 
shown as a mean ±SD, n=6 observations 
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Fig.6.30. High glucose affects metabolic profile of human transformed tubular cells. 
HK-2 cells were grown in DMEM containing 5mM (NG), 25mM (HG) glucose for 4 and 8 
days. Day before the assessment, cells were trypsinized, counted and seeded at density 
of 25 000 cells/well in different media. OCR was assessed in Seahorse analyzer. Four 
measurement of basal OCR were taken, allowing measuring basal OCR (A). Following the 
injection of oligomycin (1μM final) assessment of ATP- linked respiration (B) and proton 
leak (F) were taken. To assess maximal respiration (C), FCCP was injected at the 0.3μM 
final concentration. Reserve capacity, measured as a difference between maximal and 
basal respiration, is shown on the figure D. All the parameters were calculated by 
subtracting non-mitochondrial values for each sample (E). Data shown as a mean ±SD 
n=14 replicates from 2 independent experiments for 4 days and n=14-17 replicates from 
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Fig.6.31. Glycolytic profile of human transformed tubular cells cultured in different 
conditions for 4 and 8 days. Cells were grown in 5mM (NG), 25mM (HG) for 4 days (A), 
and 8 days (B). Day before the assessment, cells were trypsinized, counted and seeded 
at density of 35 000 cells/well in different media. Basal ECAR and ECAR after injection of 
oligomycin (1μM final) were assessed using XF96 Seahorse analyzer. Data shown as a 
mean ±SD, n=14 and n=17 for NG and HG respectively in 4 days, n=6 for both conditions 
in 8 days, Studnet’s t-test where,  *p<0.05, 
 
 
To assess the ratio between oxidative phosphorylation and glycolysis, ECAR 
versus OCR was plotted as shown on Fig.6.32. There was a slight shift in 
metabolic profile in HK-2 cells cultured in HG towards more glycolytic (Fig.6.32A) 
and less metabolic profile (Fig.6.32B), after 4 and 8 days of the exposure to HG, 
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Fig.6.32. The oxygen consumption rate (OCR) and glycolysis (ECAR) of human tubular 
cells. The mean basal OCR vs. basal ECAR in cells grown in 25mM glucose (HG) for 4 days 
(A)and 8 days (B). Arrow points a metabolic shift in energy in cells grown in HG and then 
when media was reversed to NG. Data shown as a mean ±SEM, n=6-17 observations 
 
 
These data show, that HK-2 cells are more susceptible to HG with decreased 
mitochondrial respiration basal, maximal and ATP-linked respirations following 4 
day of culture. Moreover, 8 days of exposure to hyperglycaemia caused a loss in 
the reserve capacity. Contrary to the HMCs cells, basal ECAr was increased in HK-
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6.4.7 The effect of hydrogen peroxide and acute glucose load on the 
cellular bioenergetics of human tubular cells 
It was shown in the previous paragraph that chronic exposure of HK-2 cells to 
high glucose significantly affects cells’ mitochondrial respiratory function. In the 
next series of experiments, HK-2 cells were grown for 8 days in 5mM glucose and 
treated with two different concentrations of H2O2. The aim of this experiment 
was to assess, if acute oxidative stress has the same effect on mitochondrial 
function as chronic exposure to HG. Day before the assessment, tubular cells 
were seeded in XF assay plates as described before (25 000 cells/well), and on 
the day of the experiment were treated with different concentrations either 
1μM or 5μM H2O2 for 15min in complete growth media with 5mM glucose. 
Higher than 5μM concentrations of H2O2 and longer than 15 minutes treatment 
proved to be toxic to the cells and caused cell detachment during the media 
change. Mitochondrial function was then assessed as described previously. As 
shown in Fig.6.33, basal OCR was significantly decreased (P<0.01) in response to 
1μM H2O2 in HK-2 cells when compared to the control (97±47vs. 170±19 
pmoles/min respectively, Fig.6.33A). Interestingly, both concentration of H2O2 
had the same inhibiting effect on ATP synthesis in HK-2 cells as 8 day exposure to 
HG (Fig.6.33B) but only 1μM  H2O2 treatment was statistically significant, 
probably due to the higher number of the repeats (P<0.01). H2O2 treatment 
caused also a significant decrease in the maximal respiration (P<0.05, Fig.6.33C) 
and a loss in the reserve capacity (P>0.05, Fig.6.33D). Non-mitochondrial OCR 
was also significantly down regulated in the H2O2 treatment groups (P<0.05, 
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A)                                                                            B) 














Fig.6.33. Acute oxidative stress affects bioenergetic profile of human transformed 
tubular cells. Human transformed tubular cells (HK-2) were grown in 5mM (NG)  or 
25mM (HG) glucose for 8 days. Day before the assessment, cells were trypsinized, 
counted and seeded at density of 25 000 cells/well in different media. Some of the cells 
grown under the NG were treated with 1μM or 5μM H2O2 for 15min before the OCR was 
assessed in Seahorse analyzer. Four measurement of basal OCR were taken, allowing 
measuring basal OCR (A). Following the injection of oligomycin (1μM final) assessment 
of ATP- linked respiration (B) and proton leak (F) were taken. To assess maximal 
respiration (C), FCCP was injected at the 0.3μM final concentration. Reserve capacity, 
measured as a difference between maximal and basal respiration, is shown on the figure 
D. All the parameters were calculated by subtracting non-mitochondrial values for each 
sample (E). Proton leak is presented on figure F. Data shown as a mean ±SD, n=6 for NG 
and HG respectively and n=3-4 for H2O2 treatment, One way ANOVA wit Tukey’s post 
hoc where, *P<0.05, **P<0.01, 
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Basal ECAR in cells treated with H2O2 was slightly increased, and close to reach 
the significance, when compared to NG control (P=0.052), and statistically 
significant when compared to the basal in HG group (Fig.6.34). Increase in the 
basal glycolysis was not dose dependent. However, 5μM H2O2 caused a 
significant up-regulation of glycolytic rate after the injection of oligomycin when 
compared to the basal level (P<0.001, Fig.6.34).  
 
Fig.6.34. Glycolytic profile of human transformed tubular cells cultured in different 
conditions. Human mesangial cells were grown in 5mM (NG), 25mM (HG) for 8 days. On 
the day of the experiment of some the cells grown under the NG were treated with 1μM 
or 5μM H2O2 for 15min before the basal ECAR was assessed in Seahorse analyzer.  Data 




In summary, treatment with H2O2 had the same down-regulatory effect on basal 
and ATP-linked respiration in HK-2 cells as culture in HG. Maximal respiration and 
reserve capacity were also decreased. There was a trend towards the increase in 
proton leak, and an increase in maximal glycolytic capacity, which may suggest 
damage in the ETC caused by the exposure to H2O2.  
6.4.8 Are glucose-induced changes in bioenergetic profile in tubular cells 
reversible? 
It was shown in the previous paragraph that exposure of tubular cells to high 
glucose for 4 and 8 days significantly affects cells’ mitochondrial respiratory 
function. To assess if these changes were permanent or possible reversible, a 
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‘rescue’ study was design, to test mitochondrial respiration in cells which were 
cultured in reversed media (25mM glucose media was substituted with 
5mMglucose one, HG/NG). Two time points were used, cells were grown for 2 
days ion HG and the media was changed to low glucose media for 2 days 
(HG2/NG2) and in the second time point, cells were grown under HG for 4 days 
and had the media reversed to normal glucose for 4 days (HG4/NG4). In control 
groups cells were cultured in 5mM glucose for 4 and 8 days respectively. Day 
before the assessment, cells were seeded in XF assay plates as described before,  
washed with XF assay media, and allowed to equilibrate at 37°C for 1h in a non-
CO2 incubator before assessment.  
As described previously cell cultured in HG for 4 days had a drastically reduced all 
of their bioenergetic parameters and as  illustrated on Fig.6.35A, in HG2/NG2  
group cell show the same profile as cells cultured in NG. However 2 day culture 
of the HK-2 cells in HG was not performed therefore it is difficult to assess how 
quickly these changes occur. 
Prolonged culture in NG after HG treatment (HG4/NG4) did not improve 
mitochondrial respiratory function. As shown on Fig.6.35B, basal and ATP-link 
respiration was still reduced when compared to NG control (P<0.001, P<0.01 
respectively). Maximal respiration and reserve capacity didn’t get back to normal 
levels and was still highly significantly lower when compared to NG group 
(P<0.001). Interestingly proton leak in HG4/NG4 group was significantly lower 
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Fig.6.35. Reversing the culture conditions for 4 days had no effect on metabolic profile 
of human transformed tubular cells. Cells were grown in DMEM containing 5mM (NG), 
25mM (HG)glucose for 4 days (A) or in NG and HG for 8 days (B). During the 4 day 
culture in HG, medium was changed to low glucose after 2 days (A). During 8 day 
culture, after4 days HG medium was replaced by 5mM one (B). Day before the 
assessment, cells were seeded at density of 25 000 cells/well in different media. OCR 
was assessed in Seahorse analyzer. Four measurement of basal OCR were taken, 
allowing measuring basal OCR. Following the injection of oligomycin (1μM final) 
assessment of ATP- linked respiration and proton leak were taken. To assess maximal 
respiration, FCCP was injected at the 0.3μM final concentration. All the parameters were 
calculated by subtracting non-mitochondrial values for each sample. Data shown as a 
mean ±SD, n=5-7 observations, One way ANOVA with Tukey’s post hoc test where, 




















































































202 | P a g e  
 
Chapter 6: Hyperglycaemia affects bioenergetic profile of human renal cells 
Basal ECAR and ECAR after the injection of oligomycin were also assessed in 
reversal groups. There was no difference in basal ECAR and ECAR after the 
injection of oligomycin in HG2/NG2 and HG4/NG4 groups when compared to NG 
and HG groups (Analysis of variance, P>0.05, Fig.6.33A and Fig.6.33B). Injection 

















Fig.6.36. Glycolytic profile of human transformed tubular cells cultured in different 
conditions. HK-2 cells were grown in 5mM (NG), 25mM (HG) and HG/NG conditions for 
4 (A) and 8days (B). Basal ECAR and ECAR after injection of oligomycin were assessed in 
Seahorse XF96e analyzer.  Data shown as a mean ±SD, n=5-10 for NG, n=5-6 for HG and 
n=8-15 observations for HG/NG, Student’s t-test where, *P<0.05, ** P<0.01 
 
 
Mean basal ECAR versus OCR ratio in cells from HG2/NG2 showed slightly 
improved profile when compared to cells cultured in HG for 4 days (Fig. 6.37A). 
However in HG4/NG4 group, there was no beneficial effect of media reversal on 
ECAR HG2/NG2
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OCR/ECAR ratio. Cell in HG4/NG 4 had the same metabolic profile as cells grown 




















Fig.6.37. The oxygen consumption rate (OCR) and glycolysis (ECAR) of human tubular 
cells. The mean basal OCR vs. basal ECAR in cells in DMEM containing 5mM (NG), 25mM 
(HG) glucose and 25/5 mM glucose (HG/NG) for 4 days (A) and 8 days (B). Arrow points a 
metabolic shift in energy in cells grown in HG and then when media was reversed to NG. 
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6.5 Discussion 
Since kidney cells are exposed to both, ROS and hyperglycaemia in the course of 
diabetic kidney disease, I hypothesized that their bioenergetic profile would be 
affected by the exposure to the high glucose and H2O2. By using two different 
kidney cell types, I have shown a damaging effect of hyperglycaemia on HMCs 
and HK-2 cells, and the effect of oxidative stress on HK-2 cells mitochondrial 
respiratory function. To my knowledge, this is the first study assessing 
bioenergetic profile of primary human mesangial cells (HMCs) and immortalized 
tubular cells (HK-2) grown in various concentrations of glucose.  
Bioenergetic profile of mesangial and tubular cells was negatively affected by the 
exposure to high glucose. Tubular cells proved to be more susceptible to 
hyperglycaemia, while mesangial cells showed significant down-regulation of 
their respiratory function after chronic exposure to high glucose. HMCs data was 
confirmed by independent experiments using two different Seahorse analyzers, 
XFe96 (presented in this chapter) and XFe24 (data presented in the Appendix III).  
Prolonged (8 and 12 days) exposure to the hyperglycaemia had significant down-
regulatory effect on mesangial cells’ maximal respiration and spare capacity. 
Moreover after chronic, 12 day exposure to high glucose, basal and ATP-
respiration was also affected. There was no difference in the proton leak at any 
of the investigated time-points, but there was observed a tendency for the 
increase levels of the proton leak in cells incubated in high glucose. Interestingly, 
chronic exposure to hyperglycaemia caused also a down-regulation of the ECAR 
at the basal rate, and in response to the oligomycin injection in HMCs, which 
might suggest a glycolytic block, possibly through GAPDH inhibition or by 
increased production of ROS (Brownlee, 2005, Colussi et al., 2000). Second type 
of the cells used in experiments, tubular cells proved to be highly sensitive to the 
high glucose treatment with decreased basal, ATP-linked and maximal 
respiration observed as early as after 4 days of the treatment. More significant 
effect was found after 8 days of the culture in high glucose, when mitochondria 
lost completely their reserve capacity. No difference in the proton leak was 
observed in any of the investigated time point, but tubular cells had also 
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decreased non-mitochondrial respiration when exposed to high glucose. This 
result may suggest potential antioxidant defence activation, which was 
previously observed in human endothelial cells cultured in 20mM glucose 
(Fiumicino et al., 2000).  
To my knowledge this the first report of human kidney cells’ mitochondrial 
dysfunction, assessed by the measurement of cellular bioenergetics in response 
to the culture in high glucose. The reports in the literature are either in 
accordance or contrary to our results, but none of the studies was performed in 
the same experimental design. Chacko et al., (2010) reported down-regulation of 
the mitochondrial function (including reduced ATP-linked respiration and reserve 
capacity) in primary mouse mesangial cells cultured for 14 days in high glucose 
(Chacko et al., 2010a). Trudeau at al., (2010) assessed mitochondrial 
bioenergetics in rat retinal endothelial cells cultured for 3 and 6 days in 30mM 
glucose. In their experimental design they observed a reduction in the basal and 
maximal respiration, but after prolonged, 6 day exposure. They also reported a 
compensatory increase in ECAR after 6 days of culture which is in accordance to 
the result observed in tubular cells and contrary to the mesangial cells reported 
in this study (Trudeau et al., 2010). Faulty bioenergetic profile of cultured 
neurons derived from STZ- induced rats with decreased maximal respiration and 
decreased spare capacity was also reported (Chowdhury et al., 2013). 
 On the other hand, results in the current study are contrary to the findings 
published by Stieger at al., (2011) who demonstrated an increase in the basal 
and maximal respiration of immortalized mouse podocytes cultured in high 
glucose for 10 passages. However, the discrepancy in the results might be caused 
by the lack of the normalization of the Seahorse data, as the authors suggested 
there were differences in the plated cell numbers between experimental groups 
and also reported in parallel a decrease in the complex I and III activities, which is 
contrary to oxygen consumption rate data (Stieger et al., 2012).  
When comparing results from the human studies, increased mitochondrial basal, 
and maximal respiration rate were found in peripheral blood mononuclear cells 
(PBMCs) from patients with T2D, when compared to the healthy controls 
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(Hartman et al., 2014). This report might suggest an adaptive response in 
mitochondrial respiration in order to cope with nutrient overload.  
Not every patient suffering with diabetes will develop diabetic complications and 
increase in maximal and basal respiration which is still within threshold limit for 
mitochondria without diminishing spare respiratory capacity may be still 
tolerable. In contrary, Fink at al., (2012) did not observe any changes in the 
bovine aortic endothelial cells and human platelets cultured in high glucose for 
18 hours and also after acute injection of the high glucose (Fink et al., 2012). 
Mitochondrial respiration has also been reported to be reduced in the skeletal 
muscle of T2DM patients (Kelley et al., 2002, Mogensen et al., 2007) and not 
changed in myocytes from non-diabetic, obese subjects with family history of 
T2D (Aguer et al., 2013). 
I also observed a metabolic shift in cellular bioenergetic of human mesangial cells 
after prolonged exposure to hyperglycaemia, suggesting that cells become less 
metabolically active in hyperglycaemia. The shift in the metabolism observed in 
mesangial cells was not so visible in tubular cells. On the other hand tubular cells 
had also basal glycolytic rate increased when cultured in high glucose, which in 
correlation with their falling mitochondria function might suggest and adaptive 
response to the condition when cells cannot rely on their OXPHOS energy. These 
results were surprising as tubular cells are known to have low glycolytic capacity 
(Wirthensohn and Guder, 1986), and it only highlights the differences in the 
response to the stress conditions between different cell types, even within one 
organ. 
I have also tested an effect of the acute stress conditions on cells respiration, 
with cells treated with two concentrations of H202 prior the assessment, and also 
by using acute injection of 20mM glucose during the assessment. Although these 
experiments were performed only once and require repeating, data which were 
obtained are very interesting. Treatment with H202 proved to be problematic as 
both, mesangial and tubular cells demonstrated high sensitivity to even short 
exposure to the H202, which caused cell detachment. Finally very low 
concentration was chosen, and exposure time was shorten to 5 minutes. Cells 
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were allow to recover after the treatment for about 1 h. Short exposure of HMCs 
to the oxidative stress with pre-treatment of the H2O2 had no effect on any of the 
measured mitochondrial respiration parameters bud it did significantly up-
regulated the glycolysis. However data from the tubular cells treated with H2O2, 
suggest that tubular cells are very susceptible to any form of the oxidative stress. 
Short exposure to H2O2 had the same inhibitory effect on tubular cells’ 
mitochondrial respiration as culture in high glucose for 8 days, decreasing basal 
and ATP-linked respiration. However, there was no difference in the reserve 
capacity, but glycolysis rate was significantly up-regulated.  
These data may suggest a potential damage of H2O2 to ETC and compensatory 
response in the induction of glycolysis. Contrary to my results, Sansbury at al., 
(2011), reported an increase in the oxygen consumption in mouse and rat 
cardiomyocytes, but also a decrease in respiration in smooth muscle cells 
following the cells' exposure to a lipid peroxidation product (Sansbury et al., 
2011). However, Dranka et al., (2010) observed a decreased mitochondrial 
reserve capacity in the adherent bovine aortic endothelial cells in response to NO 
or another stressor, 2,3-dimethoxy-1,4-napthoquinone (DMNQ) treatment. 
When compounds were used separately they had no impact on basal 
mitochondrial respiration and reversible effect on mitochondrial maximal 
respiration however combination of both caused a permanent damage to 
mitochondrial which led to cell death (Dranka et al., 2010). In another study the 
same group observed in primary rat myocytes a dose- and time-dependent 
increase in OCR and in ECAR in response to the reactive lipid species, but a 
reduction in the OCR and ECAR after using the same prooxidant agents in mouse 
mesangial cells (Dranka et al., 2011). 
These reports and results from current study highlight the differences in cells’ 
metabolism and may explain different responses to the stressors.  
Human primary mesangial cells proved to have a substantial bioenergetic reserve 
when compared to immortalized tubular cells. In the glucose-challenge 
experiment, where control and pre-treated cells mesangial cells were challenged 
with the injection of the 20mM glucose, a different response between the 
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groups to acute high glucose injection was observed. Acute injection of 20mM 
glucose to cells, which were cultured in normal glucose media, caused a 
‘metabolic switch’ from OXPHOS respiration to the glycolysis. This was not seen 
when cells were pre-cultured in 25mM glucose and then injected with 20mM 
glucose during the assessment. Cells cultured in 5mM glucose showed a 
metabolic flexibility when injected with high glucose, while cells grown in the 
high glucose after the injection show no difference in the basal or ATP-linked 
respiration. These results suggest that cells with compromised bioenergetic 
profile are vulnerable to any secondary stressor. However, as shown on Fig.6.18, 
control traces show some difficluties with reaching steady state, which could 
possibly affect the results, especially ATP-linked and maximal respiration, if cells 
were ‘stressed’ prior to the glucose injection. 
Data from the current study may suggest that in the conditions of chronic 
hyperglycaemia, cells which may have defective mitochondria cannot properly 
response to the changes in the glucose levels and this could lead to the possible 
disruption in glucose metabolism. The energetic state of the cells is important in 
cells’ respiration and functions in healthy conditions and may be detrimental in 
hyperglycaemia. It has been shown in the Beta-cells, that proper activation of the 
mitochondrial respiration and later B-cells’ insulin secretion due to the stimuli 
requires metabolically healthy mitochondria (Ortsater et al., 2002).  
In the current study also the effect of a ‘rescue experiment’ on cells’ 
bioenergetics was investigated. Cells were cultured in 25mM glucose and have 
their growth media changed to the one containing 5mM glucose. Results 
obtained from this part of the study in mesangial cells, suggested that toxic 
effect of hyperglycaemia on OCR and ECAR can be reverted by correcting the 
glucose levels; however the outcome of was dependent on the time of exposure 
of the cells to high glucose prior to media change.  
In similar manner to the mesangial cells, after reversing the conditions in the 
tubular cells, there was observe a loss in the recovery which seem to correlate to 
the toxic effect of glucose after prolonged time of hyperglycaemia. A similar type 
of experiment was also performed in a rat pancreatic insulinoma cells that had 
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high glucose media reversed to the low one for 24 hours, where cells recovered 
they biological bioenergetic function (Spragg et al., 1985). Ruggiero at al., (2011) 
by using mitochondria isolated from diabetic mice observed an increased levels 
of mitochondrial superoxide dismutase (MnSOD) and increased mitochondrial 
ATP-linked respiration in animals kept for 12-weeks, which was not present at 
later stages, suggesting that there is an adaptive phase to the nutrient overload, 
but over time, mitochondria became exhausted and their function start to fail 
(Ruggiero et al., 2011). 
Result shown in current study clearly suggest that high glucose had a toxic effect 
on kidney cell function however the mechanism by which it is caused is still not 
clear. Reserve capacity which was affected in the current study in cells exposed 
to high glucose describes bioenergetic mitochondrial reserve, and depends on 
many factors, like substrate supply, energy demand and integrity of ETC. Possible 
dysfunction in mitochondrial metabolism can be caused by the direct effect of 
glucose as described by others (Bickler et al., 1985, Spragg et al., 1985). But it 
also could be caused by the disruption the synthesis of mitochondrial complexes 
assembly subunit, caused by the mutations in MtDNA. I have shown in the 
previous chapters the increase in the rate of the damage in the MtDNA in 
mesangial cells cultured in high glucose as early as after 4 days, which precedes 
decline in the mitochondrial respiration. 
In conclusion, I have shown that hyperglycaemia alters metabolic profile of both, 
mesangial and tubular cells and significantly affects their reserve capacity. Also 
mesangial cells proved to have a substantial bioenergetic reserve when 
compared to the tubular cells. Proper understanding of bioenergetic responses 
of different cell types to oxidative stress and nutrient overall, present in diabetes 
and its complications may give an insight into the development of novel 
therapies. 
This study could be criticized for not using a specific kit in order to properly 
assess glycolytic function; however I am fully aware of this limitation. Also 
experiments on tubular cells should be repeated as they were performed only 
once. Fall in the reserve capacity which was observed in the tubular cells might 
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be also caused by toxic effect of oligomycin prior to the FCCP injection; therefore 
another set of experiments with FCCP only should be performed. ‘Rescue’ 
experiments with media change, need a further investigation and should be 
treated as a prelimary results. Future experiments which would involve 
mitochondrial specific antioxidant require optimization, there was an attempt to 
use MitoQ in this study however this compound proved to be very toxic to the 
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7.1 General discussion 
The expansion of extracellular matrix through induction of growth factors, 
increased ROS and chronic inflammation have all been reported in DN (Wada and 
Makino, 2013, Brownlee, 2001, Giacco and Brownlee, 2010). Is it possible, that 
dysfunction of this cell organelle, mitochondria is responsible for the activation 
of of these mechanisms? Between 30-40% of patients with diabetes will 
eventually develop DN (Singh et al., 2008, Wada and Makino, 2013, Rabol, 2011) 
and at present, 383 million people in the world are diagnosed with diabetes 
mellitus (WHO, 2013); it also accounts for more than 100 million people with 
chronic kidney disease.   
Hyperglycaemia has been linked to increased oxidative stress in patients with 
diabetes  and diabetic complications in peripheral blood cells (Lim et al., 2006, 
Madsen-Bouterse and Kowluru, 2008, Weng et al., 2009b), in-vitro cultured  cells 
(Ha and Lee, 2003, Yao and Brownlee, 2010) and animal models of diabetes 
(Ruggiero et al., 2011, Chowdhury et al., 2010). There is some indirect  evidence 
from human, animal and in-vitro studies, suggesting that  mitochondria may be 
involved in  the development of diabetic complications, including DN (Sharma et 
al., 2013, Higgins and Coughlan, 2014, Lee et al., 2014, Lee et al., 2003). 
Moreover, in several animal and human studies, it has been demonstrated that 
the increase in both ROS production and inflammation contributes to DN 
development (Wada and Makino, 2013, Navarro-Gonzalez and Mora-Fernandez, 
2008, Catherwood et al., 2002, Ahad et al., 2014).  
Based on the preliminary data from our group, the hypothesis was formed that 
altered MtDNA content may lead to mitochondrial dysfunction, which would 
contribute to the development of DN. 
The studies presented in this thesis have explored the effect of hyperglycaemia 
on MtDNA biogenesis and mitochondrial function using in-vitro and in-vivo 
models of diabetes as an early event, occurring during the development of DN. It 
has been shown that MtDNA content is elevated in renal mesangial cells cultured 
in high glucose and also in peripheral blood from diabetic mice, but decreased in 
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the diabetic mouse kidneys. MtDNA quality, mitochondrial morphology and 
function were also altered in mesangial cells in response to chronic 
hyperglycaemia, while no change were observed in mitochondrial transcription 
and translation.  The overall findings are summarised in Fig. 7.1. 
Fig. 7.1. Model arising from findings 
from this thesis. Hyperglycaemia 
leads to increased MtDNA content, 
altered mitochondrial morphology, 
increased intracellular reactive 
oxygen species (ROS) MtDNA 
damage and apoptosis in human 
mesangial cells. A decrease or no 
change in the mRNA expression of 
mitochondrial electron transport 
chain subunits was also observed. 
Molecular and physiological 
alterations lead to inflammation in 
mesangial cells. These changes 
precede the reduced respiration 
(OCR) and glycolysis (ECAR). There 
was also an increase in MtDNA 
content in the peripheral blood and 
decrease/no change in MtDNA copy 
number in diabetic mouse kidneys, 
which may be affected by processes 
observed in the in-vitro study. ↑: 
increase; ↓: decrease; ─: no change 
 
Mitochondrial biogenesis 
In the current study, it was reported for the first time, increased MtDNA content 
in human mesangial cells exposed to hyperglycaemia, with the increase in 
MtDNA copy number observed as early as 24h following incubation in high 
glucose. To my knowledge, this is also the first report of the measurement of 
MtDNA content in circulating cells in mouse blood. The MtDNA copy number was 
significantly up-regulated in the circulation but either no difference or a 
reduction in mouse kidneys was observed. The decrease of MtDNA in the mouse 
kidneys may be caused by the increased mitophagy or apoptosis (both induced in 
diabetes) (Lim et al., 2014b, Osorio, 2014, Liu et al., 2014)) or by release of 
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mitochondria and MtDNA into the circulation, caused by kidney cell apoptosis or 
necrosis (Zhang et al., 2010a).  
An increase in MtDNA could be beneficial at the early stages and an adaptive 
response to the nutrient overload or it could be the compensatory effect to the 
increased oxidative stress. In patients with DN, it was  shown that increased 
MtDNA copy number in peripheral blood was associated with lower prevalence 
of microalbuminuria (Lee et al., 2009). A study by Ying Sun et al., (2014) 
reported, that treatment with rotenone (complex I blocker) in mouse model of 
kidney interstitial fibrosis, improved kidney function and morphology, decreased 
inflammatory markers and increased MtDNA levels. Data from this study suggest 
that once mitochondria dysfunction occurs, it activates many pathways and 
keeps contributing to ROS production and pathology of the disease (Sun et al., 
2014).  
Oxidative stress and its consequences 
Tissue oxidative stress has been proposed to be a major contributor in the 
development of DN (Brownlee, 2005, Forbes et al., 2008, Coughlan et al., 2009). 
It has been demonstrated in chapter 5 of this thesis, that increased MtDNA 
content in mesangial cells correlate with increase ROS and apoptosis. Moreover, 
when MtDNA integrity was measured, the ratio of mutated MtDNA in cells 
incubated in high glucose was significantly up-regulated. This result explains why 
there was no difference in mitochondrial protein levels and also mitochondrial 
mRNAs were either not changed or down-regulated. These data taken together, 
suggest that although MtDNA was increased, it was not functional and could not 
be transcribed and translated into functional OXPHOS subunits.  
High glucose has also been shown to cause damage in nDNA and dys-regulation 
of the expression of  nDNA repair system, called base excision repair (BER) genes, 
which have been shown to be up-regulated in the early stages of 
hyperglycaemia, but decreased after the chronic exposure (Pang et al., 2012). 
The BER system has been characterised in MtDNA (Bohr, 2002, Croteau and 
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Bohr, 1997), but has not been extensively investigated and there are no reports 
about BER activation in cells exposed to hyperglycaemia. 
Mutated MtDNA background can have an effect on susceptibility to the 
development of diabetes complications. Lazar and colleagues have shown that 
diabetic rodents with mutated MtDNA were more likely to develop myocardial 
dysfunction. Moreover, rats with mutated MtDNA had lower ATP production, 
while this did not exhibit any other physiological changes in their myocardium 
(Sethumadhavan et al., 2012). 
Mitochondrial function 
As shown in chapter 6, mitochondrial function was severely affected by 
hyperglycaemia in both mesangial and tubular cells. This is the first report of the 
measurement of mitochondrial bioenergetics in human mesangial and tubular 
cells,  and our  data  are in accordance with the  reports in different cell types 
and models of diabetes including rat retinal cells (Trudeau et al., 2010), 
mitochondria from rat kidneys (Ruggiero et al., 2011, Chacko et al., 2010b) and 
muscle mitochondria from patients with T2D (Rabol, 2011) . 
 OCR is proportional to the rate of transferred electrons and influence of the 
redox status of the ETC. In conditions of lower mitochondria respiration there is 
an increased generation of ROS mostly at complex I and III, caused by a reduction 
of ETC (Wani et al., 2007, Starkov and Fiskum, 2003). Lower in- vivo 
mitochondrial “function” can be the result of several factors, including a reduced 
mitochondrial density, but also, lower mitochondrial respiratory capacity per 
mitochondrion. In healthy conditions, the amount of MtDNA is proportionally 
correlated with mitochondrial function as well as the number of mitochondria 
and is flexibly regulated due to the energy metabolism demand and redox state 
of the tissues (Williams, 1986, Hock and Kralli, 2009). However, this does not 
seem to be the case in disease state. As early as 1979, Simpson and Hecker 
(1979), proposed that any disturbances in metabolic substrates in acute acidosis 
(which is associated with DN), would initially lead to flexible changes in 
mitochondria adapting to new conditions, but eventually would cause a 
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permanent changes in a substrate shift from the cytoplasm into mitochondria 
(Simpson and Hecker, 1979). Kidney cells require large amounts of energy in the 
form of ATP, which is used for active transport of metabolites (Brown and 
Breton, 1996, Hall et al., 2008). 
However, we observed a significant increase in the ratio of mutated MtDNA 
fragments in mesangial cells, exposed to the high glucose. Energy  production in 
the kidneys, which contain many mitochondria, is largely through respiration, 
and Warburg  demonstrated that the total energy production in quiescent kidney 
cells was surprisingly similar to that produced in proliferating cancer cells, which 
indicated how much energy these cells require for proper function (Rocco et al., 
1992). The results from my study, clearly suggests that high glucose has a toxic 
effect on kidney cell function, however the mechanism by which it is caused is 
still not clear.  
It could possibly be caused by the direct effect of glucose, as described by 
Gohring et al., using rat pancreatic insulinoma, cultured for 48h in  either high 
glucose or high pyruvate, had different responses to the treatment. Cells 
cultured in high glucose had their bioenergetic profile affected, while there was 
no difference observed in the mitochondrial respiration when cells were grown 
in the pyruvate. This suggests a specific toxic effect of glucose on other 
metabolic pathways within the cells (Gohring et al., 2014).  
Glucose is known for causing specific protein modifications (oxidized 
glycosylations), which can have a detrimental effect on mitochondrial function 
and life cycle, through modification of mitochondria-localised proteins, involved 
in the respiratory chain and the TCA cycle (Tan et al., 2014). Gu at al., proposed 
that one of the O-linked-β-N-acetyl glucosamine (O-GlcNAcylation) modied 
glucose proteins, O-GlCNAc, can directly modify mitochondrial protein 
phosphorylation, contributing to mitochondrial dysfunction and insulin 
resistance (Gu et al., 2011). Increased mitochondrial O-GlcNAcylation in cardiac 
myocytes, incubated in high glucose also correlated with decreased activity of 
mitochondrial complexes (Hu et al., 2009). 
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However, another possible explanation is the activation of the pathways caused 
by the nutrient overload, when mitochondria might, through an adaptive phase, 
increase their respiration and contribute to the increased ROS production. 
Anderson at al., reported increased mitochondrial H2O2 production in human and 
rodent muscles fed with high fat diets, which correlated with a shift in cellular 
redox balance, without any changes in mitochondrial respiration. The oxidation 
state of the cells was balanced following treatment of mitochondrial specific 
antioxidants (Anderson et al., 2009).  
The ‘Crabtree effect’ may also have an inhibitory effect on mitochondrial 
respiration, when glycolytic enzymes compete with mitochondria for cytoplasmic 
ADP. Fructose 1,6-biphospate (F16bP) under physiological conditions, induces a 
decrease in mitochondrial respiration, though blockage of complexes III and IV 
(Diaz-Ruiz et al., 2008). However, in the current study, as observed by a 
metabolic shift, cells cultured in the high glucose, also had their glycolysis 
decreased, which suggests a glycolytic block occurring during prolonged culture 
in hyperglycaemia, possibly due to the direct effect of ROS (Colussi et al., 2000). 
Inflammation 
Damaged mitochondria undergo fission and are degraded via mitophagy (Twig 
and Shirihai, 2011, Ashrafi and Schwarz, 2013), but under oxidative stress, 
damaged mitochondria and MtDNA can accumulate in the cell (Scherz-Shouval 
and Elazar, 2007). Accumulation of damaged MtDNA may cause a chronic innate 
inflammatory response in the cell, through activation of TLR9, the receptor for 
microbial unmethylated CPG-DNA (Zhang et al., 2010a, Zhang et al., 2010b). In 
the current study, mRNA expression of NF-κB and MYD88 a TLR-9 signalling 
molecules were significantly up-regulated in mesangial cells, incubated in high 
glucose. This, with increased apoptosis in the cells, might suggest a potential 
inflammatory action of MtDNA. Not only MtDNA alone, but also whole 
mitochondria and mitochondrial proteins called mitochondrial Danger 
Associated Molecular Patterns (DAMPs) have the ability to start an inflammatory 
response. A study by Maeda and Fadell, has reported that mitochondria, which 
are released from cells, undergo TNF-α-induced necroptosis that eventually 
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contributes to necrosis. Data from this study suggested that mitochondria 
released into circulation can still respire and by the constant production of ATP 
can trigger inflammation (Maeda and Fadeel, 2014).  Monocytes isolated from 
patients with myocardial infarction exhibit high levels of circulating plasma 
MtDNA, which correlates with increased susceptibility to infections (Fernandez-
Ruiz et al., 2014).  
Metabolic memory 
The DCCT and EDIC studies have shown that intensive glycaemic control prevents 
the development and progression of diabetic complications in patients with 
diabetes (DCCT, 1993, de Boer and Group, 2014). Based on the results from 
these clinical trials a 'metabolic memory' phenomenon has been proposed, 
which describes the beneficial effects of immediate intensive treatment of 
hyperglycaemia (Ceriello, 2012, Aschner and Ruiz, 2012). 
Reversal and glucose oscillation experiments in the current study have shown, 
that the glucose concentration and exposure time to hyperglycaemia affects 
MtDNA content and that this increase cannot be reverted after 4 days of 
treatment. These results may be caused by the hyperglycaemia-induced 
oxidative damage, Santos et al., reported that by extending the time of the 
exposure to oxidative stress, permanent damage in the MtDNA genome 
occurred, which correlated with loss of mitochondrial function in human 
fibroblasts (Santos et al., 2003). Glucose fluctuations have been also reported 
having an adverse effect on endothelial cells in the vascular system in diabetes 
(Azuma et al., 2006, Brownlee and Hirsch, 2006) and caused increased  apoptosis 
in rat pancreatic Beta-cells (Kim et al., 2010). Rabol at el. (2011), used muscle 
mitochondria from T2D patients and did not observe a beneficial effect of short-
term correction of glucose levels in mitochondrial OXPHOS activity (Rabol, 2011). 
A different report in a rodent model of diabetic retinopathy, has shown that 
normalizing  glucose levels following 6 months exposure to hyperglycaemia, 
failed to reverse oxidative damage to MtDNA and mitochondrial function 
(Madsen-Bouterse et al., 2010). These studies only highlight the importance of 
the metabolic memory phenomenon in context of mitochondrial dysfunction, 
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where chronic hyperglycaemia can permanently damage and impair MtDNA and 
mitochondrial function. 
Threshold effect 
There is evidence for a heritable genetic susceptibility to DN, but most of the 
research reports concentrated on nDNA [reviewed in (Herrera and Coffman, 
2012)], while the problem may actually lays in the MtDNA and accumulation of 
the MtDNA mutations. In normal tissues all MtDNA copies are identical 
(homoplasmy), but with any occurring mutations, a mix of normal and mutated 
forms of MtDNA present, contributes to heteroplasmy (Dimauro and Davidzon, 
2005). Mitochondrial disease may become clinically apparent once the number 
of affected mitochondria reaches a certain level; this phenomenon is called the 
"threshold effect". MtDNA is non-Mendelian, maternally inherited, which means 
there is a possibility of accumulation of mutated MtDNA, which when exceeds 
the threshold, overcome the wild type MtDNA, potentially leading to  disease 
state (Dimauro and Davidzon, 2005). This may be the reason why healthy lean 
offspring of T2D patients show signs of MtDNA deletion and mitochondrial 
dysfunction with MtDNA serving as an indicator for insulin sensitivity (Song et al., 
2001, Morino et al., 2005). A minimum amount of the wild-type MtDNA is 
necessary for proper mitochondrial function (Navis et al., 2013). Therefore, when 
there is an imbalance between mutated and wild-type MtDNA molecules, with 
mutated MtDNA crossing the threshold, the overall imbalance in the cell redox 
status may occur, consequently affecting energy production (Wallace and Fan, 
2010, Wallace et al., 2010). This could have a detrimental effect on disease 
progression, especially in highly energetic organs, like kidneys. A study using 
cybrids with common tRNA-3243G mutation (associated diabetes and autism, 
when 10-30% of mutation present) also demonstrated that MtDNA heteroplasmy 
can affect transcriptional reprogramming, but the effect is dependent on the 
ratio of the mutated to wild type MtDNA molecules (Picard et al., 2014). These 
data suggest that a small increase in mutant MtDNAs can contribute to relatively 
modest defects in oxidative capacity, but results in significant transitions in 
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cellular phenotype and gene expression, causing changes to mitochondrial 
function, structure and cell size (Picard et al., 2014). 
Accumulation of MtDNA mutations can be tolerated for many years before 
reaching damaging levels (Chinnery et al., 2002), and a similar mechanism could 
possibly explain how diabetic complications develop over several years. 
Interestingly, it has been also shown that MtDNA haplogroups are also important 
and may contribute to the susceptibility to certain diabetic complications, such 
as DN (Achilli et al., 2011), further implicating MtDNA involvement in the 
development of DN. 
Application of the current findings to the clinical setting 
Keeping mitochondria healthy in diabetes, in order to keep the balance and the 
control of the disease, require overcoming several problems including: keeping 
reliable and uncoupled energy supply and control ROS emissions from 
mitochondria. One of the solutions is the use of antioxidants, especially the ones 
that specifically target ROS produced by mitochondria. However, so far none of 
candidate antioxidant therapies tested in clinical trials have resulted in 
satisfactory improvement of the mitochondrial dysfunction (Kerr, 2013). This 
only highlights the importance of diagnosing mitochondrial dysfunction at the 
early stages. 
Data from the current study suggest that the observed increase in MtDNA occurs 
earlier, before the mutations in MtDNA are present and much earlier than the 
observed fall in the mitochondria function, therefore the measurement of 
MtDNA in a clinical setting may be a reliable alternative to currently used 
markers to assess metabolic changes in patients with diabetes. Currently, it is 
impossible to distinguish patients with diabetes that subsequently develop DN 
from those that don’t. Also, it is impossible to recognise DN at early stages; 
patients are diagnosed based on the serum AC ratio and presence of the protein 
in the urine, which are signs of the already failing kidney function.  
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A full and proper understanding of the bioenergetic responses of different cell 
types to oxidative stress and nutrients overall, present in diabetes and its 
complications may give and insight into novel therapies. 
Future directions 
Future studies may explore the protective role of the antioxidant system 
especially mitochondria targeted antioxidants like MitoQ, in order to see if 
hyperglycaemia-induced changes in MtDNA and mitochondria function can be 
avoided. Results from current studies suggest, that an increase in MtDNA 
content precede decreased mitochondrial function. A MtDNA assay may be an 
alternative technique to monitor patients with diabetes for risk of DN 
development, as currently no available markers allow diagnosis of the early 
stages of DN. However, a longitudinal study is needed in order to establish a 
correlation between MtDNA and failing kidney function in diabetic patients. 
Measurement of the MtDNA content can be combined with the measurement of 
mitochondria function, using patients’ white blood cells and Seahorse analyzer. 
Data from our group has shown that patients with diabetes have increased  
maximal respiration (Czajka, Ajaz et al., submitted), which may be within their 
threshold limit, therefore monitoring ones mitochondrial health might help pick 
up pathological changes at an early stage of development.  A Bioenergetic Health 
Index (BHI) formula has been introduced recently, which combines all OCR 
parameters and translates them into one value, which allow to measure how 
susceptible a person with diabetes can be used to developing metabolic stress 
(Chacko et al., 2014). MtDNA content combined with BHI may be a key into 
personalised medicine, which would be used as a diagnostic tool and help to 
optimise personalised treatment. 
Conclusion 
The importance of mitochondrial ROS in oxidative stress and the kidney is well 
established; mitochondrial targeted antioxidants ameliorate certain markers of 
renal damage (Chacko et al., 2010b). In the current report, it was demonstrated 
that hyperglycaemia-induced ROS led to the up-regulation of the MtDNA content 
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and mRNA expression of the genes involved in the TLR9 pathway, NF-KB and 
Myd88, suggesting increased inflammation. Cells started to display altered 
morphology within a few hours of exposure to high glucose, with mitochondrial 
fragmentation, which may be an attempt at the initiation of an adaptive 
biogenesis program, leading to increased MtDNA content. Chronic 
hyperglycaemia can 'overpower' antioxidant defences and lead to mutations in 
MtDNA, damage to mitochondria and cause mitochondrial dysfunction. 
Accumulation of damage MtDNA can trigger an inflammatory response, through 
the activation of TLR9 receptors and further contribute to tissue damage. These 
changes may result in damaged mitochondria, blocked mitochondrial 
transcription and translation and an energy deficit. 
 
Data derived from primary mesangial cells and diabetic mouse models supports 
the hypothesis that glucose can lead to alterations in MtDNA and mitochondrial 
function. These data are representative of an early stage in diabetes.   
The data obtained from my studies further highlights the enigma which is DN; it 
illustrates the importance of mitochondrial function in the development of 
diabetic complications. If decreasing mitochondrial function and MtDNA content 
is confirmed in longitudinal studies in patients with diabetes and DN and 
continues to be linked with the progression of the DN, then this could be used as 
potential predictors for the development of DN and help in the development of 
personalized treatment. 
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Appendix II  
Fig.A2.1. Amplification of mouse β-actin in 10-fold dilutions and standard curve 
generation. Dilution standards of mouse β-actin were prepared and 2ul of each 
standard was used in qPCR reaction and amplified. Fluorescence data was acquired once 
per cycle and amplification curve (A) was generated showing dilution series from 102 to 
107 copies of hMito. Melting point analysis (B) represents specificity of multiplied 
product as one single melt peak is visible at 83.4°C. (C) Standard curve showing the 








Fig.A2.2. Amplification of mouse TFAM in 10-fold dilutions and standard curve 
generation. Dilution standards of mouse TFAM were prepared and 2ul of each standard 
was used in qPCR reaction and amplified. Fluorescence data was acquired once per cycle 
and amplification curve (A) was generated showing dilution series from 10 to 106 copies 
of TFAM. Melting point analysis (B) represents specificity of multiplied product as one 
single melt peak is visible at 79°C. (C) Standard curve showing the crossing point (Ct) for 
each of the 10-fold dilutions plotted against a log concentration.  









Fig.A2.3. Amplification of mouse PGC1-α in 10-fold dilutions and standard curve 
generation. Dilution standards of mouse PGC-1α were prepared and 2ul of each 
standard was used in qPCR reaction and amplified. Fluorescence data was acquired once 
per cycle and amplification curve (A) was generated showing dilution series from 10 to 
106 copies of PGC-1α. Melting point analysis (B) represents specificity of multiplied 
product as one single melt peak is visible at 83°C. (C) Standard curve showing the 








Fig.A2.4. Amplification of human MFN1 in 10-fold dilutions and standard curve 
generation. Dilution standards of human MFN1 were prepared and 2ul of each standard 
was used in qPCR reaction and amplified. Fluorescence data was acquired once per cycle 
and amplification curve (A) was generated showing dilution series from 10 to 106 copies 
of MFN1. Melting point analysis (B) represents specificity of multiplied product as one 
single melt peak is visible at 76°C. (C) Standard curve showing the crossing point (Ct) for 













Fig.A2.5. Amplification of human MFN2 in 10-fold dilutions and standard curve 
generation. Dilution standards of human MFN2 were prepared and 2ul of each standard 
was used in qPCR reaction and amplified. Fluorescence data was acquired once per cycle 
and amplification curve (A) was generated showing dilution series from 10 to 108 copies 
of MFN2. Melting point analysis (B) represents specificity of multiplied product as one 
single melt peak is visible at 84°C. (C) Standard curve showing the crossing point (Ct) for 








Fig.A2.6. Amplification of human OPA1 in 10-fold dilutions and standard curve 
generation. Dilution standards of human OPA1 were prepared and 2ul of each standard 
was used in qPCR reaction and amplified. Fluorescence data was acquired once per cycle 
and amplification curve (A) was generated showing dilution series from 10 to 106 copies 
of OPA1. Melting point analysis (B) represents specificity of multiplied product as one 
single melt peak is visible at 80°C. (C) Standard curve showing the crossing point (Ct) for 
each of the 10-fold dilutions plotted against a log concentration.  
 
 










Fig.A2.7. Amplification of human MYD88 in 10-fold dilutions and standard curve 
generation. Dilution standards of human MYD88 were prepared and 2ul of each 
standard was used in qPCR reaction and amplified. Fluorescence data was acquired once 
per cycle and amplification curve (A) was generated showing dilution series from 10 to 
106 copies of MYD88. Melting point analysis (B) represents specificity of multiplied 
product as one single melt peak is visible at 80°C. (C) Standard curve showing the 








Fig.A2.8. Amplification of human NF-κB in 10-fold dilutions and standard curve 
generation. Dilution standards of human NF-κB were prepared and 2ul of each standard 
was used in qPCR reaction and amplified. Fluorescence data was acquired once per cycle 
and amplification curve (A) was generated showing dilution series from 10 to 107 copies 
of NF-κB. Melting point analysis (B) represents specificity of multiplied product as one 
single melt peak is visible at 88°C. (C) Standard curve showing the crossing point (Ct) for 
each of the 10-fold dilutions plotted against a log concentration.  
 









Fig.A2.9. Amplification of human TFAM in 10-fold dilutions and standard curve 
generation. Dilution standards of human TFAM were prepared and 2ul of each standard 
was used in qPCR reaction and amplified. Fluorescence data was acquired once per cycle 
and amplification curve (A) was generated showing dilution series from 102 to 107 copies 
of TFAM. Melting point analysis (B) represents specificity of multiplied product as one 
single melt peak is visible at 79°C. (C) Standard curve showing the crossing point (Ct) for 








Fig.A2.10. Amplification of human PGC-1α in 10-fold dilutions and standard curve 
generation. Dilution standards of human PGC1-α were prepared and 2ul of each 
standard was used in qPCR reaction and amplified. Fluorescence data was acquired once 
per cycle and amplification curve (A) was generated showing dilution series from 102 to 
107 copies of PGC1-α. Melting point analysis (B) represents specificity of multiplied 
product as one single melt peak is visible at 78°C. (C) Standard curve showing the 
crossing point (Ct) for each of the 10-fold dilutions plotted against a log concentration.  
 










Fig.A2.11. Amplification of human ND1 in 10-fold dilutions and standard curve 
generation. Dilution standards of human ND1 were prepared and 2ul of each standard 
was used in qPCR reaction and amplified. Fluorescence data was acquired once per cycle 
and amplification curve (A) was generated showing dilution series from 102 to 107 copies 
of ND1. Melting point analysis (B) represents specificity of multiplied product as one 
single melt peak is visible at 80°C. (C) Standard curve showing the crossing point (Ct) for 











Fig.A2.12. Amplification of human ND6 in 10-fold dilutions and standard curve 
generation. Dilution standards of human ND6 were prepared and 2ul of each standard 
was used in qPCR reaction and amplified. Fluorescence data was acquired once per cycle 
and amplification curve (A) was generated showing dilution series from 100 to 106 copies 
of ND6. Melting point analysis (B) represents specificity of multiplied product as one 
single melt peak is visible at 81°C. (C) Standard curve showing the crossing point (Ct) for 
each of the 10-fold dilutions plotted against a log concentration 
 










Fig.A2.13. Amplification of human COX3 in 10-fold dilutions and standard curve 
generation. Dilution standards of human COX3 were prepared and 2ul of each standard 
was used in qPCR reaction and amplified. Fluorescence data was acquired once per cycle 
and amplification curve (A) was generated showing dilution series from 10 to 106 copies 
of COX3. Melting point analysis (B) represents specificity of multiplied product as one 
single melt peak is visible at 81°C. (C) Standard curve showing the crossing point (Ct) for 
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Appendix 
Appendix III Cellular bioenergetics 
Seahorse XFe24 data 















Fig. A6.1. Assessment of cellular bioenergetic in mesangial cells using Seahorse XFe24. 
Cells were culture in 5mM (NG) and 25mM (HG) glucose for 4 (A) and 8 days (B). 
Following the exposure to high glucose HMCs were seeded at the density of 30 000 
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Fig.A6.2. Bioenergetic profile of human mesangial cells is not affected after 4 days of 
culture in high glucose. HMCs were culture din 5mM (NG) and 25mM (HG) glucose for 4 




























































































































































































































































N G  4 d a y s
H g  4  d a y s




























































































































































































































































Fig.A6.3. Bioenergetic profile of human mesangial cells is altered after 8 days of 
culture in high glucose. HMCs were culture din 5mM (NG) and 25mM (HG) glucose for 4 
days and cellular bioenergetic was measured using Seahorse Analyzer. Maximal 
respiration was significantly down regulated in primary cultured mesangial c ells 
exposed to high glucose for 8 days, *P<0.05 
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